## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No: 01017/35966A

# PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. 1.53

Box Patent Application Commissioner for Patents Washington, D.C. 20231

Sir:							
Transr	nitted h	erewith	for filing is the patent application of				
Invent	or(s):	Han et	al.				
Title:		The H	uman E3α Ubiquitin Ligase Family				
1.	Туре	of Applic	plication				
			a new application for a utility patent. design patent. a continuation-in-part application of prior application no.				
2.	Applic	ation Pa	pers Enclosed				
		1	Title Page				
		106	Pages of Specification (excluding Claims, Abstract, Drawings & Sequence Listing)				
		11	Page(s) of Claims				
		1	Page(s) of Abstract				
		16	Sheet(s) of Drawings (Figs. 1 to 12)				

Formal

Informal

Page(s) of Sequence Listing

 $\boxtimes$ 

57

# **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on November 28, 2000, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EM578444884US.

Śĥaron M. Sintich

3.	Decla	ration or	Oath			
			Enclosed	b		
				Execut	ed by (c	check all applicable boxes)
			[		Invento	or(s)
			E		_	representative of inventor(s) FR 1.42 or 1.43)
			I			nventor or person showing a proprietary interest or of inventor who refused to sign or cannot be d
						The petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 are enclosed. See Item 5D below for fee.
		⊠				dersigned attorney or agent is authorized to file this of the applicant(s). An executed declaration will
4.	Smal	l Entity S	Status			
		Applio	cant claims	s small	entity :	status. See 37 CFR 1.27.
			A small	entity	stateme	ent is(are) attached.
5.	Addit	tional Pa	pers Enclo	sed		
			Prelimin	ary An	nendme	nt
			Informa	tion Di	sclosure	e Statement
			Declarat	tion of	Biologic	cal Deposit
		⊠	Comput amino a			py of sequence listing containing nucleotide and/or
			Microfic	che cor	nputer į	program
			Associa	ite Pov	ver of A	ttorney
			Verified	l transl	ation of	a non-English patent application
			An assi	gnmen	t of the	invention
		$\boxtimes$	Return r	receipt	postca	rd
		$\boxtimes$	OtherS	Statem	ent of S	Sequence Listing

6.	Priority	<b>Applications</b>	Under	35	USC	1	19
----	----------	---------------------	-------	----	-----	---	----

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

 $\square$  are attached.

COUNTRY	APPLICATION NO.	FILED
us	60/187,911	March 8, 2000
	<u> </u>	

# 7. Filing Fee Calculation (37 CFR 1.16)

A. Multility Application

	CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT (IF ANY)							
			SMALL ENTITY		OTHER THAN A SMALL ENTITY			
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE		
BASIC FEE				\$355.00	Storm to the storm	\$710.00		
TOTAL	97 -20	= 77	X 9 =	\$	X 18 =	\$1,386.00		
INDEP.	15 - 3	= 12	X 40 =	\$	X 80 =	\$960.00		
☐ First Presentation of Multiple Dependent			+ 135 =	\$	+ 270 =	\$270.00		
	75.54		Filing Fee:	\$	OR	\$3,326 00		

В.		Design Application (\$160.00/\$320.00)	Filing Fee: \$	
c.		Plant Application (\$245.00/\$490.00)	Filing Fee: \$	
D.	Other f	Fees		
		Recording Assignment [Fee \$40.00 per	assignment]	\$
		Petition fee for filing by other than all the in or person on behalf of the inventor where it to sign or cannot be reached [Fee \$130]	nventor refused	i \$
		Other		\$

Total Fees Enclosed \$3,326.00

8.	Method	of	<b>Payment</b>	of	Fees
----	--------	----	----------------	----	------

$\boxtimes$	Enclosed check in the amount of:	\$ <u>3,326.00</u>
	Charge Deposit Account No. 13-2855 in the amount of: A copy of this Transmittal is enclosed.	\$
	Not enclosed	

# 9. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-2855. A copy of this Transmittal is enclosed.

Please refund any overpayment to Marshall, O'Toole, Gerstein, Murray & Borun at the address below.

#### 10. Correspondence Address

Customer No.: 04743

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6402 (312) 474-6300 (312) 474-0448 (Telefacsimile)

By:

David W. Clough Reg. No: 36,107

November 28, 2000

#### JOINT INVENTORS

"EXPRESS MAIL" mailing label No. EM578444884US.

Date of Deposit: November 28, 2000
I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C.

Sharon M. Sintich

20231

# APPLICATION FOR UNITED STATES LETTERS PATENT

# SPECIFICATION

#### TO ALL WHOM IT MAY CONCERN:

Be it known that we, Hui-Quan Han a citizen of the United States of America, residing at 3353 Crossland Street, Thousand Oaks, California, 91362, and Keith Kwak a citizen of the United States of America, residing at 1699 Amarelle Street, Thousand Oaks, California, 91320, have invented new and useful The Human E3α Ubiquitin Ligase Family, of which the following is a specification.

5

10

# THE HUMAN E3α UBIQUITIN LIGASE FAMILY

#### RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 from U.S. provisional patent application Serial No. 60/187,911 filed March 8, 2000.

#### FIELD OF THE INVENTION

The present invention includes novel human  $E3\alpha$  ubiquitin ligase polypeptides (huE3 $\alpha$ I and huE3 $\alpha$ II) and nucleic acid molecules encoding the same. The invention also relates to vectors, host cells, selective binding agents, such as antibodies, and methods for producing huE3 $\alpha$  polypeptides. Also provided for are methods for the diagnosis, treatment, amelioration and/or prevention of diseases associated with huE3 $\alpha$  polypeptides, as well as methods for identifying modulators of huE3 $\alpha$  ligase activity.

### **BACKGROUND OF THE INVENTION**

Technical advances in the identification, cloning, expression and manipulation of nucleic acid molecules and deciphering of the human genome have greatly accelerated the discovery of novel therapeutics based upon deciphering of the human genome. Rapid nucleic acid sequencing techniques can now generate sequence information at unprecedented rates and, coupled with computational analyses, allow the assembly of overlapping sequences into the partial and entire genomes as well as the identification of polypeptide-encoding regions. A comparison of a predicted amino acid sequence against a database compilation of known amino acid sequences can allow one to determine the extent of homology to previously identified sequences and/or structural landmarks. The cloning and expression of a polypeptide-encoding region of a nucleic acid molecule provides a polypeptide product for structural and functional analyses. The manipulation of nucleic acid molecules and encoded polypeptides to create variants and derivatives thereof may confer advantageous properties on a product for use as a therapeutic.

In spite of significant technical advances in genome research over the past decade, the potential for the development of novel therapeutics based on the human genome is still largely unrealized. Many genes encoding potentially beneficial

20

25

polypeptide therapeutics, or those encoding polypeptides which may act as "targets" for therapeutic molecules, have still not been identified. In addition, structural and functional analyses of polypeptide products from many human genes have not been undertaken.

5

Accordingly, it is an object of the invention to identify novel polypeptides and nucleic acid molecules encoding the same which have diagnostic or therapeutic benefit.

10

THE THE CONTROL OF THE STREET STREET

R wills the ball of the setter with all

Roll Carle Comb wang

20

25

30

Most types of intracellular proteins are degraded through the ubiquitin-proteosome pathway. In this system, proteins are marked for protesomal degradation by the conjugation of ubiquitin molecules to the protein. Conjugation of the ubiquitin molecule initially involves activation by the E1 enzyme. Upon activation the ubiquitin molecule is transferred to the E2 enzyme which serves as a carrier-protein. The E2 enzyme interacts with a specific E3 ligase family member. The E3 ligase binds to proteins targeted for degradation and catalyzes the transfer of ubiquitin from the E2 carrier enzyme to the target protein. Since the target protein binds to the ligase prior to conjugatin, E3 ligase is the rate limiting step for ubiquitin conjugation and determines the specificity of the system. The ubiquitin chain serves as a degradation marker for the 26S proteosome (*See* Ciechanover, *EMBO J.*, *17*: 7151-7160, 1998).

There are only a few known E3 ligases and the sequence homology between them is low. The E3 $\alpha$  family is the main family of intracellular ubiquitin ligases and is involved in N-end rule pathway of protein degradation. The N-end rule states that there is a strong relation between the *in vivo* half-life of a protein and the identity of its N-terminal amino acids. Accordingly, E3 $\alpha$  enzyme binds directly to the primary destabilizing N-terminal amino acid and catalyzes ubiquitin conjugation thereby targeting the protein for degradation. E3 $\alpha$  family members also recognize non-N-end rule substrates (*See* Ciechanover, *EMBO J.*, 17: 7151-7160, 1998).

The E3α enzyme family currently consists of intracellular enzymes isolated from rabbit (Reiss and Hershiko, *J. Biol. Chem. 265*: 3685-3690, 1990), mouse (Kwon *et al.*, *Proc. Natl. Acad. Sci.*, *U.S.A 95*: 7898-7903, 1999), yeast (Bartel *et al.*, *EMBO J.*, 9: 3179-3189, 1990) and the *C. elegans* (Wilson *et al.*, *Nature*, 368: 32-38, 1994; Genebank Accession No. U88308) counterparts termed UBR-1. Comparison of these known sequences indicates regions of high similarity regions (I-V) which suggest

10

15

20

25

30

the existence of a distinct family. The regions of similarity contain essential residues for the recognition of N-end rule substrates. In region I, the residues Cys-145, Val-146, Gly-173, and Asp-176 are known to be necessary for type-1 substrate binding in yeast and are conserved in the mouse. In regions II and III, residues Asp-318, His-321, and Glu-560 are essential for type-2 substrate binding in yeast and are also conserved in the mouse. In addition, there is a conserved zinc-finger domain in region I and a conserved RING-H2 domain in region IV (Kwon *et al.*, *Proc. Natl. Acad. Sci.*, *U.S.A*, *95*: 7898-7903, 1999).

The full length mouse E3 $\alpha$  cDNA sequence and a partial human E3 $\alpha$  nucleotide sequence ( $\approx$ 1 kb) have recently been cloned and characterized as described in US 5,861,312 and Kwon *et al.* (*Proc. Natl. Acad. U.S.A., 95:* 7898-7908, 1999). The full length mouse E3 $\alpha$  cDNA sequence is 5271 bp in length and encodes a 1757 amino acid polypeptide. The mouse E3 $\alpha$  gene is localized to the central region of chromosome 2 and is highly expressed in skeletal muscle, heart and brain. The partial human E3 $\alpha$  sequence was used to characterize tissue expression and chromosomal localization. This analysis indicated that the human E3 $\alpha$  gene is located on chromosome 15 $\alpha$  and exhibits a similar expression pattern as mouse E3 $\alpha$  with high expression in skeletal muscle, heart and brain. As described herein, the present invention discloses two novel, full length, human E3 $\alpha$  sequences (huE3 $\alpha$ I and huE3 $\alpha$ II) and a novel, full length mouse E3 $\alpha$  sequence (muE3 $\alpha$ II). Expression of huE3 $\alpha$ I and huE3 $\alpha$ II mRNA is highly enriched in skeletal muscle tissues. Functionally, huE3 $\alpha$  polypeptides are intracellular enzymes that control protein conjugation and degradation.

Increased proteolysis through the ubiquitin-proteosome pathway has been determined to be a major cause of rapid muscle wasting in many pathological states including but not limited to fasting, metabolic acidosis, muscle denervation, kidney failure, renal cachexia, uremia, diabetes mellitus, sepsis, AIDS wasting syndrome, cancer cachexia, negative nitrogen balance cachexia, burns and Cushing's syndrome (See Mitch and Goldberg, New England J. Med, 335: 1897-1905, 1996). Studies in animal models have shown that muscle wasting disorders are associated with increased ubiquitin content in muscles, increased levels of mRNA transcripts encoding ubiquitin, E2 enzyme and proteosome subunit mRNA, and increased ubiquitin-conjugation to muscle-proteins (See Lecker et al., J. Nutr., 129: 227S-237S, 1999). In this context, the N-end rule

pathway has been shown to play a role in muscle atrophy. E3 $\alpha$  inhibitors, such as dipepetides and methyl ester, reduce the level of ubiquitin conjugation in atrophying rat muscles caused by sepsis, fasting and cancer cachexia (Soloman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95: 12602-12607, 1999). These observations indicate that E3 $\alpha$  plays a role in the overall increase in ubiquitination that is associated with and may mediate muscle atrophy in catabolic and other disease states.

Thus, identification of members of the N-end rule protein degradation pathway has led to a better understanding of protein degradation in human cells and the mechanisms of protein degradation in pathological condition which involve muscle atrophy. Identification of the two novel human  $E3\alpha$  ubiquitin ligase genes and polypeptides, as described herein, will further clarify the understanding of these processes and facilitate the development of therapies for pathological conditions which involve abnormal or excessive protein degradation including conditions which involve atrophy of muscle.

#### SUMMARY OF THE INVENTION

The present invention relates to novel human  $E3\alpha$  nucleic acid molecules and polypeptides encoded by these nucleic acid molecules.

The invention provides isolated nucleic acid molecules comprising or consisting of a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
- b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 and 4;
- c) a nucleotide sequence which hybridizes under moderate or highly stringent conditions to the compliments of (a) or (b); and
  - d) a nucleotide complementary to (a) (c)

The invention also provides isolated nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4, wherein the polypeptide has an activity of the polypeptide set forth in SEQ

15

20

10

5

30

ID NOS: 2 or 4 and the percent identity for these nucleic acid sequences are determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm;

- b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
- the nucleotide sequence of the DNA insert in ATCC Deposit No. PTA-1489 or PTA-1490;
- d) a nucleotide sequence of SEQ ID NOS: 1; 3; (a); or (b) encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- e) a nucleotide sequence of SEQ ID NOS: 1, 3, or (a)-(c) comprising a fragment of at least about 16 nucleotides;
- f) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(e); and
  - g) a nucleotide sequence complementary to any of (a)-(d).

The invention also provides isolated nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:

- a) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- b) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- c) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- d) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- e) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one modification selected from the group consisting of amino acid

15

5

10

20

25

10

15

20

25

30

substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

- f) a nucleotide sequence of (a)-(e) comprising a fragment of at least about 16 nucleotides;
- g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f); and
  - h) a nucleotide sequence complementary to any of (a)-(e).

The invention also provides isolated polypeptides comprising the amino acid sequence selected from the group consisting of:

- a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4;
- b) the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4 comprising a mature amino terminus at residues 1, and optionally further comprising an amino terminal methionine;
- c) an amino acid sequence that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of the polypeptide of SEQ ID NOS: 2 or 4 wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4 and the percent identity for these amino acid sequences are determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.
- d) a fragment of the amino acid sequence set forth in SEQ ID NOS: 2 or 4 comprising at least about 25, 50, 75, 100, or greater than 100 amino acid residues, wherein the fragment has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- e) the amino acid sequence encoded by the DNA insert of ATCC Deposit No. PTA-1489 or PTA-1490;
- f) an amino acid sequence for an ortholog of SEQ ID NOS: 2 or 4; including the murine ortholog set out as SEQ ID NO: 6.
  - g) an allelic variant or splice variant of (a), (b), (e) or (f);

The present invention also provides isolated polypeptides comprising the amino acid sequence selected from the group consisting of:

- a) the amino acid as sequence set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- b) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- c) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- d) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4; and
- e) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4.

The present invention provides expression vectors comprising the nucleic acid molecules set forth herein, host cells comprising the expression vectors of the invention, and a method of producing a human  $E3\alpha$  polypeptide comprising culturing the host cells and optionally isolating the polypeptide so produced. An another embodiment provides for viral vectors comprising the nucleic acid molecules of the inventions. Further provided is a process for determining whether a compound inhibits  $huE3\alpha$  polypeptide activity or production comprising exposing a host cell expressing  $huE3\alpha$  polypeptide to the compound, and measuring  $huE3\alpha$  polypeptide activity or production in said cell.

A transgenic non-human animal comprising a nucleic acid molecule encoding a huE3 $\alpha$  polypeptide is also encompassed by the invention. The huE3 $\alpha$  nucleic acid molecules are introduced into the animal in a manner that allows expression and

20

15

5

10

25

increased levels of a huE3 $\alpha$  polypeptide, which may include increased circulating levels. The transgenic non-human animal is preferably a mammal, and more preferably a rodent, such as a rat or a mouse.

Also provided are derivatives of the huE3α polypeptides of the present invention, fusion polypeptides comprising the huE3α polypeptides of the invention, and selective binding agents such as antibodies capable of specifically binding the polypeptides of the invention.

Pharmaceutical compositions comprising the nucleotides, polypeptides, or selective binding agents of the present invention and a carrier, adjuvant, solubilizer, stabilizer, anti-oxidant, or other pharmaceutically acceptable formulation agent are also encompassed by the invention. The pharmaceutical compositions include therapeutically effective amounts of the nucleotides or polypeptides of the present invention, and involve methods of using the polypeptides and nucleic acid molecules.

The  $huE3\alpha$  polypeptides and nucleic acid molecules of the present invention may be used for therapeutic or diagnostic purposes to treat, prevent, and/or detect diseases or disorders, including those recited herein.

Methods of regulating expression and modulating (*i.e.*, increasing or decreasing) levels of a huE3 $\alpha$  polypeptide are also encompassed by the invention. One method comprises administering to an animal a nucleic acid molecule encoding a huE3 $\alpha$  polypeptide. In another method, a nucleic acid molecule comprising elements that regulate or modulate the expression of a huE3 $\alpha$  polypeptide may be administered. Examples of these methods include gene therapy, cell therapy and antisense therapy as further described herein. Further provided is a method of identifying a compound which binds to a huE3 $\alpha$  polypeptide comprising.

A device, comprising a membrane suitable for implantation and host cells expressing a huE3α polypeptide encapsulated within said membrane, wherein said membrane is permeable to said protein product and impermeable to materials detrimental to said cells is also encompassed by the present invention.

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the alignment of the amino acid sequences for huE3 $\alpha$ I, huE3 $\alpha$ II, muE3 $\alpha$ II and muE3 $\alpha$ II (SEQ ID NOS: 2, 4, 15 and 6, respectively).

15

10

5

20

25

Figure 2 shows the results of a human multiple tissue Northern blot detecting  $huE3\alpha II$  expression.

Figure 3 shows the results of a human multiple tissue Northern blot detecting  $huE3\alpha I$  expression.

5

Figure 4 shows that transfection of 293T cells with huE3αI and huE3II cDNA stimulates the ubiquitination of endogenous proteins and exogenously added α-lactalbumin in cell lysates. The left panel shows the results of gel-shift assays of ubiquitinated proteins. The high molecular weight bands (above 18 kDa for endogenous proteins and above 33 kDa for α-lactalbumin) are identified as "125I-Ubiquitin-protein conjugates". The left panel plots the quantitative measurement of ubiquinated proteins measured by a PhosphoImager.

10

Figure 5 shows that transfection of  $C_2C_{12}$  and L6 myotube cells with huE3 $\alpha$ I and huE3II cDNA stimulates the ubiquitination of endogenous proteins cell lysates. The left panel shows the ubiquitinated high molecular weight bands (above 18 kDa for endogenous proteins) as "125I- Ubiquitin-protein conjugates". The left panel plots the quantitative measurement of ubiquinated proteins measured by a PhosphoImager.

15

Figure 6 shows the <sup>125</sup>I-ubiquitin conjugation to endogenous muscle proteins and its sensitivity to selective inhibitors of E3α in muscle extracts from control and YAH-tumor bearing rats. Gel-shift assays of muscle extracts from control and tumor-bearing rats revealed the ubiquitinated high molecular weight bands (above 18 kDa) denoted as "<sup>125</sup>I- Ubiquitin-protein conjugates". The left panel is muscle extracts collected 3 days post-implantation and the right panel is muscle extracts collected 5 days post-implantation.

25

20

Figure 7 shows the ubiquitin conjugation to <sup>125</sup>I-α-lactalbumin in extracts from atrophying muscles in YAH-tumor bearing rats as western blots of muscle extracts from control and tumor-bearing rats with the ubiquitinated high molecular weight bands (above 33 kDa) as "<sup>125</sup>I-Lactalbumin-ubiquitin conjugation". The left panel is muscle extracts collected 3 days post-implantation and the right panel is muscle extracts collected 5 days post-implantation.

30

Figure 8 shows Northern blot analysis of E3αI and E3αII expression in skeletal muscle in YAH-130 experimental cachexia model. The RNA expression

10

15

20

25

30

from pair-fed control rats and tumor-bearing rats were compared 3 days (3d) and 5 days (5d) post-implantation.

Figure 9 shows Northern blot analysis of E3αI and E3αII expression in skeletal (gastrocnemius) muscle and cardiac muscle in the C26 experimental cacheixia model. The RNA expression from pair-fed control rats and tumor-bearing mice were compared 12 days (12d) and 17 days (17d) post-implantation.

Figure 10 shows induction of E3 $\alpha$ II expression by proinflammatory cytokines TNF $\alpha$  and IL-6 in C<sub>2</sub>C<sub>12</sub> myotube cultures on Northern blots. The RNA levels of E3 $\alpha$ II (upper panel) and E3 $\alpha$ I (lower panel) were detected 3 or 5 days after treatment with TNF $\alpha$  (left panel) and IL-6 (right panel).

Figure 11 shows that IL-6 treatment causes a time-dependent acceleration of ubiquitination in differentiated  $C_2C_{12}$  cells. This data exhibits the results of a gel-shift assay showing the ubiquitinated high molecular weight bands denoted as "125I-ubiquitin protein conjugates" (left panel) and is quantitated by a PhosphoImager in the right panel.

Figure 12 shows that TNF $\alpha$  treatment causes a does-dependent acceleration of ubiquitination in differentiated  $C_2C_{12}$  cells. This data is displayed as gel-shift assay results with the ubiquitinated high molecular weight bands denoted as "125I-ubiquitin protein conjugates" (left panel) and is quantitated by a PhosphoImager in the right panel.

## DETAILED DESCRIPTION OF THE INVENTION

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described therein. All references cited in this application are expressly incorporated by reference herein.

### **Definitions**

The term "huE3 $\alpha$ " encompasses two novel orthologs of human E3 $\alpha$  ubiquitin ligase described herein including huE3 $\alpha$ I polynucleotide and polypeptide (SEQ ID NOS: 1 and 2, respectively) and huE3 $\alpha$ II polynucleotide and polypeptide (SEQ ID NOS: 3 and 4, respectively).

10

15

20

25

30

The term "huE3α nucleic acid molecule" or "polynucleotide" refers to a nucleic acid molecules including a nucleotide sequence as set forth in SEQ ID NOS: 1 or 3, a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 or 4, a nucleotide sequence of the DNA insert in ATCC deposit nos. PTA-1489 or PTA-1490, or nucleic acid molecule related thereto. Related nucleic acid molecules include a nucleotide sequence that is at least about 70 percent identical to the nucleotide sequence as shown in SEQ ID NOS: 1 or 3, or comprise or consist essentially of a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4. In preferred embodiments, these nucleotide sequences are about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the nucleotide sequence as shown in SEQ ID NOS: 1 or 3, or the nucleotide sequences encode a polypeptide that is about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the polypeptide sequence as set forth in SEQ ID NOS: 2 or 4.

Related nucleic acid molecules also include fragments of the huE3αI or hu E3aII nucleic acid molecules which fragments contain at least about 10 contiguous nucleotides, or about 15, or about 20, or about 25, or about 50, or about 75, or about 100, or greater than about 100 contiguous nucleotides of a huE3α nucleic acid molecule of SEQ ID NOS: 1 or 3. Related nucleic acid molecules also include fragments of the above huE3α nucleic acid molecules which encode a polypeptide of at least about 25 amino acid residues, or about 50, or about 75, or about 100, or greater than about 100 amino acid residues of the huE3α polypeptide of SEQ ID NOS: 2 or 4. Related nucleic acid molecules also include a nucleotide sequence encoding a polypeptide comprising or consisting essentially of a substitution, modification, addition and/or a deletion of one or more amino acid residues compared to the polypeptide set forth in SEQ ID NOS: 2 or 4. In addition, related huE3α nucleic acid molecules include those molecules which comprise nucleotide sequences which hybridize under moderately or highly stringent conditions as defined herein with the fully complementary sequence of any of the huE3α nucleic acid molecules of SEQ ID NOS: 1 or 3.

10

15

20

25

30

In preferred embodiments, the related nucleic acid molecules comprise sequences which hybridize under moderately or highly stringent conditions with a molecule having a sequence as shown in SEQ ID NOS: 1 or 3, or of a molecule encoding a polypeptide, which polypeptide comprises the sequence as shown in SEQ ID NOS: 2 or 4, or of a nucleic acid fragment as defined herein, or of a nucleic acid fragment encoding a polypeptide as defined herein or the complement of any or the forgoing molecules. It is also understood that related nucleic acid molecules include allelic or splice variants of a huE3α nucleic acid molecule of SEQ ID NOS: 1 or 3, and include sequences which are complementary to any of the above nucleotide sequences. The related encoded polypeptides possess at least one activity of the polypeptide depicted in SEQ ID NOS: 2 or 4.

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that is free from at least one contaminating nucleic acid molecule with which it is naturally associated. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating mammalian nucleic acid molecule(s) which would interfere with its use in polypeptide production or its therapeutic, diagnostic, or preventative use.

A "nucleic acid sequence" or "nucleic acid molecule" as used herein refer to a DNA or RNA sequence. The terms encompasses molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylamino-methyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonyl-methyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-

methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.

The term "operably linked" is used as recognized in the art to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking sequence operably linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refer to one or more formulation materials suitable for accomplishing or enhancing delivery of the huE3α polypeptide, huE3α nucleic acid molecule, or huE3α selective binding agent as a pharmaceutical composition.

The term "allelic variant" refers to one of several possible naturally occurring alternate forms of a gene occupying a given locus on a chromosome of an organism or a population of organisms.

The term "splice variant" refers to a nucleic acid molecule, usually RNA, which is generated by alternative processing of intron sequences in an RNA transcript of huE3 $\alpha$  polypeptide amino acid sequence.

The term "expression vector" refers to a vector which is suitable for transformation of a host cell and contains nucleic acid sequences which direct and/or control the expression of inserted heterologous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present.

The term "vector" is used as recognized in the art to refer to any molecule (e.g., nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.

15

10

5

20

25

The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

10

5

The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, for example, Graham et al., Virology, 52: 456, 1973; Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratories, New York, 1989; Davis et al., Basic Methods in Molecular Biology, Elsevier, 1986; and Chu et al., Gene, 13: 197, 1981. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

15

The term "transduction" is used to refer to the transfer of genes from one bacterium to another, usually by a phage. "Transduction" also refers to the acquisition and transfer of eukaryotic cellular sequences by retroviruses.

20

The term "host cell" is used to refer to a cell which has been transformed, or is capable of being transformed, by a vector bearing a selected gene of interest which is then expressed by the cell. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.

25

The term "highly stringent conditions" refers to those conditions that are designed to permit hybridization of DNA strands whose sequences are highly complementary, and to exclude hybridization of significantly mismatched DNAs. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of "highly stringent conditions" for hybridization and washing are 0.015 M sodium chloride,

0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. *See* Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989); Anderson *et al.*, *Nucleic Acid Hybridisation: A Practical Approach*, Ch. 4, IRL Press Limited (Oxford, England).

More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may also be used, however, the rate of hybridization will be affected. Other agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDodSO<sub>4</sub>, or SDS, ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although another suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. (See Anderson et al., Nucleic Acid Hybridisation: a Practical Approach, Ch. 4, IRL Press Limited (Oxford, England)).

Factors affecting the stability of DNA duplex include base composition, length, and degree of base pair mismatch. Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids. The melting temperature of a perfectly matched DNA duplex can be estimated by the following equation:

 $T_m(^{\circ}C) = 81.5 + 16.6(log[Na+]) + 0.41(\%G+C) - 600/N - 0.72(\%formamide)$  where N is the length of the duplex formed, [Na+] is the molar concentration of the sodium ion in the hybridization or washing solution, %G+C is the percentage of (guanine+cytosine) bases in the hybrid. For imperfectly matched hybrids, the melting temperature is reduced by approximately 1°C for each 1% mismatch.

The term "moderately stringent conditions" refers to conditions under which a DNA duplex with a greater degree of base pair mismatching than could occur under "highly stringent conditions" is able to form. Examples of typical "moderately

10

5

15

20

30

stringent conditions" are 0.01 5M sodium chloride, 0.0015 M sodium citrate at 50-65°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 20% formamide at 37-50°C. By way of example, a "moderately stringent" condition of 50°C in 0.015 M sodium ion will allow about a 21% mismatch.

5

It will be appreciated by those skilled in the art that there is no absolute distinction between "highly" and "moderately" stringent conditions. For example, at 0.015M sodium ion (no formamide), the melting temperature of perfectly matched long DNA is about 71°C. With a wash at 65°C (at the same ionic strength), this would allow for approximately a 6% mismatch. To capture more distantly related sequences, one skilled in the art can simply lower the temperature or raise the ionic strength.

10

A good estimate of the melting temperature in 1 M NaCl\* for oligonucleotide probes up to about 20 nt is given by:

 $Tm = 2^{\circ}C$  per A-T base pair + 4°C per G-C base pair

15

\*The sodium ion concentration in 6x salt sodium citrate (SSC) is 1M. See Suggs et al., Developmental Biology Using Purified Genes, p. 683, Brown and Fox (eds.) (1981).

20

High stringency washing conditions for oligonucleotides are usually at a temperature of 0-5°C below the Tm of the oligonucleotide in 6x SSC, 0.1% SDS for longer nucleotides.

25

The term "huE3α polypeptide" refers to a polypeptide comprising the amino acid sequence of huE3αI or huE3αII (SEQ ID NOS: 2 or 4, respectively), and related polypeptides having a natural sequence or mutated sequence. Related polypeptides include: allelic variants; splice variants; fragments; derivatives; substitution, deletion, and insertion variants; fusion polypeptides; and orthologs of the huE3α polypeptides of SEQ ID NOS: 2 or 4, which possess at least one activity of the polypeptide depicted in SEQ ID NOS: 2 or 4. Human E3α polypeptides may be mature polypeptides, as defined herein, and may or may not have an amino terminal methionine residue, depending on the method by which they are prepared.

30

The term "huE3 $\alpha$  polypeptide fragment" refers to a polypeptide that comprises less than the full length amino acid sequence of a huE3 $\alpha$ I or huE3 $\alpha$ II polypeptide set forth in SEQ ID NOS: 2 or 4, respectively. Such huE3 $\alpha$  fragments can be 6 amino acids or more in length, and may arise, for example, from a truncation at the

10

15

20

25

30

amino terminus (with or without a leader sequence), a truncation at the carboxy terminus, and/or an internal deletion of one or more residues from the amino acid sequence. Human E3 $\alpha$  fragments may result from alternative RNA splicing or from *in vivo* protease activity. Membrane-bound forms of huE3 $\alpha$  are also contemplated by the present invention. In preferred embodiments, truncations and/or deletions comprise about 10 amino acids, or about 20 amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or more than about 100 amino acids. The polypeptide fragments so produced will comprise about 25 contiguous amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or about 150 amino acids, or about 200 amino acids. Such huE3 $\alpha$  polypeptide fragments may optionally comprise an amino terminal methionine residue. It will be appreciated that such fragments can also be used, for example, to generate antibodies to huE3 $\alpha$  polypeptides.

The term "huE3 $\alpha$  polypeptide variants" refers to huE3 $\alpha$  polypeptides which contain one or more amino acid sequence substitutions, deletions, and/or additions as compared to the huE3 $\alpha$  polypeptide amino acid sequence set forth as huE3 $\alpha$ I or huE3 $\alpha$ II (SEQ ID NOS: 2 or 4, respectively). Variants may be naturally occurring or artificially constructed. Such huE3 $\alpha$  polypeptide variants may be prepared from the corresponding nucleic acid molecules encoding said variants, which have a DNA sequence that varies accordingly from the DNA sequences for wild type huE3 $\alpha$  polypeptides as set forth in SEQ ID NOS: 1 or 3. In preferred embodiments, the variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from 1 to 20, or from 1 to 25, or from 1 to 50, or from 1 to 75, or from 1 to 100, or more than 100 amino acid substitutions, insertions, additions and/or deletions, wherein the substitutions may be conservative, or non-conservative, or any combination thereof.

One skilled in the art will be able to determine suitable variants of the native  $huE3\alpha$  polypeptide using well known techniques. For example, one may predict suitable areas of the molecule that may be changed without destroying biological activity. Also, one skilled in the art will realize that even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

For predicting suitable areas of the molecule that may be changed without destroying activity, one skilled in the art may target areas not believed to be important for activity. For example, when similar polypeptides with similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of huE3α polypeptide to such similar polypeptides. After making such a comparison, one skilled in the art can determine residues and portions of the molecules that are conserved among similar polypeptides. One skilled in the art would know that changes in areas of the huE3α molecule that are not conserved would be less likely to adversely affect the biological activity and/or structure of a huE3α polypeptide. One skilled in the art would also know that, even in relatively conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (conservative amino acid residue substitutions).

Additionally, one skilled in the art can review structure-function studies identifying residues in similar polypeptides that are important for activity or structure. In view of such a comparison, one skilled in the art can predict the importance of amino acid residues in a huE3 $\alpha$  polypeptide that correspond to amino acid residues that are important for activity or structure in similar polypeptides. One skilled in the art may opt for chemically similar amino acid substitutions for such predicted important amino acid residues of huE3 $\alpha$  polypeptides.

If available, one skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure in similar polypeptides. In view of that information, one skilled in the art may predict the alignment of amino acid residues of huE3α polypeptide with respect to its three dimensional structure. One skilled in the art may choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, since such residues may be involved in important interactions with other molecules.

Additional methods of predicting secondary structure include "threading" (Jones et al., Current Opin. Struct. Biol., 7(3):377-87 (1997); Sippl et al., Structure, 4(1):15-9 (1996)), "profile analysis" (Bowie et al., Science, 253:164-170 (1991); Gribskov et al., Meth. Enzym., 183:146-159 (1990); Gribskov et al., Proc. Nat. Acad. Sci., 84(13):4355-4358 (1987)), and "evolutionary linkage" (See Home, supra, and Brenner, supra 1997).

15

5

10

20

25

Moreover, one skilled in the art may generate test variants containing a single amino acid substitution at each amino acid residue. The variants could be screened using activity assays described herein. Such variants could be used to gather information about suitable variants. For example, if one discovered that a change to a particular amino acid residue resulted in destroyed, undesirably reduced, or unsuitable activity, variants with such a change would be avoided. In other words, based on information gathered from such routine experiments, one skilled in the art can readily determine the amino acids where further substitutions should be avoided either alone or in combination with other mutations.

10

5

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a its hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

15

20

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte *et al.*, *J. Mol. Biol.*, *157*: 105-131, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

25

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functionally equivalent protein or peptide thereby created is intended for use in immunological embodiments, as in the present case.

30

The U.S. Patent No. 4,554,101 states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.*, with a biological property of the protein. As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity

10

15

20

values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5  $\pm$  1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. Through the methods disclosed in U.S. Patent No. 4,554,101 one of skill in the art is able to identify epitopes from within a given amino acid sequence. These regions are also referred to as "epitopic core regions".

Numerous scientific publications have been devoted to the prediction of secondary structure, and to the identification of epitopes, from analyses of amino acid sequences. See Chou et al., Biochemistry, 13(2): 222-245, 1974; Chou et al., Biochemistry, 113(2): 211-222, 1974; Chou et al., Adv. Enzymol. Relat. Areas Mol. Biol., 47: 45-148, 1978; Chou et al., Ann. Rev. Biochem., 47: 251-276 and Chou et al., Biophys. J., 26: 367-384, 1979. Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based upon the Jameson-Wolf analysis (Jameson et al., Comput. Appl. Biosci., 4(1): 181-186, 1998 and Wolf et al., Comput. Appl. Biosci., 4(1): 187-191, 1988, the program PepPlot® (Brutlag et al., CABS, 6: 237-245 1990, and Weinberger et al., Science, 228: 740-742, 1985) and other new programs for protein tertiary structure prediction (Fetrow et al., Biotechnology, 11: 479-483 1993).

In preferred embodiments, the variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from 1 to 15, or from 1 to 20, or from 1 to 25, or from 1 to 50, or from 1 to 75, or from 1 to 100, or more than 100 amino acid substitutions, insertions, additions and/or deletions, wherein the substitutions may be conservative, as described herein, or non-conservative, or any combination thereof. In addition, the variants can have additions of amino acid residues either at the carboxy terminus or at the amino terminus (with or without a leader sequence).

25

10

15

20

25

30

Preferred huE3α polypeptide variants include glycosylation variants wherein the number and/or type of glycosylation sites has been altered compared to native huE3α polypeptide. In one embodiment, huE3α polypeptide variants comprise a greater or a lesser number of N-linked glycosylation sites. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X may be any amino acid residue except proline. substitution(s) of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional preferred huE3α variants include cysteine variants, wherein one or more cysteine residues are deleted or substituted with another amino acid (e.g., serine). Cysteine variants are useful when huE3α polypeptides must be refolded into a biologically active conformation such as after the isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

The term "huE3α fusion polypeptide" refers to a fusion of huE3αI or huE3αII polypeptide, fragment, and/or variant thereof, with a heterologous peptide or polypeptide. IN addition, the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4 or huE3α polypeptide variant many be fused to a homologous polypeptide to form a homodimer or to a heterologous polypeptide to form a heterodimer. Heterologous peptides and polypeptides include, but are not limited to: an epitope to allow for the detection and/or isolation of a huE3α fusion polypeptide; a transmembrane receptor protein or a portion thereof, such as an extracellular domain, or a transmembrane and intracellular domain; a ligand or a portion thereof which binds to a transmembrane receptor protein; an enzyme or portion thereof which is catalytically active; a polypeptide or peptide which promotes oligomerization, such as a leucine zipper domain; a polypeptide or peptide which increases stability, such as an immunoglobulin constant region, and a polypeptide which has a therapeutic activity different from the huE3α polypeptide.

10

15

In addition, a huE3α polypeptide may be fused to itself or to a fragment, variant, or derivative thereof. Fusions can be made either at the amino terminus or at the carboxy terminus of a huE3α polypeptide. Fusions may be direct with no linker or adapter molecule or indirect using through a linker or adapter molecule. A linker or adapter molecule may be one or more amino acid residues, typically from 20 amino acids residues, or up to about 50 amino acid residues. A linker or adapter molecule may also be designed with a cleavage site for a DNA restriction endonuclease or for a protease to allow for the separation of the fused moieties. It will be appreciated that once constructed, the fusion polypeptides can be derivatized according to the methods described herein.

In a further embodiment of the invention, a huE3α polypeptide, including a fragment, variant, and/or derivative, is fused to an Fc region of human IgG. Antibodies comprise two functionally independent parts, a variable domain known as "Fab", which binds antigens, and a constant domain known as "Fc", which is involved in effector functions such as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas an Fab is short-lived (Capon *et al.*, *Nature*, *337*: 525-31, 1989). When constructed together with a therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation and perhaps even placental transfer (Capon *et al.*, *Nature*, *337*: 525-31. 1989). Table I summarizes the use of certain Fc fusions known in the art, including materials and methods applicable to the production of fused huE3α polypeptides.

Therapeutic implications

Hodgkin's disease;

Reference

U.S. Patent No.

		C	of CD30-L	anaplastic lymphoma; T- cell leukemia	5,480,981
		Murine Fcγ2a	IL-10	anti-inflammatory; transplant rejection	Zheng et al., J. Immunol., 154: 5590-600, 1995
		IgG1	TNF receptor	septic shock	Fisher et al., N. Engl. J. Med., 334: 1697-1702, 1996; Van Zee et al., , J. Immunol., 156: 2221-30, 1996
The state of the s	10	IgG, IgA, IgM, or IgE (excluding the first domain)	TNF receptor	inflammation, autoimmune disorders	U.S. Pat. No. 5,808,029, issued September 15, 1998
10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15	IgG1	CD4 receptor	AIDS	Capon et al., Nature 337: 525-31, 1989
The part that the part state of the		IgG1, IgG3	N-terminus of IL-2	anti cancer, antiviral	Harvill <i>et al.</i> , <i>Immunotech.</i> , 1: 95-105 1995
1 M 1 M 2 M		IgG1	C-terminus of OPG	osteoarthritis; bone density	WO 97/23614, published July 3, 1997
25		IgG1	N-terminus of leptin	anti-obesity	PCT/US 97/23183, filed December 11, 1997
•	20	Human Ig Cγ1	CTLA-4	autoimmune disorders	Linsley, <i>J. Exp. Med.</i> , <i>174</i> : 561-9, 1991

In one example, all or portion of the human IgG hinge, CH2 and CH3 regions may be fused at either the N-terminus or C-terminus of the huE3α polypeptides using methods known to the skilled artisan. In another example, a portion of a hinge regions and CH2 and CH3 regions may be fused. The resulting huE3α Fc-fusion polypeptide may be purified by use of a Protein A affinity column. Peptides and proteins fused to an Fc region have been found to exhibit a substantially greater half-life in vivo Also, a fusion to an Fc region allows for than the unfused counterpart. dimerization/multimerization of the fusion polypeptide. The Fc region may be a naturally occurring Fc region, or may be altered to improve certain qualities, such as therapeutic qualities, circulation time, reduce aggregation, etc.

5

Form of

Fc

IgG1

**Fusion** partner

N-terminus

25

The term "huE3 $\alpha$  polypeptide derivatives" refers to huE3 $\alpha$ I or huE3 $\alpha$ II polypeptides, fragments, or variants, as defined herein, that have been chemically modified. The derivatives are modified in a manner that is different from naturally occurring huE3 $\alpha$ , polypeptides either in the type or location of the molecules attached to the polypeptide. Derivatives may further include molecules formed by the deletion of one or more chemical groups which are naturally attached to the huE3 $\alpha$  polypeptide.

For example, the polypeptides may be modified by the covalent attachment of one or more polymers, including, but not limited to, water soluble polymers, N-linked or O-linked carbohydrates, sugars, phosphates, and/or other such molecules. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. The polymer may be of any molecular weight, and may be branched or unbranched. Included within the scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

Suitable water soluble polymers or mixtures thereof include, but are not limited to, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran (such as low molecular weight dextran, of, for example about 6 kD), cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional PEG crosslinking molecules which may be used to prepare covalently attached huE3α multimers.

For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono  $C_1$ - $C_{10}$  alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

The pegylation of huE3α polypeptides may be carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis *et al.*, *Focus on Growth Factors*, 3: 4-10, 1992; EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. Pegylation may be carried out via an acylation

10

5

15

20

25

reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein.

Polyethylene glycol (PEG) is a water-soluble polymer suitable for use herein. As used herein, the terms "polyethylene glycol" and "PEG" are meant to encompass any of the forms of PEG that have been used to derivatize proteins, including mono- $(C_1-C_{10})$  alkoxy- or aryloxy-polyethylene glycol.

In general, chemical derivatization may be performed under any suitable conditions used to react a biologically active substance with an activated polymer molecule. Methods for preparing pegylated huE3α polypeptides will generally comprise the steps of (a) reacting the polypeptide with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby huE3α polypeptide becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s). In general, the optimal reaction conditions for the acylation reactions will be determined based on known parameters and the desired result. For example, the larger the ratio of PEG:protein, the greater the percentage of poly-pegylated product. In one embodiment, the huE3α polypeptide derivative may have a single PEG moiety at the amino terminus. *See*, for example, U.S. Patent No. 5,234,784.

Generally, conditions which may be alleviated or modulated by the administration of the present huE3α polypeptide derivative include those described herein for huE3α polypeptides. However, the huE3α polypeptide derivative disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to the non-derivatized molecules.

The terms "biologically active huE3 $\alpha$  polypeptides", "biologically active huE3 $\alpha$  polypeptide fragments", "biologically active huE3 $\alpha$  polypeptide variants", and "biologically active huE3 $\alpha$  polypeptide derivatives" refer to huE3 $\alpha$ I or huE3 $\alpha$ II polypeptides having at least one activity characteristic of a human E3 $\alpha$  ubiquitin ligase, such as the activity of the polynucleotide set forth in SEQ ID NOS: 2 or 4. In general, huE3 $\alpha$  polypeptides, fragments, variants, and derivatives thereof, will have at least one activity characteristic of a huE3 $\alpha$  polypeptide such as depicted in SEQ ID NOS: 2 or 4. In addition, a huE3 $\alpha$  polypeptide may be active as an immunogen, that is, the polypeptide contains at least one epitope to which antibodies may be raised.

10

5

15

20

25

10

15

20

"Naturally occurring" or "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to materials which are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" as used herein refers to a material that is not found in nature or that has been structurally modified or synthesized by man.

The term "isolated polypeptide" refers to a polypeptide of the present invention that is free from at least one contaminating polypeptide that is found in its natural environment. Preferably, the isolated polypeptide is substantially free from any other contaminating mammalian polypeptides which would interfere with its therapeutic, preventative, or diagnostic use.

The term "ortholog" refers to a polypeptide that corresponds to a polypeptide identified from a different species that corresponds to huE3 $\alpha$ polypeptide amino acid sequence. For example, mouse and human E3 $\alpha$  polypeptides are considered orthologs.

The term "mature huE3 $\alpha$  polypeptide" refers to a polypeptide lacking a leader sequence. A mature polypeptide may also include other modifications such as proteolytic processing of the amino terminus (with or without a leader sequence) and/or the carboxy terminus, cleavage of a smaller polypeptide from a larger precursor, N-linked and/or O-linked glycosylation, and the like. An exemplary mature huE3 $\alpha$  polypeptide is depicted by SEQ ID NOS: 2 or 4.

The terms "effective amount" and "therapeutically effective amount" refer to the amount of a huE3 $\alpha$  polypeptide or huE3 $\alpha$  nucleic acid molecule used to support an observable level of one or more biological activities of the huE3 $\alpha$  polypeptides as set forth herein.

The term "selective binding agent" refers to a molecule or molecules having specificity for huE3 $\alpha$  molecules. Selective binding agents include antibodies, such as polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, CDR-grafted antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as well as fragments, regions, or derivatives thereof

30

which are provided by known techniques, including, but not limited to enzymatic cleavage, peptide synthesis, or recombinant techniques.

As used herein, the terms, "specific" and "specificity" refer to the ability of the selective binding agents to bind to human  $huE3\alpha$  polypeptides. It will be appreciated, however, that the selective binding agents may also bind orthologs of huE3 $\alpha$ , polypeptides, that is, interspecies versions of E3 $\alpha$ , such as mouse and rat E3 $\alpha$ polypeptides. A perferred embodiment relates to antibodies that are highly specific to  $huE3\alpha$  polypeptides yet do not cross-react (that is, they fail to bind) with specificity to non-huE3α polypeptides.

10

5

The term "antigen" refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antibody, which is additionally capable of inducing an animal to produce antibodies capable of binding to an epitope of that antigen. An antigen can have one or more epitopes. The specific binding reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which can be evoked by other antigens.

used to prepare huE3α selective binding agents using methods known in the art.

Thus, antibodies and antibody fragments that bind huE3a polypeptides are within the

scope of the present invention. Antibody fragments include those portions of the

antibody which bind to an epitope on the huE3a polypeptide. Examples of such

fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-

length antibodies. Other binding fragments include those generated by recombinant

DNA techniques, such as the expression of recombinant plasmids containing nucleic

acid sequences encoding antibody variable regions. These antibodies may be, for

example, polyclonal monospecific polyclonal, monoclonal, recombinant, chimeric,

Human E3α polypeptides, fragments, variants, and derivatives may be

15

20

25

30

Relatedness of Nucleic Acid Molecules and/or Polypeptides

humanized, human, single chain, and/or bispecific.

The term "identity", as known in the art, refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic

acid molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between nucleic acid molecule or polypeptide sequences, as the case may be, as determined by the match between strings of two or more nucleotide or two or more amino acid sequences. "Identity" measures the percent of identical matches between two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer programs (*i.e.*, "algorithms").

The term "similarity" is a related concept, but in contrast to "identity", refers to a measure of similarity which includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, 10/20 identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If in the same example, there are 5 more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (15/20). Therefore, in cases where there are conservative substitutions, the degree of similarity between two polypeptide sequences will be higher than the percent identity between those two sequences.

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates or other materials with which it is naturally found when total DNA is isolated from the source cells, (2) is not linked to all or a portion of a polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecule(s) or other contaminants that are found in its natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, phophylactic or research use.

The term "isolated polypeptide" refers to a polypeptide of the present invention that (1) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates or other materials with which it is naturally found when isolated from the source cell, (2) is not linked (by covalent or noncovalent interaction) to all or

20

15

5

10

25

They give divisit over the separate production of the production of the second state o

a portion of a polypeptide to which the "isolated polypeptide" is linked in nature, (3) is operably linked (by covalent or noncovalent interaction) to a polypeptide with which it is not linked in nature, or (4) does not occur in nature. Preferably, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic or research use.

The term "conservative amino acid substitution" refers to a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. For example, a conservative substitution results from the replacement of a non-polar residue in a polypeptide with any other non-polar residue. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for "alanine scanning mutagenesis." General rules for conservative amino acid substitutions are set forth in Table II.

15

10

Table II

Amino Acid Substitutions

	Original	Exemplary Substitutions	Preferred Substitutions
5	Residues		
	Ala	Val, Leu, Ile	Val
	Arg	Lys, Gln, Asn	Lys
	Asn	Gln	Gln
	Asp	Glu	Glu
10	Cys	Ser, Ala	Ser
	Gln	Asn	Asn
	Glu	Asp	Asp
	Gly	Pro, Ala	Ala
•	His	Asn, Gln, Lys, Arg	Arg
15	Ile	Leu, Val. Met, Ala,	Leu
		Phe, Norleucine	
	Leu	Norleucine, Ile,	Ile
		Val, Met, Ala, Phe	
	Lys	Arg, 1,4 Diamino-butyric	Arg
		Acid, Gln, Asn	
	Met	Leu, Phe, Ile	Leu
	Phe	Leu, Val, Ile, Ala, Tyr	Leu
20	Pro	Ala	Gly
	Ser	Thr, Ala, Cys	Thr
	Thr	Ser	Ser
	Trp	Tyr, Phe	Tyr
	Tyr	Trp, Phe, Thr, Ser	Phe
25	Val	Ile, Met, Leu, Phe,	Leu
		Ala, Norleucine	

Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties. It will be appreciated by those skilled in the art the nucleic acid and polypeptide molecules

described herein may be chemically synthesized as well as produced by recombinant means.

Conservative modifications to the amino acid sequence (and the corresponding modifications to the encoding nucleotides) will produce  $huE3\alpha$  polypeptides having functional and chemical characteristics similar to those of naturally occurring  $huE3\alpha$  polypeptides. In contrast, substantial modifications in the functional and/or chemical characteristics of  $huE3\alpha$  polypeptides may be accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues may be divided into classes based on common side chain properties:

- 1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
- 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- 3) acidic: Asp, Glu;
- 4) basic: His, Lys, Arg;
- 5) residues that influence chain orientation: Gly, Pro; and
- 6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the human  $E3\alpha$  polypeptide that are homologous with non-human  $E3\alpha$  polypeptides, or into the non-homologous regions of the molecule.

Identity and similarity of related nucleic acid molecules and polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M.

15

10

5

20

30

Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math., 48: 1073, 1988.

Preferred methods to determine identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are described in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res., 12: 387, 1984; Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol., 215: 403-410, 1990). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al., NCB/NLM/NIH Bethesda, MD 20894; Altschul et al., supra). The well known Smith Waterman algorithm may also be used to determine identity.

Certain alignment schemes for aligning two amino acid sequences may result in the matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full length sequences. Accordingly, in a preferred embodiment, the selected alignment method (GAP program) will result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span", as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal; the "average diagonal" is the average of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff *et al.*, *Atlas of Protein Sequence and Structure*, vol. 5, supp.3 (1978) for the PAM 250 comparison matrix; Henikoff *et al.*, *Proc. Natl. Acad. Sci* USA, 89: 10915-10919, 1992 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

20

15

5

10

30

10

15

20

25

30

Preferred parameters for a polypeptide sequence comparison include the following:

Algorithm: Needleman et al., J. Mol. Biol., 48, 443-453, 1970;

Comparison matrix: BLOSUM 62 from Henikoff et al., Proc. Natl. Acad. Sci.

USA, 89: 10915-10919, 1992)

Gap Penalty: 12

Gap Length Penalty: 4

Threshold of Similarity: 0

The GAP program is useful with the above parameters. The aforementioned parameters are the default parameters for polypeptide comparisons (along with no penalty for end gaps) using the GAP algorithm.

Preferred parameters for nucleic acid molecule sequence comparisons include the following:

Algorithm: Needleman et al., J. Mol Biol., 48: 443-453, 1970;

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

The GAP program is also useful with the above parameters. The aforementioned parameters are the default parameters for nucleic acid molecule comparisons.

Other exemplary algorithms, gap opening penalties, gap extension penalties, comparison matrices, thresholds of similarity, etc. may be used by those of skill in the art, including those set forth in the Program Manual, Wisconsin Package, Version 9, September, 1997. The particular choices to be made will be apparent to those of skill in the art and will depend on the specific comparison to be made, such as DNA to DNA, protein to protein, protein to DNA; and additionally, whether the comparison is between given pairs of sequences (in which case GAP or BestFit are generally preferred) or between one sequence and a large database of sequences (in which case FASTA or BLASTA are preferred).

## **Synthesis**

It will be appreciated by those skilled in the art the nucleic acid and polypeptide molecules described herein may be produced by recombinant and other means.

5

10

15

#### **Nucleic Acid Molecules**

positives obtained from the screen.

Recombinant DNA methods used herein are generally those set forth in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and/or Ausubel et al., eds., Current Protocols in Molecular Biology, Green Publishers Inc. and Wiley and Sons, NY (1994). The present invention provides for nucleic acid molecules as described herein and methods for obtaining the molecules. Human E3α (huE3α) refers to the nucleotide sequence of either huE3αI or huE3αII. A gene or cDNA encoding a huE3α polypeptide or fragment thereof may be obtained by hybridization screening of a genomic or cDNA library, or by PCR amplification. Where a gene encoding a huE3α polypeptide has been identified from one species, all or a portion of that gene may be used as a probe to identify corresponding genes from other species (orthologs) or related genes from the same species (homologs). The probes or primers may be used to screen cDNA libraries from various tissue sources believed to express the huE3a gene. In addition, part or all of a nucleic acid molecule having the sequence as set forth in SEQ ID NOS: 1 or 3 may be used to screen a genomic library to identify and isolate a gene encoding a huE3\alpha polypeptide. Typically, conditions of moderate or high stringency will be employed for screening to minimize the number of false

25

20

Nucleic acid molecules encoding huE3 $\alpha$  polypeptides may also be identified by expression cloning which employs the detection of positive clones based upon a property of the expressed protein. Typically, nucleic acid libraries are screened by the binding of an antibody or other binding partner (e.g., receptor or ligand) to cloned proteins which are expressed and displayed on a host cell surface. The antibody or binding partner is modified with a detectable label to identify those cells expressing the desired clone.

Additional methods of predicting secondary structure include "threading" (Jones et al., Current Opin. Struct. Biol., 7(3):377-87 (1997); Sippl et al., Structure, 4(1):15-9 (1996)), "profile analysis" (Bowie et al., Science, 253:164-170 (1991); Gribskov et al., Meth. Enzym., 183:146-159 (1990); Gribskov et al., Proc. Nat. Acad. Sci., 84(13):4355-4358 (1987)), and "evolutionary linkage" (See Home, supra, and Brenner, supra 1997).

Another means of preparing a nucleic acid molecule encoding a huE3 $\alpha$  polypeptide, including a fragment or variant, is chemical synthesis using methods well known to the skilled artisan such as those described by Engels *et al.*, *Angew. Chem. Intl. Ed.*, 28: 716-734, 1989. These methods include, *inter alia*, the phosphotriester, phosphoramidite, and H-phosphonate methods for nucleic acid synthesis. A preferred method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, the DNA encoding the huE3 $\alpha$  polypeptide will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides can be synthesized as several fragments using these methods. The fragments can then be ligated together to form the full length huE3 $\alpha$  polypeptide. Usually, the DNA fragment encoding the amino terminus of the polypeptide will have an ATG, which encodes a methionine residue. This methionine may or may not be present on the mature form of the huE3 $\alpha$  polypeptide, depending on whether the polypeptide produced in the host cell is designed to be secreted from that cell.

In some cases, it may be desirable to prepare nucleic acid molecules encoding huE3α polypeptide variants. Nucleic acid molecules encoding variants may be produced using site directed mutagenesis, PCR amplification, or other appropriate methods, where the primer(s) have the desired point mutations (see Sambrook *et al.*, *supra*, and Ausubel *et al.*, *supra*, for descriptions of mutagenesis techniques). Chemical synthesis using methods described by Engels *et al.*, *supra*, may also be used to prepare such variants. Other methods known to the skilled artisan may be used as well.

In certain embodiments, nucleic acid variants contain codons which have been altered for the optimal expression of a huE3 $\alpha$  polypeptide in a given host cell. Particular codon alterations will depend upon the huE3 $\alpha$  polypeptide(s) and host cell(s) selected for expression. Such "codon optimization" can be carried out by a variety of methods, for example, by selecting codons which are preferred for use in highly

10

5

15

20

25

expressed genes in a given host cell. Computer algorithms which incorporate codon frequency tables such as "Ecohigh.cod" for codon preference of highly expressed bacterial genes may be used and are provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI. Other useful codon frequency tables include "Celegans\_high.cod", "Celegans\_low.cod", "Drosophila\_high.cod", "Human high.cod", "Maize high.cod", and "Yeast high.cod".

In other embodiments, nucleic acid molecules encode huE3 $\alpha$  variants with conservative amino acid substitutions as described herein, huE3 $\alpha$  variants comprising an addition and/or a deletion of one or more N-linked or O-linked glycosylation sites, huE3 $\alpha$  variants having deletions and/or substitutions of one or more cysteine residues, or huE3 $\alpha$  polypeptide fragments as described herein. In addition, nucleic acid molecules may encode any combination of huE3 $\alpha$  variants, fragments, and fusion polypeptides described herein.

## **Vectors and Host Cells**

15

20

25

5

10

A nucleic acid molecule encoding a huE3 $\alpha$  polypeptide is inserted into an appropriate expression vector using standard ligation techniques wherein huE3 $\alpha$  refers to either the polypeptide sequence of huE3 $\alpha$ I or huE3 $\alpha$ II. The vector is typically selected to be functional in the particular host cell employed (*i.e.*, the vector is compatible with the host cell machinery such that amplification of the gene and/or expression of the gene can occur). A nucleic acid molecule encoding a huE3 $\alpha$  polypeptide may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems), and/or eukaryotic host cells. Selection of the host cell will depend in part on whether a huE3 $\alpha$  polypeptide is to be post-translationally modified (*e.g.*, glycosylated and/or phosphorylated). If so, yeast, insect, or mammalian host cells are preferable. For a review of expression vectors, see *Meth. Enz.*, v.185, D.V. Goeddel, ed. Academic Press Inc., San Diego, CA (1990).

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences" in certain embodiments will typically include one or more of the following nucleotides: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor

. 5

10

15

20

25

30

splice site, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Each of these sequences is discussed below.

Optionally, the vector may contain a "tag"-encoding sequence, *i.e.*, an oligonucleotide sequence located at the 5' or 3' end of the huE3 $\alpha$  polypeptide coding sequence; the oligonucleotide molecule encodes polyHis (such as hexaHis), or another "tag" such as FLAG, HA (hemaglutinin influenza virus) or *myc* for which commercially available antibodies exist. This tag is typically fused to the polypeptide upon expression of the polypeptide, and can serve as a means for affinity purification of the huE3 $\alpha$  polypeptide from the host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can subsequently be removed from the purified huE3 $\alpha$  polypeptide by various means such as using certain peptidases for cleavage.

Flanking sequences may be homologous (i.e., from the same species and/or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), or synthetic, or the flanking sequences may be native sequences which normally function to regulate huE3 $\alpha$  polypeptide expression. As such, the source of a flanking sequence may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequences is functional in, and can be activated by, the host cell machinery.

The flanking sequences useful in the vectors of this invention may be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein other than endogenous  $huE3\alpha$  gene flanking sequences will have been previously identified by mapping and/or by restriction endonuclease digestion and can thus be isolated from the proper tissue source using the appropriate restriction endonucleases. In some cases, the full nucleotide sequence of one or more flanking sequence may be known. Here, the flanking sequence may be synthesized using the methods described herein for nucleic acid synthesis or cloning.

10

15

20

Where all or only a portion of the flanking sequence is known, it may be obtained using PCR and/or by screening a genomic library with suitable oligonucleotide and/or flanking sequence fragments from the same or another species. Where the flanking sequence is not known, a fragment of DNA containing a flanking sequence may be isolated from a larger piece of DNA that may contain, for example, a coding sequence or even another gene or genes. Isolation may be accomplished by restriction endonuclease digestion to produce the proper DNA fragment followed by isolation using agarose gel purification, Qiagen® column chromatography (Chatsworth, CA), or other methods known to the skilled artisan. The selection of suitable enzymes to accomplish this purpose will be readily apparent to one of ordinary skill in the art.

An origin of replication is typically a part of those prokaryotic expression vectors purchased commercially, and the origin aids in the amplification of the vector in a host cell. Amplification of the vector to a certain copy number can, in some cases, be important for the optimal expression of the huE3α polypeptide. If the vector of choice does not contain an origin of replication site, one may be chemically synthesized based on a known sequence, and ligated into the vector. For example, the origin of replication from the plasmid pBR322 (Product No. 303-3s, New England Biolabs, Beverly, MA) is suitable for most gram-negative bacteria and various origins (e.g., SV40, polyoma, adenovirus, vesicular stomatitus virus (VSV) or papillomaviruses such as HPV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (for example, the SV40 origin is often used only because it contains the early promoter).

A transcription termination sequence is typically located 3' of the end of a polypeptide coding region and serves to terminate transcription. Usually, a transcription termination sequence in prokaryotic cells is a G-C rich fragment followed by a poly T sequence. While the sequence is easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described herein.

A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other

25

toxins, e.g., ampicillin, tetracycline, or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex media. Preferred selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the tetracycline resistance gene. A neomycin resistance gene may also be used for selection in prokaryotic and eukaryotic host cells.

Other selection genes may be used to amplify the gene which will be expressed. Amplification is the process wherein genes which are in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Examples of suitable selectable markers for mammalian cells include dihydrofolate reductase (DHFR) and thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of the selection gene present in the vector. Selection pressure is imposed by culturing the transformed cells under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to the amplification of both the selection gene and the DNA that encodes  $huE3\alpha$  polypeptides. As a result, increased quantities of  $huE3\alpha$  polypeptides are synthesized from the amplified DNA.

A ribosome binding site is usually necessary for translation initiation of mRNA and is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). The element is typically located 3′ to the promoter and 5′ to the coding sequence of the huE3α polypeptide to be expressed. The Shine-Dalgarno sequence is varied but is typically a polypurine (*i.e.*, having a high A-G content). Many Shine-Dalgarno sequences have been identified, each of which can be readily synthesized using methods set forth above and used in a prokaryotic vector.

A leader, or signal, sequence may be used to direct a huE3 $\alpha$  polypeptide out of the host cell. Typically, a nucleotide sequence encoding the signal sequence is positioned in the coding region of the huE3 $\alpha$  nucleic acid molecule, or directly at the 5' end of the huE3 $\alpha$  polypeptide coding region. Many signal sequences have been identified, and any of those that are functional in the selected host cell may be used in conjunction with the huE3 $\alpha$  nucleic acid molecule. Therefore, a signal sequence may be homologous (naturally occurring) or heterologous to the huE3 $\alpha$  gene or cDNA.

20

15

5

10

25

Additionally, a signal sequence may be chemically synthesized using methods described herein. In most cases, the secretion of a huE3 $\alpha$  polypeptide from the host cell via the presence of a signal peptide will result in the removal of the signal peptide from the huE3 $\alpha$  polypeptide. The signal sequence may be a component of the vector, or it may be a part of huE3 $\alpha$  DNA that is inserted into the vector.

Included within the scope of this invention is the use of either a nucleotide sequence encoding a native huE3 $\alpha$  signal sequence joined to a huE3 $\alpha$  polypeptide coding region or a nucleotide sequence encoding a heterologous signal sequence joined to a huE3 $\alpha$  polypeptide coding region. The heterologous signal sequence selected should be one that is recognized and processed, *i.e.*, cleaved by a signal peptidase, by the host cell. For prokaryotic host cells that do not recognize and process the native huE3 $\alpha$  signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin II leaders. For yeast secretion, the native huE3 $\alpha$  signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders. In mammalian cell expression the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.

In some cases, such as where glycosylation is desired in a eukaryotic host cell expression system, one may manipulate the various presequences to improve glycosylation or yield. For example, one may alter the peptidase cleavage site of a particular signal peptide, or add presequences, which also may affect glycosylation. The final protein product may have, in the -1 position (relative to the first amino acid of the mature protein) one or more additional amino acids incident to expression, which may not have been totally removed. For example, the final protein product may have one or two amino acid residues found in the peptidase cleavage site, attached to the N-terminus. Alternatively, use of some enzyme cleavage sites may result in a slightly truncated form of the desired huE3α polypeptide, if the enzyme cuts at such area within the mature polypeptide.

In many cases, transcription of a nucleic acid molecule is increased by the presence of one or more introns in the vector; this is particularly true where a polypeptide is produced in eukaryotic host cells, especially mammalian host cells. The introns used may be naturally occurring within the  $huE3\alpha$  gene, especially where the

10

5

15

20

25

10

15

20

25

30

gene used is a full length genomic sequence or a fragment thereof. Where the intron is not naturally occurring within the gene (as for most cDNAs), the intron(s) may be obtained from another source. The position of the intron with respect to flanking sequences and the huE3α gene is generally important, as the intron must be expressed to be effective. Thus, when a huE3α cDNA molecule is being expressed, the preferred position for the intron is 3' to the transcription start site, and 5' to the polyA transcription termination sequence. Preferably, the intron or introns will be located on one side or the other (*i.e.*, 5' or 3') of the cDNA such that it does not interrupt the coding sequence. Any intron from any source, including any viral, prokaryotic and eukaryotic (plant or animal) organisms, may be used to practice this invention, provided that it is compatible with the host cell(s) into which it is inserted. Also included herein are synthetic introns. Optionally, more than one intron may be used in the vector.

The expression and cloning vectors of the present invention will each typically contain a promoter that is recognized by the host organism and operably linked to the molecule encoding a huE3a polypeptide. Promoters are untranscribed sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of the structural gene. Promoters are conventionally grouped into one of two classes, inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature. Constitutive promoters, on the other hand, initiate continual gene product production; that is, there is little or no control over gene expression. A large number of promoters, recognized by a variety of potential host cells, are well known. A suitable promoter is operably linked to the DNA encoding a huE3a polypeptide by removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector. The native huE3α promoter sequence may be used to direct amplification and/or expression of huE3α DNA. A heterologous promoter is preferred, however, if it permits greater transcription and higher yields of the expressed protein as compared to the native promoter, and if it is compatible with the host cell system that has been selected for use.

Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems; alkaline phosphatase, a tryptophan (trp) promoter system; and hybrid promoters such as the tac promoter. Other known bacterial promoters are also suitable. Their sequences have been published, thereby enabling one skilled in the art to ligate them to the desired DNA sequence(s), using linkers or adapters as needed to supply any useful restriction sites.

Suitable promoters for use with yeast hosts are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for use with mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowl pox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, *e.g.*, heat-shock promoters and the actin promoter.

Additional promoters which may be of interest in controlling  $huE3\alpha$ gene transcription include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, Nature, 290: 304-310, 1981); the CMV promoter; the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell, 22: 787-797, 1980); the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci. USA, 78: 144-1445, 1981); the regulatory sequences of the metallothionine gene (Brinster et al., Nature, 296: 39-42, 1982); prokaryotic expression vectors such as the beta-lactamase promoter (Villa-Kamaroff, et al., Proc. Natl. Acad. Sci. USA, 75: 3727-3731, 1978); or the tac promoter (DeBoer, et al., Proc. Natl. Acad. Sci. USA, 80: 21-25, 1983). Also of interest are the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: the elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell, 38: 639-646, 1984; Ornitz et al., Cold Spring Harbor Symp. Quant. Biol., 50: 399-409, 1986; MacDonald, Hepatology, 7: 425-515, 1987); the insulin gene control region which is active in pancreatic beta cells (Hanahan, Nature, 315: 115-122, 1985); the immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., Cell, 38: 647-658 (1984); Adames et al., Nature, 318: 533-538 (1985); Alexander et al., Mol. Cell. Biol., 7: 1436-1444,

15

10

5

20

25

10

15

20

1987); the mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, *Cell*, *45*: 485-495, 1986); the albumin gene control region which is active in liver (Pinkert *et al.*, *Genes and Devel.*, *1*: 268-276, 1987); the alphafetoprotein gene control region which is active in liver (Krumlauf *et al.*, *Mol. Cell. Biol.*, *5*: 1639-1648, 1985; Hammer *et al.*, *Science*, *235*: 53-58, 1987); the alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, *Genes and Devel.*, *1*: 161-171, 1987); the beta-globin gene control region which is active in myeloid cells (Mogram *et al.*, *Nature*, *315*: 338-340, 1985; Kollias *et al.*, *Cell*, *46*: 89-94, 1986); the myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, *Cell*, *48*: 703-712, 1987); the myosin light chain-2 gene control region which is active in skeletal muscle (Sani, *Nature*, *314*: 283-286, 1985); and the gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, Science, *234*: 1372-1378, 1986).

An enhancer sequence may be inserted into the vector to increase the transcription of a DNA encoding a huE3 $\alpha$  polypeptide of the present invention by higher eukaryotes. Enhancers are cis-acting elements of DNA, usually about 10-300 bp in length, that act on the promoter to increase its transcription. Enhancers are relatively orientation and position independent. They have been found 5' and 3' to the transcription unit. Several enhancer sequences available from mammalian genes are known (e.g., globin, elastase, albumin, alpha-feto-protein and insulin). Typically, however, an enhancer from a virus will be used. The SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers are exemplary enhancing elements for the activation of eukaryotic promoters. While an enhancer may be spliced into the vector at a position 5' or 3' to huE3 $\alpha$  DNA, it is typically located at a site 5' from the promoter.

Expression vectors of the invention may be constructed from a starting vector such as a commercially available vector. Such vectors may or may not contain all of the desired flanking sequences. Where one or more of the desired flanking sequences are not already present in the vector, they may be individually obtained and ligated into the vector. Methods used for obtaining each of the flanking sequences are well known to one skilled in the art.

25

10

15

20

Preferred vectors for practicing this invention are those which are compatible with bacterial, insect, and mammalian host cells. Such vectors include, *inter alia*, pCRII, pCR3, and pcDNA3.1 (Invitrogen Company, Carlsbad, CA), pBSII (Stratagene Company, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlueBacII; Invitrogen), pDSR-alpha (PCT Publication No. WO90/14363) and pFastBacDual (Gibco/BRL, Grand Island, NY).

Additional suitable vectors include, but are not limited to, cosmids, plasmids, or modified viruses, but it will be appreciated that the vector system must be compatible with the selected host cell. Such vectors include, but are not limited to plasmids such as Bluescript® plasmid derivatives (a high copy number ColE1-based phagemid, Stratagene Cloning Systems Inc., La Jolla CA), PCR cloning plasmids designed for cloning Taq-amplified PCR products (e.g., TOPO<sup>TM</sup> TA Cloning® Kit, PCR2.1® plasmid derivatives, Invitrogen, Carlsbad, CA), and mammalian, yeast, or virus vectors such as a baculovirus expression system (pBacPAK plasmid derivatives, Clontech, Palo Alto, CA). The recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, or other known techniques.

After the vector has been constructed and a nucleic acid molecule encoding a huE3 $\alpha$  polypeptide has been inserted into the proper site of the vector, the completed vector may be inserted into a suitable host cell for amplification and/or polypeptide expression. Host cells may be prokaryotic host cells (such as *E. coli*) or eukaryotic host cells (such as a yeast cell, an insect cell, or a vertebrate cell). The host cell, when cultured under appropriate conditions, synthesizes a huE3 $\alpha$  polypeptide which can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted). The selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity, such as glycosylation or phosphorylation, and ease of folding into a biologically active molecule.

A number of suitable host cells are known in the art and many are available from the American Type Culture Collection (ATCC), 10801 University Boulavard, Manassas, VA 20110-2209. Examples include, but are not limited to, mammalian cells, such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61) CHO DHFR-cells (Urlaub *et al.*, *Proc. Natl. Acad. Sci. USA*, 97: 4216-4220, 1980), human

25

embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRL1573), or 3T3 cells (ATCC No. CCL92). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines, are the monkey COS-1 (ATCC No. CRL1650) and COS-7 cell lines (ATCC No. CRL1651), and the CV-1 cell line (ATCC No. CCL70). Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or may contain a dominantly acting selection gene. Other suitable mammalian cell lines include but are not limited to, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines, which are available from the American Type Culture Collection, Manassas, VA. Each of these cell lines is known by and available to those skilled in the art of protein expression.

Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of *E. coli* (*e.g.*, HB101, (ATCC No. 33694) DH5α, DH10, and MC1061 (ATCC No. 53338)) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas spp.*, other *Bacillus spp.*, *Streptomyces spp.*, and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for the expression of the polypeptides of the present invention. Preferred yeast cells include, for example, *Saccharomyces cerivisae* and *Pichia pastoris*.

Additionally, where desired, insect cell systems may be utilized in the methods of the present invention. Such systems are described for example in Kitts *et al.*, *Biotechniques*, *14*: 810-817 (1993); Lucklow, *Curr. Opin. Biotechnol.*, *4*: 564-572, 1993; and Lucklow *et al. J. Virol.*, *67*: 4566-4579, 1993. Preferred insect cells are Sf-9 and Hi5 (Invitrogen, Carlsbad, CA).

The transformation of an expression vector for a huE3 $\alpha$  polypeptide into a selected host cell may be accomplished by well known methods including methods such as transfection, infection, calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method or other known techinques. The method selected will in part be a function of the type of host cell to be used. These methods and

20

25

5

10

15

other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook et al., supra.

One may also use transgenic animals to express glycosylated huE3 $\alpha$  polypeptides. For example, one may use a transgenic milk-producing animal (a cow or goat, for example) and obtain the present glycosylated polypeptide in the animal milk. One may also use plants to produce huE3 $\alpha$  polypeptides, however, in general, the glycosylation occurring in plants is different from that produced in mammalian cells, and may result in a glycosylated product which is not suitable for human therapeutic use.

### Polypeptide Production

Host cells comprising a huE3α expression vector may be cultured using standard media well known to the skilled artisan. The huE3α expression vector refers a vector which expresses either huE3αI or huE3αII. The media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells include, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells are, Roswell Park Memorial Institute medium 1640 (RPMI 1640), Minimal Essential Medium (MEM), and/or Dulbecco's Modified Eagle Medium (DMEM), all of which may be supplemented with serum and/or growth factors as indicated by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate, and/or fetal calf serum as necessary.

Typically, an antibiotic or other compound useful for selective growth of transformed cells is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin. Other compounds for selective growth include ampicillin, tetracycline, and neomycin.

The amount of a huE3 $\alpha$  polypeptide produced by a host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, High Performance Liquid Chromatography (HPLC) separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

15

5

10

20

25

If a huE3 $\alpha$  polypeptide has been designed to be secreted from the host cells, the majority of polypeptide may be found in the cell culture medium. If however, the huE3 $\alpha$  polypeptide is not secreted from the host cells, it will be present in the cytoplasm and/or the nucleus (for eukaryotic host cells) or in the cytosol (for bacterial host cells).

For a huE3 $\alpha$  polypeptide situated in the host cell cytoplasm and/or nucleus, the host cells are typically first disrupted mechanically or with a detergent to release the intracellular contents into a buffered solution. Human E3 $\alpha$  polypeptide can then be isolated from this solution.

10

15

5

The purification of a huE3α polypeptide from solution can be accomplished using a variety of techniques. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine (huE3α polypeptide/hexaHis) or other small peptide such as FLAG (Eastman Kodak Co., New Haven, CT) or *myc* (Invitrogen, Carlsbad, CA) at either its carboxyl or amino terminus, it may essentially be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag or for the polypeptide directly (*i.e.*, a monoclonal antibody specifically recognizing and binding to the huE3α polypeptide). For example, polyhistidine binds with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen® nickel columns) can be used for purification of huE3α polypeptide/polyHis. See for example, Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, Section 10.11.8, John Wiley & Sons, New York (1993).

20

Where a huE3 $\alpha$  polypeptide is prepared without a tag attached, and no antibodies are available, other well known procedures for purification can be used. Such procedures include, without limitation, ion exchange chromatography, molecular sieve chromatography, High Performance Liquid Chromatography (HPLC), native gel electrophoresis in combination with gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific, San Francisco, CA). In some cases, two or more of these techniques may be combined to achieve increased purity.

30

25

If a huE3α polypeptide is produced intracellularly, the intracellular material (including inclusion bodies for gram-negative bacteria) can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be lysed to release the contents of the periplasm/cytoplasm by French press, homogenization, and/or sonication followed by centrifugation.

If a huE3α polypeptide has formed inclusion bodies in the cytosol, the inclusion bodies can often bind to the inner and/or outer cellular membranes and thus will be found primarily in the pellet material after centrifugation. The pellet material can then be treated at pH extremes or with chaotropic agent such as a detergent, guanidine, guanidine derivatives, urea, or urea derivatives in the presence of a reducing agent such as dithiothreitol at alkaline pH or tris carboxyethyl phosphine at acid pH to release, break apart, and solubilize the inclusion bodies. The solubized huE3α polypeptide can then be analyzed using gel electrophoresis, immunoprecipitation or the like. If it is desired to isolate the huE3α polypeptide, isolation may be accomplished using standard methods such as those described herein and in Marston *et al.*, *Meth. Enz.*, 182: 264-275 1990.

In some cases, a huE3α polypeptide may not be biologically active upon isolation. Various methods for "refolding" or converting the polypeptide to its tertiary structure and generating disulfide linkages, can be used to restore biological activity. Such methods include exposing the solubilized polypeptide to a pH usually above 7 and in the presence of a particular concentration of a chaotrope. The selection of chaotrope is very similar to the choices used for inclusion body solubilization, but usually the chaotrope is used at a lower concentration and is not necessarily the same as chaotropes used for the solubilization. In most cases the refolding/oxidation solution will also contain a reducing agent or the reducing agent plus its oxidized form in a specific ratio to generate a particular redox potential allowing for disulfide shuffling to occur in the formation of the protein's cysteine bridge(s). Some of the commonly used redox couples include cysteine/cystamine, glutathione (GSH)/dithiobis GSH, cupric chloride, dithiothreitol(DTT)/ dithiane DTT, and 2-2mercaptoethanol(βME)/dithi(βME). A cosolvent may be used to increase the efficiency of the refolding, and the more common reagents used for this purpose include glycerol, polyethylene glycol of various molecular weights, arginine and the like.

If inclusion bodies are not formed to a significant degree upon expression of a huE3 $\alpha$  polypeptide, then the polypeptide will be found primarily in the supernatant after centrifugation of the cell homogenate. The polypeptide may be further isolated from the supernatant using methods such as those described herein.

In situations where it is preferable to partially or completely purify a huE3α polypeptide such that it is partially or substantially free of contaminants, standard methods known to those skilled in the art may be used. Such methods include, without limitation, separation by electrophoresis followed by electroelution, various types of

20

5

10

15 ±

25

10

15

20

25

30

chromatography (affinity, immunoaffinity, molecular sieve, and/or ion exchange), and/or high pressure liquid chromatography. In some cases, it may be preferable to use more than one of these methods for complete purification.

Human E3 $\alpha$  polypeptides, including fragments, variants, and/or derivatives thereof may also be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, such as those set forth by Merrifield *et al.*, *J. Am. Chem. Soc.*, 85:2149, 1963, Houghten *et al.*, *Proc Natl Acad. Sci. USA*, 82:5132 1985, and Stewart and Young, *Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, IL (1984). Such polypeptides may be synthesized with or without a methionine on the amino terminus. Chemically synthesized huE3 $\alpha$  polypeptides may be oxidized using methods set forth in these references to form disulfide bridges. Chemically synthesized huE3 $\alpha$  polypeptides are expected to have comparable biological activity to the corresponding huE3 $\alpha$  polypeptides produced recombinantly or purified from natural sources, and thus may be used interchangeably with a recombinant or natural huE3 $\alpha$  polypeptide.

Another means of obtaining a huE3 $\alpha$  polypeptide is via purification from biological samples such as source tissues and/or fluids in which the huE3 $\alpha$  polypeptide is naturally found. Such purification can be conducted using methods for protein purification as described herein. The presence of the huE3 $\alpha$  polypeptide during purification may be monitored using, for example, using an antibody prepared against recombinantly produced huE3 $\alpha$  polypeptide or peptide fragments thereof.

A number of additional methods for producing nucleic acids and polypeptides are known in the art, and the methods can be used to produce polypeptides having specificity for h2520-109. *See* for example, Roberts *et al.*, *Proc. Natl. Acad. Sci U.S.A.*, 94:12297-12303, 1997, which describes the production of fusion proteins between an mRNA and its encoded peptide. See also Roberts, R., *Curr. Opin. Chem. Biol.*, 3:268-273, 1999. Additionally, U.S. Patent No. 5,824,469 describes methods of obtaining oligonucleotides capable of carrying out a specific biological function. The procedure involves generating a heterogeneous pool of oligonucleotides, each having a 5′ randomized sequence, a central preselected sequence, and a 3′ randomized sequence. The resulting heterogeneous pool is introduced into a population of cells that do not exhibit the desired biological function. Subpopulations of the cells are then screened for those which exhibit a predetermined biological function. From that subpopulation, oligonucleotides capable of carrying out the desired biological function are isolated.

10

15

20

25

30

U.S. Patent Nos. 5,763,192; 5,814,476; 5,723,323; and 5,817,483 describe processes for producing peptides or polypeptides. This is done by producing stochastic genes or fragments thereof, and then introducing these genes into host cells which produce one or more proteins encoded by the stochastic genes. The host cells are then screened to identify those clones producing peptides or polypeptides having the desired activity.

Another method for producing peptides or polypeptides is described in PCT/US98/20094 (WO99/15650) filed by Athersys, Inc. Known as "Random Activation of Gene Expression for Gene Discovery" (RAGE-GD), the process involves the activation of endogenous gene expression or over-expression of a gene by in situ recombination methods. For example, expression of an endogenous gene is activated or increased by integrating a regulatory sequence into the target cell which is capable of activating expression of the gene by non-homologous or illegitimate recombination. The target DNA is first subjected to radiation, and a genetic promoter inserted. The promoter eventually locates a break at the front of a gene, initiating transcription of the gene. This results in expression of the desired peptide or polypeptide.

It will be appreciated that these methods can also be used to create comprehensive IL-17 like protein expression libraries, which can subsequently be used. for high throughput phenotypic screening in a variety of assays, such as biochemical assays, cellular assays, and whole organism assays (e.g., plant, mouse, etc.).

## **Chemical Derivatives**

Chemically modified derivatives of the h2520-109 polypeptides may be prepared by one skilled in the art, given the disclosures set forth herein below. h2520-109 polypeptide derivatives are modified in a manner that is different, either in the type or location of the molecules naturally attached to the polypeptide. Derivatives may include molecules formed by the deletion of one or more naturally-attached chemical groups. The polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or a h2520-109 polypeptide variant, may be modified by the covalent attachment of one or more polymers. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Included within the scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

The polymers each may be of any molecular weight and may be branched

5

10

15

20

25

30

or unbranched. The polymers each typically have an average molecular weight of between about 2 kDa to about 100 kDa (the term "about" indicating that in preparations of a water soluble polymer, some molecules will weigh more, some less, than the stated molecular weight). The average molecular weight of each polymer is preferably between about 5 kDa and about 50 kDa, more preferably between about 12 kDa and about 40 kDa and most preferably between about 20 kDa to about 35 kDa. Suitable water soluble polymers or mixtures thereof include, but are not limited to, N-linked or O-linked carbohydrates; sugars; phosphates; polyethylene glycol (PEG) (including the forms of PEG that have been used to derivatize proteins, including mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol), monomethoxy-polyethylene glycol; dextran (such as low molecular weight dextran of, for example about 6 kD;, cellulose, or other carbohydrat-based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional crosslinking molecules which may be used to prepare covalently attached multimers of the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a h2520-109 polypeptide variant.

In general, chemical derivatization may be performed under any suitable condition used to react a protein with an activated polymer molecule. Methods for preparing chemical derivatives of polypeptides will generally comprise the steps of (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions whereby the polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or a h2520-109 polypeptide variant becomes attached to one or more polymer molecules, and (b) obtaining the reaction product(s). The optimal reaction conditions will be determined based on known parameters and the desired result. For example, the larger the ratio of polymer molecules:protein, the greater the percentage of attached polymer molecule. In one embodiment, the h2520-109 polypeptide derivative may have a single polymer molecule moiety at the amino terminus. (See, for example, U.S. Patent No. 5,234,784). The pegylation of the polypeptide may be specifically carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis et al., Focus on Growth Factors, 3:4-10 (1992); EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. For example, pegylation may be carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein. For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

In another embodiment, h2520-109 polypeptides may be chemically coupled to biotin, and the biotin/h2520-109 polypeptide molecules which are conjugated are then allowed to bind to avidin, resulting in tetravalent avidin/biotin/h2520-109 polypeptide molecules. h2520-109 polypeptides may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNP-IgM to form decameric conjugates with a valency of 10.

Generally, conditions which may be alleviated or modulated by the administration of the present h2520-109 polypeptide derivatives include those described herein for h2520-109 polypeptides. However, the h2520-109 polypeptide derivatives disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to the non-derivatized molecules.

## **Selective Binding Agents**

As used herein, ther term "selective binding agent" refers to a molecule which has specificity for one or more huE3 $\alpha$  polypeptides. Suitable selective binding agents include, but are not limited to, antibodies and derivatives thereof, polypeptides, and small molecules. Suitable selective binding agents may be prepared using methods known in the art. An exemplary huE3 $\alpha$  polypeptide selective binding agent of the present invention is capable of binding a certain portion of the huE3 $\alpha$  polypeptide thereby inhibiting the binding of a cofactor to the huE3 $\alpha$  polypeptide.

Human E3 $\alpha$  polypeptides, fragments, variants, and derivatives may be used to prepare selective binding agents (such as antibodies) using methods known in the art; wherein huE3 $\alpha$  polypeptide refers to either huE3 $\alpha$ I or huE3 $\alpha$ II polypeptide. Thus, selective binding agents such as antibodies and antibody fragments that bind huE3 $\alpha$  polypeptides are within the scope of the present invention. The antibodies may

20

25

30

5

10

HOW HITH THE MELLER H. A. MAN HALL BY THE AND AND HER HOUSE HE HALL HE

be polyclonal, monospecific polyclonal, monoclonal, recombinant, chimeric, humanized, human, single chain, and/or bispecific.

Polyclonal antibodies directed toward a huE3 $\alpha$  polypeptide generally are raised in animals (e.g., rabbits or mice) by multiple subcutaneous or intraperitoneal injections of huE3 $\alpha$  polypeptide and an adjuvant. It may be useful to conjugate a huE3 $\alpha$  polypeptide, or a variant, fragment, or derivative thereof to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet heocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals are bled and the serum is assayed for anti-huE3 $\alpha$  antibody titer.

Monoclonal antibodies directed toward huE3α polypeptides are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler *et al.*, *Nature*, *256*: 495-497, 1975 and the human B-cell hybridoma method, Kozbor, *J. Immunol.*. *133*: 3001, 1984; Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). Also provided by the invention are hybridoma cell lines which produce monoclonal antibodies reactive with huE3α polypeptides.

Monoclonal antibodies of the invention may be modified for use as therapeutics. One embodiment is a "chimeric" antibody in which a portion of the heavy and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci.*, 81: 6851-6855 (1985).

In another embodiment, a monoclonal antibody of the invention is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be performed following methods known in the art (Jones *et al.*, *Nature 321*: 522-525, 1986; Riechmann *et al.*, *Nature*, *332*: 323-327 (1988); Verhoeyen *et al.*, *Science 239*:1534-

20

5

10

15

25

10

15

20

25

30

1536, 1988), by substituting rodent complementarity-determining regions (CDRs) for the corresponding regions of a human antibody.

Also encompassed by the invention are human antibodies which bind huE3α polypeptides, fragments, variants and/or derivatives. Such antibodies are produced by immunization with a huE3α antigen (i.e., having at least 6 contiguous amino acids), optionally conjugated to a carrier, of transgenic animals (e.g., mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production. See, for example, Jakobovits et al., Proc. Natl. Acad. Sci., 90: 2551-2555, 1993; Jakobovits et al., Nature 362: 255-258, 1993; Bruggermann et al., Year in Immuno., 7:33 (1993). In one method, such transgenic animals are produced by incapacitating the endogenous loci encoding the heavy and light immunoglobulin chains therein, and inserting loci encoding human heavy and light chain proteins into the genome thereof. Partially modified animals, that is those having less than the full complement of modifications, are then cross-bred to obtain an animal having all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies with human variable regions, including human (rather than e.g., murine) antibodies which are immunospecific for these antigens. See PCT application Nos. PCT/US96/05928 and PCT/US93/06926. Additional methods are described in U.S. Patent No. 5,545,807, PCT application Nos. PCT/US91/245, PCT/GB89/01207, and in EP 546073B1 and EP 546073A1.

Human antibodies can also be produced from phage-display libraries (Hoogenboom *et al.*, *J. Mol. Biol.* 227: 381 1991; Marks *et al.*, *J. Mol. Biol.* 222: 581, 1991). These processes mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Application WO99/10494, filed in the name of Adams *et al.*, which describes the isolation of high affinity and functional agonistic antibodies for MPL- and msk-receptors using such an approach.

Chimeric, CDR grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein. In a preferred embodiment, the antibodies are produced in mammalian host cells, such as CHO cells. Human antibodies may be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

For diagnostic applications, in certain embodiments, anti-huE3 $\alpha$  antibodies typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^{3}$ H,  $^{14}$ C,  $^{32}$ P,  $^{35}$ S, or  $^{125}$ I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase,  $\beta$ -galactosidase, or horseradish peroxidase (Bayer *et al.*, *Meth. Enz.*, *184*: 138-163 1990).

The anti-huE3α antibodies of the invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, *Monoclonal Antibodies: A Manual of Techniques*, pp. 147-158 (CRC Press, Inc., 1987)) for the detection and quantitation of huE3α polypeptides. The antibodies will bind huE3α polypeptides with an affinity which is appropriate for the assay method being employed.

Competitive binding assays rely on the ability of a labeled standard (e.g., a huE3α polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (a huE3α polypeptide) for binding with a limited amount of antihuE3α antibody. The amount of a huE3α polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three part complex. *See*, *e.g.*, U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

The selective binding agents, including anti-h2520-109 antibodies, are also useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be

15

10

5

20

25

administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

5

10

Selective binding agents of the invention, including anti-h2520-109 antibodies, may be used as therapeutics. These therapeutic agents are generally agonists or antagonists, in that they either enhance or reduce, respectively, at least one of the biological activities of a h2520-109 polypeptide. In one embodiment, antagonist antibodies of the invention are antibodies or binding fragments thereof which are capable of specifically binding to a h2520-109 polypeptide and which are capable of inhibiting or eliminating the functional activity of a h2520-109 polypeptide *in vivo* or *in vitro*. In preferred embodiments, the selective binding agent, *e.g.*, an antagonist antibody will inhibit the functional activity of a h2520-109 polypeptide by at least about 50%, and preferably by at least about 80%. In another embodiment, the selective binging agent may be an antibody that is capable of interacting with a h2520-109 binding partner (a ligand, co-factor, or receptor) thereby inhibiting or eliminating h2520-109 activity *in vutro* or *in vivo*. Selective binding agents, including agonist and antagonist anti-h2520-109 antibodies are identified by screening assays which are well known in the art.

20

15

The invention also relates to a kit comprising huE3 $\alpha$  selective binding agents (such as antibodies) and other reagents useful for detecting huE3 $\alpha$  levels in biological samples. Such reagents may include a secondary activity, a detectable label, blocking serum, positive and negative control samples, and detection reagents.

## **Genetically Engineered Non-Human Animals**

25

Additionally included within the scope of the present invention are non-human animals such as mice, rats, or other rodents, rabbits, goats, or sheep, or other farm animals, in which the gene (or genes) encoding a native  $E3\alpha$  ubiquitin ligase polypeptide (such as  $E3\alpha$ I or  $E3\alpha$ II) has (have) been disrupted ("knocked out") such that the level of expression of this gene or genes is (are) significantly decreased or completely abolished. Such animals may be prepared using techniques and methods such as those described in U.S. Patent No. 5,557,032.

30

The present invention further includes non-human animals such as mice, rats, or other rodents, rabbits, goats, or sheep, or other farm animals, in which either the native form of the  $E3\alpha$  ubiquitin ligase polypeptide gene(s) for that animal or a

The present invention further includes non-human animals in which the promoter for one or more of the E3 $\alpha$  ubiquitin ligase polypeptides of the present invention is either activated or inactivated (e.g., by using homologous recombination methods) to alter the level of expression of one or more of the native E3 $\alpha$  ubiquitin ligase polypeptides.

10

The first of the state of the s

5

4.4

WE GIR WITH BUILD

These non-human animals may be used for drug candidate screening. In such screening, the impact of a drug candidate on the animal may be measured. For example, drug candidates may decrease or increase the expression of the  $E3\alpha$  ubiquitin ligase polypeptide gene. In certain embodiments, the amount of  $E3\alpha$  ubiquitin ligase polypeptide, or a fragment(s), that is produced may be measured after the exposure of the animal to the drug candidate. Additionally, in certain embodiments, one may detect the actual impact of the drug candidate on the animal. For example, the overexpression of a particular gene may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease expression of the gene or its ability to prevent or inhibit a pathological condition. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product or its ability to prevent or inhibit a pathological condition.

20

25

30

15

#### Microarray

It will be appreciated that DNA microarray technology can be utilized in accordance with the present invention. DNA microarrays are miniature, high density arrays of nucleic acids positioned on a solid support, such as glass. Each cell or element within the array has numerous copies of a single species of DNA which acts as a target for hybridization for its cognate mRNA. In expression profiling using DNA microarray technology, mRNA is first extracted from a cell or tissue sample and then converted enzymatically to fluorescently labeled cDNA. This material is hybridized to the microarray and unbound cDNA is removed by washing. The expression of discrete genes represented on the array is then visualized by quantitating the amount of labeled

cDNA which is specifically bound to each target DNA. In this way, the expression of thousands of genes can be quantitated in a high throughput, parallel manner from a single sample of biological material.

This high throughput expression profiling has a broad range of applications with respect to the h2520-109 molecules of the invention, including, but not limited to: the identification and validation of h2520-109 disease-related genes as targets

for therapeutics; molecular toxicology of h2520-109 molecules and inhibitors thereof; stratification of populations and generation of surrogate markers for clinical trials; and the enhancement of an h2520-109-related small molecule drug discovery by aiding in the identification of selective compounds in high throughput screens (HTS).

# Assaying for other modulators of huE3a polypeptide activity

In some situations, it may be desirable to identify molecules that are modulators, *i.e.*, antagonists and agonists, of the activity of huE3 $\alpha$  polypeptide.

Natural or synthetic molecules that modulate huE3α polypeptides can be identified using one or more screening assays, such as those described herein. Such molecules may be administered either in an *ex vivo* manner, or in an *in vivo* manner by injection, or by oral delivery, implantation device, or the like.

The following definition is used herein for describing the assays. "Test molecule(s)" refers to the molecule(s) that is/are under evaluation for the ability to modulate (*i.e.*, increase or decrease) the activity of a huE3 $\alpha$  polypeptide. Most commonly, a test molecule will interact directly with a huE3 $\alpha$  polypeptide. However, it is also contemplated that a test molecule may also modulate huE3 $\alpha$  polypeptide activity indirectly, such as by affecting huE3 $\alpha$  gene expression, or by binding to a huE3 $\alpha$  binding partner (*e.g.*, receptor, co-factor or ligand). In one embodiment, a test molecule will bind to a huE3 $\alpha$  polypeptide with an affinity constant of at least about 10<sup>-6</sup> M, preferably about 10<sup>-8</sup> M, more preferably about 10<sup>-9</sup> M, and even more preferably about 10<sup>-10</sup> M.

Methods for identifying compounds which interact with  $huE3\alpha$  polypeptides are encompassed by the present invention. In certain embodiments, a  $huE3\alpha$  polypeptide is incubated with a test molecule under conditions which permit the interaction of the test molecule with a  $huE3\alpha$  polypeptide, and the extent of the interaction can be measured. The test molecule(s) can be screened in a substantially purified form or in a crude mixture. Test molecule(s) can be nucleic acid molecules,

15

5

10

20

25

proteins, peptides, carbohydrates, lipids, or small molecular weight organic or inorganic compounds. Once a set of has been identified as interacting with a huE3 $\alpha$  polypeptide, the molecules may be further evaluated for their ability to increase or decrease huE3 $\alpha$  activity.

5

The measurement of the interaction of test molecules with huE3 $\alpha$  polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test molecules are incubated with a huE3 $\alpha$  polypeptide for a specified period of time, and huE3 $\alpha$  activity is determined by one or more assays described herein for measuring biological activity.

10

The interaction of test molecules with huE3α polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay. Alternatively, modified forms of huE3α polypeptides containing epitope tags as described herein may be used in solution and ammunoassays.

15

In certain embodiments, a huE3 $\alpha$  polypeptide agonist or antagonist may be a protein, peptide, carbohydrate, lipid, or small molecular weight molecule which interacts with huE3 $\alpha$  polypeptide to regulate its activity. Molecules which regulate huE3 $\alpha$  polypeptide expression include nucleic acids which are complementary to nucleic acids encoding a huE3 $\alpha$  polypeptide, or are complementary to nucleic acids sequences which direct or control the expression of huE3 $\alpha$  polypeptide, and which act as antisense regulators of expression.

20

Once a set of test molecules has been identified as interacting with a h2520-109 polypeptide, the molecules may be further evaluated for their ability to increase or decrease h2520-109 polypeptide activity. The measurement of the interaction of test molecules with h2520-109 polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test molecules are incubated with a h2520-109 polypeptide for a specified period of time, and h2520-109 polypeptide activity is determined by one or more assays for measuring biological activity.

30

25

The interaction of test molecules with h2520-109 polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay. Alternatively, modified forms of h2520-109 polypeptides containing epitope tags as described herein may be used in immunoassays.

10

15

20

25

30

In the event that h2520-109 polypeptides display biological activity through an interaction with a binding partner (e.g., a receptor, a ligand or a co-factor), a variety of in vitro assays may be used to measure the binding of a h2520-109 polypeptide to the corresponding binding partner (such as a selective binding agent, receptor, ligand, or cofactor). These assays may be used to screen test molecules for their ability to increase or decrease the rate and/or the extent of binding of a h2520-109 polypeptide to its binding partner. In one assay, a h2520-109 polypeptide is immobilized in the wells of a microtiter plate. Radiolabeled h2520-109 binding partner (for example, iodinated h2520-109 binding partner) and the test molecule(s) can then be added either one at a time (in either order) or simultaneously to the wells. After incubation, the wells can be washed and counted using a scintillation counter, for radioactivity to determine the extent to which the binding partner bound to h2520-109 polypeptide. Typically, the molecules will be tested over a range of concentrations, and a series of control wells lacking one or more elements of the test assays can be used for accuracy in the evaluation of the results. An alternative to this method involves reversing the "positions" of the proteins, i.e., immobilizing h2520-109 binding partner to the microtiter plate wells, incubating with the test molecule and radiolabeled h2520-109 polypeptide, and determining the extent of h2520-109 polypeptide binding. See, for example, chapter 18, Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, New York, NY (1995).

As an alternative to radiolabelling, a h2520-109 polypeptide or its binding partner may be conjugated to biotin and the presence of biotinylated protein can then be detected using streptavidin linked to an enzyme, such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), that can be detected colorometrically, or by fluorescent tagging of streptavidin. An antibody directed to a h2520-109 polypeptide or to a h2520-109 binding partner and conjugated to biotin may also be used and can be detected after incubation with enzyme-linked streptavidin linked to AP or HRP.

A h2520-109 polypeptide or a h2520-109 like binding partner can also be immobilized by attachment to agarose beads, acrylic beads or other types of such inert solid phase substrates. The substrate-protein complex can be placed in a solution containing the complementary protein and the test compound. After incubation, the beads can be precipitated by centrifugation, and the amount of binding between a h2520-109 polypeptide and its binding partner can be assessed using the methods described herein. Alternatively, the substrate-protein complex can be immobilized in a column,

10

15

25

20

30

and the test molecule and complementary protein are passed through the column. The formation of a complex between a h2520-109 polypeptide and its binding partner can then be assessed using any of the techniques set forth herein, *i.e.*, radiolabelling, antibody binding or the like.

Another *in vitro* assay that is useful for identifying a test molecule which increases or decreases the formation of a complex between a h2520-109 polypeptide and a h2520-109 binding partner is a surface plasmon resonance detector system such as the BIAcore assay system (Pharmacia, Piscataway, NJ). The BIAcore system may be carried out using the manufacturer's protocol. This assay essentially involves the covalent binding of either h2520-109 polypeptide or a h2520-109 binding partner to a dextran-coated sensor chip which is located in a detector. The test compound and the other complementary protein can then be injected, either simultaneously or sequentially, into the chamber containing the sensor chip. The amount of complementary protein that binds can be assessed based on the change in molecular mass which is physically associated with the dextran-coated side of the sensor chip; the change in molecular mass can be measured by the detector system.

In some cases, it may be desirable to evaluate two or more test compounds together for their ability to increase or decrease the formation of a complex between a h2520-109 polypeptide and a h2520-109 binding partner. In these cases, the assays set forth herein can be readily modified by adding such additional test compound(s) either simultaneous with, or subsequent to, the first test compound. The remainder of the steps in the assay are set forth herein.

In vitro assays such as those described herein may be used advantageously to screen large numbers of compounds for effects on complex formation by h2520-109 polypeptide and h2520-109 binding partner. The assays may be automated to screen compounds generated in phage display, synthetic peptide, and chemical synthesis libraries.

Compounds which increase or decrease the formation of a complex between a h2520-109 polypeptide and a h2520-109 binding partner may also be screened in cell culture using cells and cell lines expressing either h2520-109 polypeptide or h2520-109 binding partner. Cells and cell lines may be obtained from any mammal, but preferably will be from human or other primate, canine, or rodent sources. The binding of a h2520-109 polypeptide to cells expressing h2520-109 binding partner at the surface is evaluated in the presence or absence of test molecules, and the extent of binding may be

10

15

20

25

30

determined by, for example, flow cytometry using a biotinylated antibody to a h2520-109 binding partner. Cell culture assays can be used advantageously to further evaluate compounds that score positive in protein binding assays described herein

Cell cultures can be used to screen the impact of a drug candidate. For example, drug candidates may decrease or increase the expression of the huE3 $\alpha$  polypeptide gene. In certain embodiments, the amount of huE3 $\alpha$  polypeptide or a fragment(s) that is produced may be measured after exposure of the cell culture to the drug candidate. In certain embodiments, one may detect the actual impact of the drug candidate on the cell culture. For example, the overexpression of a particular gene may have a particular impact on the cell culture. In such cases, one may test a drug candidate's ability to increase or decrease the expression of the gene or its ability to prevent or inhibit a particular impact on the cell culture. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product in a cell culture.

A yeast two hybrid system (Chien *et al.*, *Proc. Natl. Acad. Sci. USA*, 88: 9578-9583, 1991) can be used to identify novel polypeptides that bind to a yeast-two hybrid bait construct can be generated in a vector(such as the pAS2-1 form Clontech) which encodes a yeast-two hybrid domain fused to the huE3 $\alpha$  polynucleotide. This bait construct may be used to screen human cDNA libraries wherein the cDNA library sequences are fused to GAL4 activation domains. Positive interactions will result in the activation of a reporter gene such as  $\beta$ -gal. Positive clones emerging from the screening may be characterized further to identify interacting proteins.

### Internalizing Proteins

The TAT protein sequence (from HIV) can be used to internalize proteins into a cell by targeting the lipid bi-layer component of the cell membrane. See e.g., Falwell et al., Proc. Natl. Acad. Sci., 91: 664-668, 1994. For example, an 11 amino acid sequence (YGRKKRRQRRR; SEQ ID NO: 16) of the HIV TAT protein (termed the "protein transduction domain", or TAT PDT) has been shown to mediate delivery of large bioactive proteins such as  $\beta$ -galactosidase and p27Kip across the cytoplasmic membrane and the nuclear membrane of a cell. See Schwarze et al., Science, 285: 1569-1572, 1999; and Nagahara et al., Nature Medicine, 4: 1449-1452, 1998. Schwarze et al. (Science, 285: 1569-72, 1999) demonstrated that cultured cells acquired  $\beta$ -gal

activity when exposed to a fusion of the TAT PDT and  $\beta$ -galactosidase. Injection of mice with the TAT- $\beta$ -gal fusion proteins resulted in  $\beta$ -gal expression in a number of tissues, including liver, kidney, lung, heart, and brain tissue.

It will thus be appreciated that the TAT protein sequence may be used to internalize a desired protein or polypeptide into a cell. In the context of the present invention, the TAT protein sequence can be fused to another molecule such as a  $huE3\alpha$  antagonist (i.e.: anti- $huE3\alpha$  selective binding agent or small molecule) and administered intracellularly to inhibit the activity of the  $huE3\alpha$  molecule. Where desired, the  $huE3\alpha$  protein itself, or a peptide fragment or modified form of  $huE3\alpha$ , may be fused to such a protein transducer for administrating to cells using the procedures, described above.

### Therapeutic Uses

The huE3α nucleic acid molecules, polypeptides, and antagonists thereof (including, but not limited to, anti-huE3α selective binding agents) can be used to treat, diagnose, and/or prevent a number of diseases, conditions, and disorders, including but not limited to cachexia, muscle wasting diseases and other catabolic disorders such as cancer cachexia, renal cachexia, inflammatory cachexia, muscle wasting disorders associated with metabolic acidosis, uremia, burns, hyperthyroidism, Cushing's syndrome and fasting, and denervation atrophy, diabetes mellitus, sepsis and AIDS wasting syndrome.

Those skilled in the art will recognize that many combinations of deletions, insertions, and substitutions (individually or collectively "variant(s)" herein) can be made within the amino acid sequences of the huE3α polypeptide, provided that the resulting molecule is biologically active (e.g., possesses the ability to affect one or more of the diseases and disorders such as those recited herein).

As contemplated by the present invention, a polypeptide, or antagonist thereof (including, but not limited to, anti-huE3α selective binding agents) may be administered as an adjunct to other therapy and also with other pharmaceutical compositions suitable for the indication being treated. A polypeptide and any of one or more additional therapies or pharmaceutical formulations may be administered separately, sequentially, or simultaneously.

In a specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) thereof in combination (pretreatment, post-treatment, or concurrent

20

25

5

10

15

treatment) with secreted or soluble human fas antigen or recombinant versions thereof (WO96/20206 and Mountz *et al.*, *J. Immunology*, *155*: 4829-4837; and EP 510 691. WO96/20206 discloses secreted human fas antigen (native and recombinant, including an Ig fusion protein), methods for isolating the genes responsible for coding the soluble recombinant human fas antigen, methods for cloning the gene in suitable vectors and cell types, and methods for expressing the gene to produce the inhibitors. EP 510 691 teaches DNAs coding for human fas antigen, including soluble fas antigen, vectors expressing for said DNAs and transformants transfected with the vector. When administered parenterally, doses of a secreted or soluble fas antigen fusion protein each are generally from about 1 microgram/kg to about 100 micrograms/kg.

Treatment of the diseases and disorders recited herein can include the use of first line drugs for control of pain and inflammation; these drugs are classified as non-steroidal, anti-inflammatory drugs (NSAIDs). Secondary treatments include corticosteroids, slow acting antirheumatic drugs (SAARDs), or disease modifying (DM) drugs. Information regarding the following compounds can be found in The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck, Sharp & Dohme Research Laboratories, Merck & Co., Rahway, NJ (1992) and in Pharmaprojects, PJB Publications Ltd.

In a specific embodiment, the present invention is directed to the use of a huE3α, or antagonist (including, but not limited to, anti-huE3α selective binding agents) and any of one or more NSAIDs for the treatment of the diseases and disorders recited herein. NSAIDs owe their anti-inflammatory action, at least in part, to the inhibition of prostaglandin synthesis (Goodman and Gilman in "The Pharmacological Basis of Therapeutics," MacMillan 7th Edition (1985)). NSAIDs can be characterized into at least nine groups: (1) salicylic acid derivatives; (2) propionic acid derivatives; (3) acetic acid derivatives; (4) fenamic acid derivatives; (5) carboxylic acid derivatives; (6) butyric acid derivatives; (7) oxicams; (8) pyrazoles and (9) pyrazolones.

In another specific embodiment, the present invention is directed to the use of an huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more salicylic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. Such salicylic acid derivatives, prodrug esters and pharmaceutically acceptable salts thereof comprise: acetaminosalol, aloxiprin, aspirin, benorylate, bromosaligenin, calcium acetylsalicylate, choline magnesium

20

15 .

5

10

25

10

15

20

25

30

trisalicylate, magnesium salicylate, choline salicylate, diflusinal, etersalate, fendosal, gentisic acid, glycol salicylate, imidazole salicylate, lysine acetylsalicylate, mesalamine, morpholine salicylate, 1-naphthyl salicylate, olsalazine, parsalmide, phenyl acetylsalicylate, phenyl salicylate, salacetamide, salicylamide O-acetic acid, salsalate, sodium salicylate and sulfasalazine. Structurally related salicylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of an huE3α polypeptide, or antagonist (including, but not limited to, antihuE3α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more propionic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The propionic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: alminoprofen, benoxaprofen, bucloxic acid, carprofen, dexindoprofen, fenoprofen, flunoxaprofen, fluprofen, flurbiprofen, furcloprofen, ibuprofen, ibuprofen aluminum, ibuproxam, indoprofen, isoprofen, ketoprofen, loxoprofen, miroprofen, naproxen, naproxen sodium, oxaprozin, piketoprofen, pimeprofen, pirprofen, pranoprofen, protizinic acid, pyridoxiprofen, suprofen, tiaprofenic acid and tioxaprofen. Structurally related propionic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In yet another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more acetic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The acetic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: acemetacin, alclofenac, amfenac, bufexamac, cinmetacin, clopirac, delmetacin, diclofenac potassium, diclofenac sodium, etodolac, felbinac, fenclofenac, fenclorac, fenclozic acid, fentiazac, furofenac, glucametacin, ibufenac, indomethacin, isofezolac, isoxepac, lonazolac, metiazinic acid, oxametacin, oxpinac, pimetacin, proglumetacin, sulindac, talmetacin, tiaramide, tiopinac, tolmetin, tolmetin sodium, zidometacin and zomepirac. Structurally related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more fenamic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The fenamic acid derivatives, prodrug esters and pharmaceutically acceptable salts thereof comprise: enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, meclofenamate sodium, medofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, tolfenamic acid and ufenamate. Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more carboxylic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The carboxylic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof which can be used comprise: clidanac, diflunisal, flufenisal, inoridine, ketorolac and tinoridine. Structurally related carboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In yet another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more butyric acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The butyric acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: bumadizon, butibufen, fenbufen and xenbucin. Structurally related butyric acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more oxicams, prodrug esters, or pharmaceutically acceptable salts thereof. The oxicams, prodrug esters, and pharmaceutically acceptable salts thereof comprise: droxicam, enolicam, isoxicam, piroxicam, sudoxicam, tenoxicam and 4-hydroxyl-1,2-benzothiazine 1,1-dioxide 4-(N-phenyl)-carboxamide. Structurally

20

5

10

15

25

10

15

20

25

30

related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more pyrazoles, prodrug esters, or pharmaceutically acceptable salts thereof. The pyrazoles, prodrug esters, and pharmaceutically acceptable salts thereof which may be used comprise: difenamizole and epirizole. Structurally related pyrazoles having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment or, concurrent treatment) with any of one or more pyrazolones, prodrug esters, or pharmaceutically acceptable salts thereof. The pyrazolones, prodrug esters and pharmaceutically acceptable salts thereof which may be used comprise: apazone, azapropazone, benzpiperylon, feprazone, mofebutazone, morazone, oxyphenbutazone, phenylbutazone, pipebuzone, propylphenazone, ramifenazone, suxibuzone and thiazolinobutazone. Structurally related pyrazalones having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more of the following NSAIDs: e-acetamidocaproic acid, S-adenosyl-methionine, 3-amino-4-hydroxybutyric acid, amixetrine, anitrazafen, antrafenine, bendazac, bendazac lysinate, benzydamine, beprozin, broperamole, bucolome, bufezolac, ciproquazone, cloximate, dazidamine, deboxamet, detomidine, difenpiramide, difenpyramide, difisalamine, ditazol, emorfazone, fanetizole mesylate, fenflumizole, floctafenine, flumizole, flunixin, fluproquazone, fopirtoline, fosfosal, guaimesal, guaiazolene, isonixirn, lefetamine HCl, leflunomide, lofemizole, lotifazole, lysin clonixinate, meseclazone, nabumetone, nictindole, nimesulide, orgotein, orpanoxin, oxaceprol, oxapadol, paranyline, perisoxal, perisoxal citrate, pifoxime, piproxen, pirazolac, pirfenidone, proquazone, proxazole, thielavin B, tiflamizole, timegadine, tolectin, tolpadol, tryptamid and those designated by company code number such as

10

15

20

25

30

480156S, AA861, AD1590, AFP802, AFP860, AI77B, AP504, AU8001, BPPC, BW540C, CHINOIN 127, CN100, EB382, EL508, F1044, FK-506, GV3658, ITF182, KCNTEI6090, KME4, LA2851, MR714, MR897, MY309, ONO3144, PR823, PV102, PV108, R830, RS2131, SCR152, SH440, SIR133, SPAS510, SQ27239, ST281, SY6001, TA60, TAI-901 (4-benzoyl-1-indancarboxylic acid), TVX2706, U60257, UR2301 and WY41770. Structurally related NSAIDs having similar analgesic and anti-inflammatory properties to the NSAIDs are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment or concurrent treatment) with any of one or more corticosteroids, prodrug esters or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. Corticosteroids, prodrug esters and pharmaceutically acceptable salts thereof include hydrocortisone and compounds which are derived from hydrocortisone, such as 21-acetoxypregnenolone, alclomerasone, algestone, amcinonide, beclomethasone, betamethasone, betamethasone valerate, budesonide, chloroprednisone, clobetasol, clobetasol propionate, clobetasone, clobetasone butyrate, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacon, desonide, desoximerasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, fluctoronide, flumethasone, flumethasone pivalate, flucinolone acetonide, flunisolide, fluocinonide, fluorocinolone acetonide, fluocortin butyl, fluocortolone, fluocortolone hexanoate, diflucortolone valerate, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandenolide, formocortal, halcinonide, halometasone, halopredone acetate, hydro-cortamate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone phosphate, hydrocortisone 21-sodium succinate, hydrocortisone tebutate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 21diedryaminoacetate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone sodium 21-m-sulfobenzoate, prednisolone sodium 21-stearoglycolate, prednisolone tebutate, prednisolone 21-trimethylacetate, prednisone, prednival, prednylidene, prednylidene 21-diethylaminoacetate, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide and triamcinolone hexacetonide.

10

15

20

25

30

Structurally related corticosteroids having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of an huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more slow-acting antirheumatic drugs (SAARDs) or disease modifying antirheumatic drugs (DMARDS), prodrug esters, or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation such as rheumatic diseases, graft versus host SAARDs or DMARDS, prodrug esters and disease and multiple sclerosis. pharmaceutically acceptable salts thereof comprise: allocupreide sodium, auranofin, aurothioglucose, aurothioglycanide, azathioprine, brequinar sodium, bucillamine, calcium 3-aurothio-2-propanol-1-sulfonate, chlorambucil, chloroquine, clobuzarit, cuproxoline, cyclo-phosphamide, cyclosporin, dapsone, 15-deoxyspergualin, diacerein, glucosamine, gold salts (e.g., cycloquine gold salt, gold sodium thiomalate, gold sodium thiosulfate), hydroxychloroquine, hydroxychloroquine sulfate, hydroxyurea, kebuzone, levamisole, lobenzarit, melittin, 6-mercaptopurine, methotrexate, mizoribine, mycophenolate mofetil, myoral, nitrogen mustard, D-penicillamine, pyridinol imidazoles such as SKNF86002 and SB203580, rapamycin, thiols, thymopoietin and vincristine. Structurally related SAARDs or DMARDs having similar analgesic and antiinflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3α polypeptide, or antagonist (including, but not limited to, anti-huE3α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more COX2 inhibitors, prodrug esters or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation. Examples of COX2 inhibitors, prodrug esters or pharmaceutically acceptable salts thereof include, for example, celecoxib. Structurally related COX2 inhibitors having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3 $\alpha$  polypeptide, or antagonist (including, but not limited to, anti-huE3 $\alpha$  selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more antimicrobials, prodrug esters or pharmaceutically

First start with the start start start and with with their start shall shall start and other start shall sha

5

10

15

20

25

30

acceptable salts thereof for the treatment of the diseases and disorders recited herein, including cachexia, muscle wasting diseases and other catabolic disorders. Antimicrobials include, for example, the broad classes of penicillins, cephalosporins and other beta-lactams, aminoglycosides, azoles, quinolones, macrolides, rifamycins, tetracyclines, sulfonamides, lincosamides and polymyxins. The penicillins include, but are not limited to penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, floxacillin, ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanate, hetacillin, cyclacillin, bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin, ticarcillin/clavulanate, azlocillin, mezlocillin, peperacillin, and mecillinam. The cephalosporins and other beta-lactams include, but are not limited to cephalothin, cephapirin, cephalexin, cephradine, cefazolin, cefadroxil, cefaclor, cefamandole, cefotetan, cefoxitin, ceruroxime, cefonicid, ceforadine, cefixime, cefotaxime, moxalactam, ceftizoxime, cetriaxone, cephoperazone, ceftazidime, imipenem and aztreonam. The aminoglycosides include, but are not limited to streptomycin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin and neomycin. The azoles include, but are not limited to fluconazole. The quinolones include, but are not limited to nalidixic acid, norfloxacin, enoxacin, ciprofloxacin, ofloxacin, sparfloxacin and temafloxacin. The macrolides include, but are not limited to erythomycin, spiramycin and azithromycin. The rifamycins include, but are not limited tetracyclines include, but are not limited to spicycline, The to rifampin. chlortetracycline, clomocycline, demeclocycline, deoxycycline, guamecycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, pipacycline, rolitetracycline, sancycline, senociclin and tetracycline. The sulfonamides include, but are not limited to sulfanilamide, sulfamethoxazole, sulfadiazine, sulfisoxazole and co-trimoxazole sulfacetamide, (trimethoprim/sulfamethoxazole). The lincosamides include, but are not limited to clindamycin and lincomycin. The polymyxins (polypeptides) include, but are not limited to polymyxin B and colistin.

#### Human E3a Compositions and Administration

Therapeutic compositions are within the scope of the present invention. Such compositions may comprise a therapeutically effective amount of a huE3 $\alpha$  polypeptide, including a fragment, variant, derivative, or one or more selective binding agents which either inhibit or stimulate an activity of huE3 $\alpha$  in admixture with a

10

15

20

25

30

pharmaceutically acceptable agent such as a pharmaceutically acceptable formulation agent; wherein  $huE3\alpha$  refers to the polypeptide sequence of  $huE3\alpha$ I or  $huE3\alpha$ II.

Human E3α pharmaceutical compositions typically include a therapeutically or prophylactically effective amount of huE3a polypeptide, (an inhibitor of huE3α action) nucleic acid molecule or selective binding agent in a mixture with one or more pharmaceutically and physiologically acceptable formulation agents selected for suitability with the mode of administration. Suitable formulation materials or pharmaceutically acceptable agents include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants. For example, a suitable vehicle or carrier may be water for injection, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation agents suitable for accomplishing or enhancing the delivery of the huE3α polypeptide, nucleic acid molecule or selective binding agent as a pharmaceutical composition.

Acceptable formulation materials preferably are nontoxic to recipients and are preferably inert at the dosages and concentrations employed. The materials may include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as ethylenediamine tetraacetic acid (EDTA); sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as tween, pluronics, or polyethylene glycol (PEG).

Typically, a huE3 $\alpha$  molecule pharmaceutical composition will be administered in the form of a composition comprising a purified polypeptide, in conjunction with one or more physiologically acceptable agents. It will be appreciated that when used herein, the term "huE3 $\alpha$  molecule pharmaceutical composition" also encompasses compositions containing a nucleic acid molecule or selective binding agent of the present invention.

Neutral buffered saline or saline mixed with serum albumin are exemplary appropriate carriers. Other standard pharmaceutically acceptable agents such as diluents and excipients may be included as desired. For example, the  $huE3\alpha$  polypeptide product may be formulated as a lyophilizate using appropriate excipients such as sucrose. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor.

The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. In addition, the composition may contain other formulation materials for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the composition may contain additional formulation materials for modifying or maintaining the rate of release of huE3 $\alpha$  polypeptide, nucleic acid molecule or selective binding agent, or for promoting the absorption or penetration of huE3 $\alpha$  such molecules.

The huE3α molecule pharmaceutical compositions can be administered parenterally. Alternatively, the compositions may be administered through the digestive tract, such as orally, or by inhalation. When parenterally administered, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such pharmaceutically acceptable compositions, with due regard to pH, isotonicity, stability and the like, is within the skill of the art.

A particularly suitable vehicle for parenteral injection is sterile distilled water in which a huE3α polypeptide is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles or beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered as a depot injection. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

The pharmaceutical compositions of the present invention may include other components, for example parenterally acceptable preservatives, tonicity agents, cosolvents, wetting agents, complexing agents, buffering agents, antimicrobials, antioxidants and surfactants, as are well known in the art. For example, suitable tonicity enhancing agents include alkali metal halides (preferably sodium or potassium chloride),

15

10

5

20

25

mannitol, sorbitol, and the like. Suitable preservatives include, but are not limited to, benzalkonium chloride, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, and the like. Hydrogen peroxide may also be used as preservative. Suitable cosolvents are for example glycerin, propylene glycol and polyethylene glycol. Suitable complexing agents are for example caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin. Suitable surfactants or wetting agents include sorbitan esters, polysorbates such as polysorbate 80, tromethamine, lecithin, cholesterol, tyloxapal, and the like. The buffers can be conventional buffers such as borate, citrate, phosphate, bicarbonate, or Tris-HCl.

10

5

The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.

15

In one embodiment of the present invention, huE3α polypeptide compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (*Remington's pharmaceutical sciences*, 18<sup>th</sup> edition, A.R. Gennaro, ed., Mack Publishing Company (1990)) in the form of a lyophilized cake or an aqueous solution.

20

The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. See for example, *Remington's Pharmaceutical Sciences*, pp. 1435-1712. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the present huE3α polypeptides.

25

An effective amount of a huE3 $\alpha$  polypeptide composition to be employed therapeutically will depend, for example, upon the therapeutic objectives such as the indication for which the huE3 $\alpha$  polypeptide is being used, the route of administration, and the condition of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range from about 0.1 µg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 1 µg/kg up to about 100 mg/kg; or 5 µg/kg up to about 100 mg/kg; or 0.1 µg/kg up to about 100 mg/kg; or 1 µg/kg up to about 100 mg/kg.

Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter.

One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the therapeutic context, type of disorder under treatment, the age, and general health of the recipient.

10

5

The huE3 $\alpha$  molecule pharmaceutical composition to be used for *in vivo* administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using these methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

15.

Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

20

In a specific embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits may each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multichambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

25

An effective amount of a h2520-109 pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the h2520-109 molecule is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range

from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to about 100 mg/kg.

The frequency of dosing will depend upon the pharmacokinetic parameters of the h2520-109 molecule in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter.

Pharmaceutical compositions such as (1) slow-release formulations, (2) inhalant mists, or (3) orally active formulations are also envisioned. The huE3 $\alpha$  molecule pharmaceutical composition generally is formulated for parenteral administration. Such parenterally administered therapeutic compositions are typically in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the desired huE3 $\alpha$  molecule in a pharmaceutically acceptable vehicle. The huE3 $\alpha$  molecule pharmaceutical compositions also may include particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or the introduction of the molecule into liposomes. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation.

In one embodiment, a pharmaceutical composition may be formulated for inhalation. For example, huE3α polypeptide may be formulated as a dry powder for inhalation. Human E3α polypeptide or nucleic acid molecule inhalation solutions may also be formulated in a liquefied propellant for aerosol delivery, with or without a liquified propellant. In yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT WO94/20069, which describes pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention,  $huE3\alpha$  polypeptides which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the  $huE3\alpha$  polypeptide. Diluents, flavorings, low melting point waxes, vegetable oils,

10

5

15

20

25

lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

Another pharmaceutical composition may involve an effective quantity of  $huE3\alpha$  polypeptides in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

10

5

Additional huE3α molecule formulations will be evident to those skilled in the art, including formulations involving huE3α molecules in combination with one or more other therapeutic agents. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT/US93/00829 which describes controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions.

20

15

Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, *e.g.* films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, *22*: 547-556, 1983), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, *J. Biomed. Mater. Res.*, *15*: 167-27, 1981; and Langer, *Chem. Tech.*, *12*: 98-105, 1982), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also may include liposomes, which can be prepared by any of several methods known in the art. (*See e.g.*, Eppstein *et al.*, *Proc. Natl. Acad. Sci. USA*, *82*: 3688-3692, 1985; EP 36,676; EP 88,046; EP 143,949.)

25

Regardless of the manner of administration, the specific dose may be calculated according to body weight, body surface area or organ size. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.

30

The route of administration of the pharmaceutical composition is in accord with known methods, *e.g.* oral, inhalation, injection or infusion by intravenous,

5

High gives ready many at the distribution than the

But the first way offer the m

20

25

30

intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, or intralesional routes, or by sustained release systems or implantation device. Where desired, the compositions may be administered continuously by infusion, by bolus injection devices or by implantation device.

Alternatively or additionally, the composition may be administered locally via implantation into the affected area of a membrane, sponge, or other appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be directly through the device via diffusion, time-released bolus, or via continuous administration, or via catheter using continuous infusion.

It will further be appreciated that the huE3 $\alpha$  polypeptides, including fragments, variants, and derivatives, may be employed alone, together, or in combination with other polypeptides and pharmaceutical compositions. For example, the huE3 $\alpha$  polypeptides may be used in combination with cytokines, growth factors, antibiotics, anti-inflammatories, and/or chemotherapeutic agents as is appropriate for the indication being treated.

In some cases, it may be desirable to use huE3α pharmaceutical compositions in an *ex vivo* manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to huE3α pharmaceutical compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In other cases, a huE3 $\alpha$  polypeptide can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein, to express and secrete the polypeptides. Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be immortalized. However, in order to decrease the chance of an immunological response, the cells may be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

Additional embodiments of the present invention relate to cells and methods (e.g., homologous recombination and /or other recombinant production methods) for both the *in vitro* production of therapeutic polypeptides by means of

10

15

20

25

30

homologous recombination and for the production and delivery of therapeutic polypeptides by gene therapy or cell therapy.

It is further envisioned that huE3α polypeptides can be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding huE3α polypeptides. For example, homologous recombination methods may be used to modify a cell that contains a normally transcriptionally silent huE3 a gene, or an under expressed gene, and thereby produce a cell which expresses therapeutically efficacious amounts of huE3a polypeptides. Homologous recombination is a technique originally developed for targeting genes to induce or correct mutations in transcriptionally active genes. Kucherlapati, Prog. in Nucl. Acid Res. & Mol. Biol., 36:301, 1989. The basic technique was developed as a method for introducing specific mutations into specific regions of the mammalian genome (Thomas et al., Cell, 44: 419-428, 1986; Thomas and Capecchi, Cell, 51:503-512, 1987; Doetschman et al., Proc. Natl. Acad. Sci., 85: 8583-8587, 1988) or to correct specific mutations within defective genes (Doetschman et al., Nature, 330: 576-578, 1987). Exemplary homologous recombination techniques are described in U.S. Patent No. 5,272,071 (EP 9193051, EP Publication No. 505500; PCT/US90/07642, International Publication No. WO 91/09955).

Through homologous recombination, the DNA sequence to be inserted into the genome can be directed to a specific region of the gene of interest by attaching it to targeting DNA. The targeting DNA is a nucleotide sequence that is complementary (homologous) to a region of the genomic DNA. Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during the DNA replication process. It is a general property of DNA that has been inserted into a cell to hybridize, and therefore, recombine with other pieces of endogenous DNA through shared homologous regions. If this complementary strand is attached to an oligonucleotide that contains a mutation or a different sequence or an additional nucleotide, it too is incorporated into the newly synthesized strand as a result of the recombination. As a result of the proofreading function, it is possible for the new sequence of DNA to serve as the template. Thus, the transferred DNA is incorporated into the genome.

Attached to these pieces of targeting DNA are regions of DNA which may interact with or control the expression of a huE3α polypeptide, e.g., flanking sequences. For example, a promoter/enhancer element, a suppressor, or an exogenous

10

15

20

25

30

transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired huE3α polypeptide. The control element controls a portion of the DNA present in the host cell genome. Thus, the expression of huE3α polypeptide may be achieved not by transfection of DNA that encodes the huE3α gene itself, but rather by the use of targeting DNA (containing regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the endogenous gene sequence with recognizable signals for transcription of a huE3α polypeptide.

In an exemplary method, the expression of a desired targeted gene in a cell (*i.e.*, a desired endogenous cellular gene) is altered by the introduction, by homologous recombination into the cellular genome at a preselected site, by the introduction of DNA which includes at least a regulatory sequence, an exon and a splice donor site. These components are introduced into the chromosomal (genomic) DNA in such a manner that this, in effect, results in the production of a new transcription unit (in which the regulatory sequence, the exon and the splice donor site present in the DNA construct are operatively linked to the endogenous gene). As a result of the introduction of these components into the chromosomal DNA, the expression of the desired endogenous gene is altered.

Altered gene expression, as described herein, encompasses activating (or causing to be expressed) a gene which is normally silent (unexpressed) in the cell as obtained, as well as increasing the expression of a gene which is not expressed at physiologically significant levels in the cell as obtained. The embodiments further encompass changing the pattern of regulation or induction such that it is different from the pattern of regulation or induction that occurs in the cell as obtained, and reducing (including eliminating) the expression of a gene which is expressed in the cell as obtained.

One method by which homologous recombination can be used to increase, or cause, huE3α polypeptide production from a cell's endogenous huE3α gene involves first using homologous recombination to place a recombination sequence from a site-specific recombination system (e.g., Cre/loxP, FLP/FRT) (Sauer, Current Opinion In Biotechnology, 5: 521-527, 1994; Sauer, Methods In Enzymology, 225: 890-900, 1993) upstream (that is, 5′ to) of the cell's endogenous genomic huE3α coding region. A plasmid containing a recombination site homologous to the site that was placed just upstream of the genomic huE3α coding region is introduced into the modified cell line

along with the appropriate recombinase enzyme. This recombinase causes the plasmid to integrate, via the plasmid's recombination site, into the recombination site located just upstream of the genomic huE3α coding region in the cell line (Baubonis and Sauer, *Nucleic Acids Res.*, 21: 2025-2029, 1993; O'Gorman *et al.*, *Science*, 251: 1351-1355, 1991). Any flanking sequences known to increase transcription (*e.g.*, enhancer/promoter, intron, translational enhancer), if properly positioned in this plasmid, would integrate in such a manner as to create a new or modified transcriptional unit resulting in *de novo* or increased huE3α polypeptide production from the cell's endogenous huE3α gene.

10

5

A further method to use the cell line in which the site specific recombination sequence had been placed just upstream of the cell's endogenous genomic huE3α coding region is to use homologous recombination to introduce a second recombination site elsewhere in the cell line's genome. The appropriate recombinase enzyme is then introduced into the two-recombination-site cell line, causing a recombination event (deletion, inversion, translocation) (Sauer, *Current Opinion In Biotechnology*, 5: 521-527, 1994; Sauer, *Methods In Enzymology*, 225: 890-900, 1993) that would create a new or modified transcriptional unit resulting in *de novo* or increased huE3α polypeptide production from the cell's endogenous huE3α gene.

20

15.

An additional approach for increasing, or causing, the expression of huE3 $\alpha$  polypeptide from a cell's endogenous huE3 $\alpha$  gene involves increasing, or causing, the expression of a gene or genes (e.g., transcription factors) and/or decreasing the expression of a gene or genes (e.g., transcriptional repressors) in a manner which results in de novo or increased huE3 $\alpha$  polypeptide production from the cell's endogenous huE3 $\alpha$  gene. This method includes the introduction of a non-naturally occurring polypeptide (e.g., a polypeptide comprising a site specific DNA binding domain fused to a transcriptional factor domain) into the cell such that de novo or increased huE3 $\alpha$  polypeptide production from the cell's endogenous huE3 $\alpha$  gene results.

30

25

The present invention further relates to DNA constructs useful in the method of altering expression of a target gene. In certain embodiments, the exemplary DNA constructs comprise: (a) one or more targeting sequences; (b) a regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site. The targeting sequence in the DNA construct directs the integration of elements (a)-(d) into a target gene in a cell such that the elements (b)-(d) are operatively linked to sequences of the endogenous target gene. In another embodiment, the DNA constructs comprise: (a) one or more

10

15

20

25

30

targeting sequences, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that the elements of (b)-(f) are operatively linked to the endogenous gene. The targeting sequence is homologous to the preselected site in the cellular chromosomal DNA with which homologous recombination is to occur. In the construct, the exon is generally 3' of the regulatory sequence and the splice-donor site is 3' of the exon.

If the sequence of a particular gene is known, such as the nucleic acid sequence encoding a huE3α polypeptide presented herein, a piece of DNA that is complementary to a selected region of the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece serves as a targeting sequence upon insertion into the cell and will hybridize to its homologous region within the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence attached thereto, will act as an Okazaki fragment and will be incorporated into the newly synthesized daughter strand of DNA. The present invention, therefore, includes nucleotides encoding a huE3α polypeptide, which nucleotides may be used as targeting sequences.

Human E3 $\alpha$  polypeptide cell therapy, e.g., the implantation of cells producing huE3 $\alpha$  polypeptides, is also contemplated. This embodiment involves implanting cells capable of synthesizing and secreting a biologically active form of huE3 $\alpha$  polypeptide. Such huE3 $\alpha$  polypeptide-producing cells can be cells that are natural producers of huE3 $\alpha$  polypeptides or may be recombinant cells whose ability to produce huE3 $\alpha$  polypeptides has been augmented by transformation with a gene encoding the desired huE3 $\alpha$  polypeptide or with a gene augmenting the expression of huE3 $\alpha$  polypeptide. Such a modification may be accomplished by means of a vector suitable for delivering the gene as well as promoting its expression and secretion. In order to minimize a potential immunological reaction in patients being administered a huE3 $\alpha$  polypeptide, as may occur with the administration of a polypeptide of a foreign species, it is preferred that the natural cells producing huE3 $\alpha$  polypeptide be of human origin and produce huE3 $\alpha$  polypeptide. Likewise, it is preferred that the recombinant cells producing huE3 $\alpha$  polypeptide be transformed with an expression vector containing a gene encoding a human huE3 $\alpha$  polypeptide.

10

15

20

25

30

Implanted cells may be encapsulated to avoid the infiltration of surrounding tissue. Human or non-human animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow the release of huE3α polypeptide, but that prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue. Alternatively, the patient's own cells, transformed to produce huE3α polypeptides *ex vivo*, may be implanted directly into the patient without such encapsulation.

Techniques for the encapsulation of living cells are known in the art, and the preparation of the encapsulated cells and their implantation in patients may be routinely accomplished. For example, Baetge et al. (WO95/05452; PCT/US94/09299) describe membrane capsules containing genetically engineered cells for the effective delivery of biologically active molecules. The capsules are biocompatible and are easily The capsules encapsulate cells transfected with recombinant DNA retrievable. molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. The devices provide for the delivery of the molecules from living cells to specific sites within a recipient. In addition, see U.S. Patent Nos. 4,892,538, 5,011,472, and 5,106,627. A system for encapsulating living cells is described in PCT Application WO91/10425 of Aebischer et al. See also, PCT Application WO91/10470 of Aebischer et al., Winn et al., Exper. Neurol., 113: 322-329, 1991, Aebischer et al., Exper. Neurol., 111: 269-275, 1991; and Tresco et al., ASAIO, 38: 17-23, 1992.

In vivo and in vitro gene therapy delivery of huE3α polypeptides is also envisioned. In vivo gene therapy may be accomplished by introducing the gene encoding huE3α polypeptide into cells via local injection of a huE3α nucleic acid molecule or by other appropriate viral or non-viral delivery vectors (Hefti, Neurobiology, 25: 1418-1435, 1994). For example, a nucleic acid molecule encoding a huE3α polypeptide may be contained in an adeno-associated virus vector for delivery to the targeted cells (e.g., Johnson, International Publication No. WO95/34670; International Application No. PCT/US95/07178). The recombinant adeno-associated virus (AAV) genome typically contains AAV inverted terminal repeats flanking a DNA sequence encoding a huE3α polypeptide operably linked to functional promoter and polyadenylation sequences.

10

15

20

25

Alternative suitable viral vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus, lentivirus, hepatitis virus, parvovirus, papovavirus, poxvirus, alphavirus, coronavirus, rhabdovirus, paramyxovirus, and papilloma virus vectors. U.S. Patent No. 5,672,344 describes an *in vivo* viral-mediated gene transfer system involving a recombinant neurotrophic HSV-1 vector. U.S. Patent No. 5,399,346 provides examples of a process for providing a patient with a therapeutic protein by the delivery of human cells which have been treated *in vitro* to insert a DNA segment encoding a therapeutic protein. Additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 5,631,236 involving adenoviral vectors; U.S. Patent No. 5,672,510 involving retroviral vectors; and U.S. 5,635,399 involving retroviral vectors expressing cytokines.

Nonviral delivery methods include, but are not limited to, liposomemediated transfer, naked DNA delivery (direct injection), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation, and microparticle bombardment (e.g., gene gun). Gene therapy materials and methods may also include the use of inducible promoters, tissue-specific enhancer-promoters, DNA sequences designed for site-specific integration, DNA sequences capable of providing a selective advantage over the parent cell, labels to identify transformed cells, negative selection systems and expression control systems (safety measures), cell-specific binding agents (for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as methods of vector manufacture. Such additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 4,970,154 involving electroporation techniques; WO96/40958 involving nuclear ligands; U.S. Patent No. 5,679,559 describing a lipoprotein-containing system for gene delivery; U.S. Patent No. 5,676,954 involving liposome carriers; U.S. Patent No. 5,593,875 concerning methods for calcium phosphate transfection; and U.S. Patent No. 4,945,050 wherein biologically active particles are propelled at cells at a speed whereby the particles penetrate the surface of the cells and become incorporated into the interior of the cells.

In yet other embodiments, regulatory elements can be included for the controlled expression of the  $huE3\alpha$  gene in the target cell. Such elements are turned on in response to an appropriate effector. In this way, a therapeutic polypeptide can be expressed when desired. One conventional control means involves the use of small molecule dimerizers or rapalogs (as described in WO9641865 (PCT/US96/099486);

WO9731898 (PCT/US97/03137) and WO9731899 (PCT/US95/03157)) used to dimerize chimeric proteins which contain a small molecule-binding domain and a domain capable of initiating biological process, such as a DNA-binding protein or transcriptional activation protein. The dimerization of the proteins can be used to initiate transcription of the huE3 $\alpha$  gene.

Other suitable control means or gene switches include, but are not limited to, the following systems. Mifepristone (RU486) is used as a progesterone antagonist. The binding of a modified progesterone receptor ligand-binding domain to the progesterone antagonist activates transcription by forming a dimer of two transcription factors which then pass into the nucleus to bind DNA. The ligand binding domain is modified to eliminate the ability of the receptor to bind to the natural ligand. The modified steroid hormone receptor system is further described in U.S. 5,364,791; WO9640911, and WO9710337.

Yet another control system uses ecdysone (a fruit fly steroid hormone) which binds to and activates an ecdysone receptor (cytoplasmic receptor). The receptor then translocates to the nucleus to bind a specific DNA response element (promoter from ecdysone-responsive gene). The ecdysone receptor includes a transactivation domain/DNA-binding domain/ligand-binding domain to initiate transcription. The ecdysone system is further described in U.S. 5,514,578; WO9738117; WO963 7609; and WO9303162.

Another control means uses a positive tetracycline-controllable transactivator. This system involves a mutated tet repressor protein DNA-binding domain (mutated tet R-4 amino acid changes which resulted in a reverse tetracycline-regulated transactivator protein, *i.e.*, it binds to a tet operator in the presence of tetracycline) linked to a polypeptide which activates transcription. Such systems are described in U.S. Patent Nos. 5,464,758; 5,650,298 and 5,654,168.

Additional expression control systems and nucleic acid constructs are described in U.S. Patent Nos. 5,741,679 and 5,834,186 to Innovir Laboratories Inc.

One example of a gene therapy technique is to use the huE3 $\alpha$  gene (either genomic DNA, cDNA, and/or synthetic DNA encoding a huE3 $\alpha$  polypeptide which may be operably linked to a constitutive or inducible promoter to form a "gene therapy DNA construct". The promoter may be homologous or heterologous to the endogenous huE3 $\alpha$  gene, provided that it is active in the cell or tissue type into which the construct will be inserted. Other components of the gene therapy DNA construct may optionally include,

10

5

15:-

20

25

DNA molecules designed for site-specific integration (*e.g.*, endogenous sequences useful for homologous recombination), tissue-specific promoter, enhancer(s) or silencer(s), DNA molecules capable of providing a selective advantage over the parent cell, DNA molecules useful as labels to identify transformed cells, negative selection systems, cell specific binding agents (as, for example, for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as factors to enable vector manufacture.

This gene therapy DNA construct can then be introduced into cells (either ex vivo or in vivo). One means for introducing the gene therapy DNA construct is by means of viral vectors as described herein. Certain vectors, such as retroviral vectors, will deliver the gene therapy DNA construct to the chromosomal DNA of the cells, and the gene therapy DNA construct can integrate into the chromosomal DNA. Other vectors will function as episomes, and the gene therapy DNA construct will remain in the cytoplasm.

Another means to increase endogenous huE3 $\alpha$  polypeptide expression in a cell via gene therapy is to insert one or more enhancer elements into the huE3 $\alpha$  polypeptide promoter, where the enhancer element(s) can serve to increase transcriptional activity of the huE3 $\alpha$  gene. The enhancer element(s) used will be selected based on the tissue in which one desires to activate the gene(s); enhancer elements known to confer promoter activation in that tissue will be selected. For example, if a gene encoding a huE3 $\alpha$  polypeptide is to be "turned on" in T-cells, the *lck* promoter enhancer element may be used. Here, the functional portion of the transcriptional element to be added may be inserted into a fragment of DNA containing the huE3 $\alpha$  polypeptide promoter (and optionally, inserted into a vector and/or 5' and/or 3' flanking sequence(s), etc.) using standard cloning techniques. This construct, known as a "homologous recombination construct", can then be introduced into the desired cells either *ex vivo* or *in vivo*.

Gene therapy can be used to decrease huE3α polypeptide expression by modifying the nucleotide sequence of the endogenous promoter(s). Such modification is typically accomplished via homologous recombination methods. For example, a DNA molecule containing all or a portion of the promoter of the huE3α gene(s) selected for inactivation can be engineered to remove and/or replace pieces of the promoter that regulate transcription. For example the TATA box and/or the binding site of a transcriptional activator of the promoter may be deleted using standard molecular

15.

10

5

20

25

10

15

20

25

30

biology techniques; such deletion can inhibit promoter activity thereby repressing the transcription of the corresponding huE3 $\alpha$  gene. The deletion of the TATA box or the transcription activator binding site in the promoter may be accomplished by generating a DNA construct comprising all or the relevant portion of the  $huE3\alpha$  polypeptide promoter(s) (from the same or a related species as the huE3α gene(s) to be regulated) in which one or more of the TATA box and/or transcriptional activator binding site nucleotides are mutated via substitution, deletion and/or insertion of one or more nucleotides. As a result, the TATA box and/or activator binding site has decreased activity or is rendered completely inactive. This construct, which also will typically contain at least about 500 bases of DNA that correspond to the native (endogenous) 5' and 3' DNA sequences adjacent to the promoter segment that has been modified, may be introduced into the appropriate cells (either ex vivo or in vivo) either directly or via a viral vector as described herein. Typically, the integration of the construct into the genomic DNA of the cells will be via homologous recombination, where the 5' and 3' DNA sequences in the promoter construct can serve to help integrate the modified promoter region via hybridization to the endogenous chromosomal DNA.

Other gene therapy methods may also be employed where it is desirable to inhibit the activity of one or more huE3 $\alpha$  polypeptides. For example, antisense DNA or RNA molecules, which have a sequence that is complementary to at least a portion of the selected huE3 $\alpha$  gene(s) can be introduced into the cell. Typically, each such antisense molecule will be complementary to the start site (5' end) of each selected huE3 $\alpha$  gene. When the antisense molecule then hybridizes to the corresponding huE3 $\alpha$  mRNA, translation of this mRNA is prevented or reduced. It will also be appreciated by those skilled in the art that antisense and ribozyme molecules may also be administered directly.

Alternatively, gene therapy may be employed to create a dominant-negative inhibitor of one or more huE3 $\alpha$  polypeptides. In this situation, the DNA encoding a mutant full length or truncated polypeptide of each selected huE3 $\alpha$  polypeptide can be prepared and introduced into the cells of a patient using either viral or non-viral methods as described herein. Each such mutant is typically designed to compete with endogenous polypeptide in its biological role.

## Additional Uses of huE3a Nucleic Acids and Polypeptides

Nucleic acid molecules of the present invention may be used to map the locations of the huE3 $\alpha$  gene and related genes on chromosomes. Mapping may be done by techniques known in the art, such as PCR amplification and *in situ* hybridization.

5

The nucleic acid molecules are also used as antisense inhibitors of huE3 $\alpha$  polypeptide expression. Such inhibition may be effected by nucleic acid molecules which are complementary to and hybridize to expression control sequences (triple helix formation) or to huE3 $\alpha$  mRNA. Antisense probes may be designed by available techniques using the sequence of huE3 $\alpha$  nucleic acid molecules disclosed herein. Antisense inhibitors provide information relating to the decrease or absence of a huE3 $\alpha$  polypeptide in a cell or organism.

10

Hybridization probes may be prepared using the huE3 $\alpha$  nucleic acid sequences provided herein to screen cDNA, genomic or synthetic DNA libraries for related sequences. Regions of the DNA and/or amino acid sequence of huE3 $\alpha$  polypeptide that exhibit significant identity to known sequences are readily determined using sequence alignment algorithms as described herein and those regions may be used to design probes for screening.

15.

Human  $E3\alpha$  nucleic acid molecules, as well as fragments, variants, and/or derivatives that do not themselves encode biologically active polypeptides, may be useful as hybridization probes in diagnostic assays to test, either qualitatively or quantitatively, for the presence of huE3 $\alpha$  DNA or corresponding RNA in mammalian

tissue or bodily fluid samples.

20

Human E3 $\alpha$  polypeptide fragments, variants, and/or derivatives, whether biologically active or not, are also useful for preparing antibodies that bind to a huE3 $\alpha$  polypeptide. The antibodies may be used for *in vitro* diagnostic purposes, including, but not limited to, use in labeled form to detect the presence of huE3 $\alpha$  polypeptide in a body fluid or cell sample.

25

The full length cDNAs encoding huE3 $\alpha$ I was subcloned into pCR 2.1 vector (Invitrogen, Cat.# K2030-40). The full length cDNA encoding huE3 $\alpha$ II was subcloned into pcDNA 3.1/His A vector (Invitrogen Cat.#V38-20). The full length cDNA encoding muE3 $\alpha$ II was subcloned into pCR 2.1 vector (Invitrogen). The above plasmids were deposited on March 15, 2000 to the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 . The plasmid containing

huE3α1 is designated PTA-1489, the plasmid containing huE3αII is designated PTA-1490 and the plasmid containing muE3αII is designated PTA-1488.

The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

5

#### **EXAMPLE 1**

### Cloning of cDNA Encoding Human E3aI

Materials and methods for cDNA cloning and analysis are described in Sambrook *et al.*, *supra*. which is incorporated herein by reference.

10

BLAST analysis of the Genebank dbEST database with the full length murine E3 $\alpha$  ubiquitin ligase nucleotide sequence (muE3I; Genebank Accession No.: AF061555; SEQ ID NO: 15), revealed 4 human EST sequences (Genebank accession numbers AI187306, AI92195, AI87306, and AI400279) which potentially encode different regions of a novel human E3 $\alpha$  ubiquitin ligase ortholog (huE3 $\alpha$ I) gene. Based on these EST sequences, two sets of PCR primers (#2282-91/2282-93 and #2282-94/2282-97) were designed. These sequences are set out below in Table III.

15

Table III

20

1	Primer	Sequence	SEQ ID NO:
ļ	2282-91	CTC CTC GAG TCT GCG TCA AAC	7
t	2385-35	TCT GCA TAT GTT CAG CCT TGC TA	8
l	2282-94	GTA TGA ACT TGC CGA GGC TTT TA	9
Ì	2294-37	CAA TAC TTT CCC AGC CCT CAG AA	10

25

The primer sets #2282-91/2282-93 (SEQ ID NOS: 7 and 8) and #2282-94/2294-37 (SEQ ID NOS: 9 and 10) were used to generate two PCR products which span the whole huE3 $\alpha$ I gene including the 5' and 3' untranslated regions. Polymerase chain reactions (PCR) were performed using a Perkin-Elmer 9600 thermocycler. In general, 50  $\mu$ l PCR reactions contained 24  $\mu$ l of H<sub>2</sub>O, 5  $\mu$ l of 10x cDNA PCR Reaction Buffer (Clontech), 2  $\mu$ l of 10 mM dNTP mix (dATP, dCTP, dGTP, dTTP), 1  $\mu$ l of Primer 2282-91 or 2282-94 (20  $\mu$ l), 1  $\mu$ l of Primer 2285-35 or 2294-37 (20 $\mu$ l), 2  $\mu$ l of 50x Advantage 2 Polymerase Mix (Clontech) and 15  $\mu$ l of Marathon Ready cDNA from a human heart library (Clontech cat.# 7404-1) or a human muscle library (Clontech cat. # 7413-1). The reaction mixture was incubated at 94°C for 30 seconds, followed by 40 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 5 minutes.

30

10

15

20

25

30

The PCR products were electrophoresed on a 1% agarose gel as described by Sambrook *et al.*, *supra*. The appropriate sized bands (14 kB and 3 kB) were excised from the agarose gel and purified with the QIAquick Gel Extraction kit (Qiagen, cat# 28704). The two purified DNA fragments were subcloned into pCR2.1 vectors and transformed into *E. coli* (Strain INV $\alpha$ F) utilizing the Invitrogen Original TA Cloning kit (cat.# K2000-40).

After subcloning, DNA plasmids were purified with the QIAprep Spin Miniprep kit (cat# 27104). The sequence of the PCR products were verified by automated sequencing with the Prism 377 Sequencer and the BIg Dye Terminator Ready Reaction mix with AmpliTaq DNA polymerase (Perkin Elmer Applied Biosystems). Each sequencing reaction was performed in a Perkin Elmer 9600 thermocycler with 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 2 minutes. The samples were purified using Centriflex Gel Filtration cartridges (Edge Biosystems). The samples were heated to 85oC for 2 minutes and inserted into the Prism 377 Sequencer. The sequences were analyzed using the Sequencher<sup>TM</sup> Sequence Analysis software (Gene Codes Corp.). The sequences of the PCR product generated from human heart and human muscle were identical. The full length huE3αI clone was obtained by ligating the two PCR products together at their XbaI site.

The nucleic acid sequence of huE3αI (SEQ ID NO: 1), consists of an open reading frame of 5247 nucleotides which encodes a 1749 amino acid polypeptide, in addition to 695 bp in the 5' untranslated region and 362 bp in the 3' untranslated region. Alignment of the human and mouse amino acid sequence, as shown in Figure 1 (SEQ ID NOS: 2 and 15, respectively), exhibited 92.5% overall sequence identity.

In the present invention, a novel full length human E3 $\alpha$  cDNA (huE3 $\alpha$ I; SEQ ID NO: 1) was isolated and cloned and the full length polypeptide sequence (SEQ ID NO: 2) was disclosed. A partial sequence of the human E3 $\alpha$  gene had been previously reported. (See U.S. Patent 5,861,312; Kwon et al., Proc. Natl. Acad. of Sci. USA, 95: 7898-7903, 1998). The reported partial sequence is encompassed in SEQ ID NO: 1; but only represents a small portion of the entire full length gene (nucleotides 702 to 1066).

#### **EXAMPLE 2**

## Cloning of cDNA Encoding Human E3α Ortholog, huE3αII

BLAST analysis of the Amgenesis database (Amgen internal EST database) with the human E3 $\alpha$ I amino acid sequences revealed 4 Amgenesis EST sequences (amgi-039645, smop2-0079f12 and zhgb-aa693825 and Genebank accession no.: AA002347) which encode potential regions of the human and mouse E3 $\alpha$  ubiquitin ligase ortholog nucleotide sequences which are deonted as E3 $\alpha$ II. Based on the zhgb-aa693825 and AA002347 sequences, two PCR primer sets (#2380-88/2378-32 and #2381-48/2385-94) were designed. These sequences are set out below in Table IV.

10

15

20

25

30

5

Table IV

Primer	Sequence	SEQ ID NO:
2380-88	ATG GCG TCG CTA GAG CCA	11
2378-32	CAA AGC GGC TGA GCA TGA TCA TC	12
2381-48	TGA ACA GCC AAT CAC ACT AAG CA	13
2385-94	TTA TAA ATG CCA GTC AAT GCC AA	14

The primer sets #2380-88/2378-32 (SEQ1D NOS: 11 and 12) and #2381-48/2385-94 (SEQ ID NOS: 13 and 14) were used to generate two PCR products which encode the coding region of a novel ortholog of human  $E3\alpha$  ligase (hu $E3\alpha$ II). The 5' and 3' untranslated regions of huE3aII were determined based on the EST sequences amgi-03645 and smop2-0079fl2 in order to obtain the full length huE3αII cDNA. PCR was performed as described above utilizing Marathon-Ready cDNA from human heart and human muscle libraries. The two PCR products were electrophoresed on a 1% gel as described by Sambrook et al., supra. The appropriate sized bands (2.2 kB and 3.5 kB) were excised from the agarose and purified by QIAquick Gel Extraction kit (cat.# The PCR products were subcloned into the pcDNA3.1-HisA vector 28704). (Invitrogen cat.# V385-20) and transformed into E.coli (Strain INVαF) using the Invitrogen Original TA Cloning kit. The insert DNA was purified with the QIAprep Spin Miniprep kit (QIAGEN cat.# 27104) and subsequenly digested with NotI/SacI for the 2 kB product and SacI/XhoI for the 3.3 kB product. The PCR products were sequenced as described in Example 1 and the products generated from human heart and human muscle cDNA libraries were identical. The full length huE3αII gene was generated by ligating these two PCR products at their SacI sites.

The nucleic acid sequence of huE3 $\alpha$ II (SEQ ID NO: 3), consists of an open reading frame of 5265 nucleotides which encodes a 1755 amino acid polypeptide, in addition to 294 bp in the 5' untranslated region and 740 bp in the 3' untranslated region. Alignment of the human and mouse amino acid E3 $\alpha$ II sequences, as shown in Figure 1 (SEQ ID NOS: 4 and 6, respectively), exhibited 90.4% overall sequence identity. There is a 48.1% overall amino acid sequence identity between human E3 $\alpha$ II and human E3 $\alpha$ II (SEQ ID NOS:2 and 4, respectively).

In the present invention, a novel full length cDNA sequence encoding  $huE3\alpha II$  (SEQ ID NO: 3) was cloned and isolated, and the full length polypeptide sequence was disclosed (SEQ ID NO: 4). A partial sequence of  $huE3\alpha II$  was identified in WO9904265 as one of many partial sequences with unknown identities that were speculated to be cancer markers.

## **EXAMPLE 3**

## Cloning of the Murine E3aII Ortholog

BLAST analysis of the Amgen internal database, Amgensis, with human E3αII amino acid sequences identified the mouse cDNA clone (Smop2-00079-fl2) as a potential mouse ortholog of E3αII ubiquitin ligase. The Amgenesis database contained the entire coding region of the mouse E3αII ubiquitin ligase (muE3αII) gene. The cDNA clone of was obtained from the Amgen sequencing group. The sequence of the clone was confirmed to be the full cDNA of muE3αII as described in Example 1. The nucleic acid sequence of muE3αII (SEQ ID NO: 5), consists of an open reading frame of 5265 nucleotides which encodes a 1755 amino acid polypeptide, in addition to 765 bp in the 5′ untranslated region and 56 bp in the 3′ untranslated region.

#### **EXAMPLE 4**

#### Human E3aII Tissue Expression

Tissue expression patterns of huE3 $\alpha$ I and huE3 $\alpha$ II mRNA were analyzed by Northern blot analysis. To detect the presence of huE3 $\alpha$ II transcript in various tissues, a  $^{32}$ P-labeled fragment of huE3 $\alpha$ II, which was 452 bp and corresponded to nucleotides 3557-4009 of SEQ ID NO: 3, was used as a probe. For detection of huE3 $\alpha$ I transcript in various tissues, a  $^{32}$ P-labeled fragment of huE3 $\alpha$ I, which was 696 bp and corresponded to nucleotides 3468-4164 of SEQ ID NO: 1, was used as a probe.

15°

10

5

20

25

10

15

The probes were labeled by random priming method using Prime-it RMT labeling kit (Stratagene, Cat# 300392). The specific activities was 1.436 x 10<sup>6</sup> cpm/µl for the huE3αII probe and 1.207 x 10<sup>6</sup> cpm/µl for the huE3αI probe. Human multiple tissue poly A+ RNA blots (Clontech cat.# 7780-1) were prehybridized in Church hybridization solution (1% BSA, 7% SDS, 0.5 M sodium phosphate, pH 7.0, 1 mM EDTA) for 4 hour at 65°C. The blots are then hybridized in Church hybridization solution with 3.0 x 10<sup>6</sup> cpm/ml <sup>32</sup>P labeled probe for overnight at 65°C. The blots are then washed 3 times in Wash B buffer (1% SDS, 0.04 M sodium phosphate, 1 mM EDTA) for 5 minutes each at room temperature, followed by two times at 65°C. The blots were exposed to X-ray film at room temperature overnight (for huE3αII detection) or one week (for huE3αI detection).

The Northern blot analysis revealed that huE3 $\alpha$ II (Figure 2) is predominantly expressed in skeletal muscle, with moderate expression in heart and kidney tissue and minimal or no expression in other tissues examined including brain, colon, thymus, spleen, liver, small intestines, placenta, lung and peripheral white blood cells. In contrast, the expression of huE3 $\alpha$ I (Figure 3) is less muscle-specific. Although heart and skeletal muscle had relative high levels of huE3 $\alpha$ I transcripts, moderate levels of huE3 $\alpha$ I was found to spread through the various tissues examined. The results indicate that huE3 $\alpha$ II is the more muscle-specific form of huE3 $\alpha$  which is predominantly expressed in skeletal muscle tissue.

## **EXAMPLE 5**

## Production of huE3a Polypeptides

## A. Bacterial Expression of huE3α Polypeptides

25

30

20

PCR is used to amplify template DNA sequences encoding a huE3α polypeptide using primers corresponding to the 5′ and 3′ ends of the sequence. The amplified DNA products may be modified to contain restriction enzyme sites to allow for insertion into expression vectors. PCR products are gel purified and inserted into expression vectors using standard recombinant DNA methodology. An exemplary vector, such as pAMG21 (ATCC No. 98113) containing the *lux* promoter and a gene encoding kanamycin resistance is digested with BamHI and NdeI for directional cloning of inserted DNA. The ligated mixture is transformed into an *E. coli* host strain by electroporation and transformants are selected for kanamycin resistance. Plasmid DNA

from selected colonies is isolated and subjected to DNA sequencing to confirm the presence of the insert.

Transformed host cells are incubated in 2x YT medium containing 30  $\mu$ g/ml kanamycin at 30°C prior to induction. Gene expression is induced by the addition of N-(3-oxohexanoyl)-dl-homoserine lactone to a final concentration of 30 ng/ml followed by incubation at either 30°C or 37°C for six hours. The expression of  $\mu$ E3 $\alpha$  polypeptide is evaluated by centrifugation of the culture, resuspension and lysis of the bacterial pellets, and analysis of host cell proteins by SDS-polyacrylamide gel electrophoresis.

10

15

20

25

30

5

Inclusion bodies containing huE3α polypeptide are purified as follows. Bacterial cells are pelleted by centrifugation and resuspended in water. The cell suspension is lysed by sonication and pelleted by centrifugation at 195,000 x g for 5 to 10 minutes. The supernatant is discarded, and the pellet is washed and transferred to a homogenizer. The pellet is homogenized in 5 ml of a Percoll solution (75% liquid Percoll/0.15 M NaCl) until uniformly suspended and then diluted and centrifuged at 21,600 x g for 30 minutes. Gradient fractions containing the inclusion bodies are recovered and pooled. The isolated inclusion bodies are analyzed by SDS-PAGE. A single band on an SDS polyacrylamide gel corresponding to *E. coli*-produced huE3α polypeptide is excised from the gel, and the N-terminal amino acid sequence is determined essentially as described by Matsudaira *et al.*, *J. Biol. Chem.*, 262: 10-35 (1987).

## B. Mammalian Cell Production of huE3α Polypeptides

The huE3α DNA was subcloned into a mammalian expression vector as described above using standard DNA technology. An exemplary expression vector, pCEP4 (Invitrogen, Carlsbad, CA), which contains an Epstein-Barr virus origin of replication, may be used for the expression of huE3α in 293-EBNA-1 cells. Amplified and gel purified PCR products are ligated into pCEP4 vector and lipofected into 293-EBNA cells. The transfected cells are selected in 100 μg/ml hygromycin and the resulting drug-resistant cultures are grown to confluence. The cells are then cultured in serum-free media for 72 hours. The conditioned media is removed and, huE3α protein polypeptide expression is analyzed by SDS-PAGE. Human E3α polypeptide expression may be detected by silver staining. Alternatively, huE3α polypeptide is produced as a

fusion protein with an epitope tag, such as an IgG constant domain or a FLAG epitope, which may be detected by Western blot analysis using antibodies to the tag peptide.

Human E3 $\alpha$  polypeptides may be excised from an SDS-polyacrylamide gel, or huE3 $\alpha$  fusion proteins are purified by affinity chromatography to the epitope tag, and subjected to N-terminal amino acid sequence analysis as described herein.

## **EXAMPLE 6**

## Production of Anti-huE3a Polypeptide Antibodies

Antibodies to huE3 $\alpha$  polypeptides may be obtained by immunization with purified protein or with huE3 $\alpha$  peptides produced by biological or chemical synthesis. Suitable procedures for generating antibodies include those described in Hudson and Bay, *Practical Immunology*, *Second Edition*", *Edition*, Blackwell Scientific Publications.

In one procedure for the production of antibodies, animals (typically mice or rabbits) are injected with a huE3α antigen (such as an recombinant truncated forms of huE3α polypeptide), and those with sufficient serum titer levels as determined by ELISA are selected for hybridoma production. Spleens of immunized animals are collected and prepared as single cell suspensions from which splenocytes are recovered. The splenocytes are fused to mouse myeloma cells (such as Sp2/0-Ag14 cells), allowed to incubate in DMEM with 200 U/ml penicillin, 200 μg/ml streptomycin sulfate, and 4 mM glutamine, then incubated in HAT selection medium (Hypoxanthine; Aminopterin; Thymidine). After selection, the tissue culture supernatants are taken from each fusion well and tested for anti-huE3α antibody production by ELISA.

Alternative procedures for obtaining anti-huE3 $\alpha$  antibodies may also be employed, such as the immunization of transgenic mice harboring human Ig loci for production of human antibodies, and the screening of synthetic antibody libraries, such as those generated by mutagenesis of an antibody variable domain.

#### EXAMPLE 7

## Biological Activity of huE3α polypeptides

Human  $E3\alpha$  family members are known to catalyze the ubiquitin conjugation reaction which ultimately results in protein degradation. To determine the biological activity of huE3 $\alpha$  polypeptide, the rate of ubiquitin conjugation and the

10

5

15

20

25

rate of protein degradation are measured. The following are examples of assays to measure these biological activities.

## A. Ubiquitin Conjugation Assay:

5

The enzymatic activity of E3α family members is thought to be the rate limiting step in ubiquitin conjugation. Rat skeletal muscles are dissected, homogenized, and centrifuged at 100,000 x g to remove proteosomes. The soluble extract is incubated with <sup>125</sup>I-ubiquitin (Amersham, Arlington Heights, IL) (0.15 mg/ml) in 20 mM Tris (pH 7.4), 1 mM DTT, 5 mM MgCl<sub>2</sub>, and 2 mM ATPγS at 37°C in the presence and absence of huE3α polypeptide. At various time points, the reactions are terminated by the addition of sample buffer and SDS-PAGE is performed on a 12% gel. The gel is then dried and autoradiographed. If huE3α acts as an E3α family member, the level of ubiquitination should increase in extracts treated with the huE3α polypeptide (Soloman *et al.*, *Proc. Natl. Acad. of Sci. U.S.A.*, *95*: 12602-07, 1998).

15

10

## **B. Protein Degradation Assays:**

20

Measurement of tyrosine release is a preferred method for determining the rate of protein turnover in skeletal muscles. Rat skeletal muscles are dissected and homogenated. The extracts are incubated at 37°C for 2 hours in 20 mM Tris (pH 7.6), 5 mM MgCl<sub>2</sub>, 2 mM DTT, ATP-regenerating system (10 μg creatine phosphokinase and 10 mM creatine phosphate), 1 mM ATP, and 25 mg of ubiquitin in the presence and absence of huE3α polypeptide. Subsequently, the reactions are terminated with 20% TCA. After centrifugation, the concentrations of tyrosine in the supernatant is measured by fluorescence spectroscopy according to the method of Waakkes and Udenfriend (*J. Lab. Clin. Med.*, 50: 733-736, 1957).

25

Measurement of radiolabeled proteins will also indicate if huE3α polypeptide exhibits E3α family biological activity. Rat skeletal muscle homogenates are incubated at 37°C for 2 hours with <sup>125</sup>I-labeled N-end pathway substrates, such as <sup>125</sup>I-lyzozyme and <sup>125</sup>I-lactalbumin, in the presence and absence of huE3α polypeptide. Following the incubation, 20% TCA is added to precipitate the radioactivity. The release of TCA-soluble radioactivity is measured using a gamma counter and correlates the rate of protein degradation. The addition of huE3α polypeptide should increase the rate of protein degradation in both of these assays.

10

15

20

#### **EXAMPLE 8**

## Identification of Modulators of the Biological Activity of huE3a Polypeptides

The assays described in Example 7 demonstrate preferred methods to measure the biological activity of huE3 $\alpha$  as an ubiquitin ligase. These methods are also useful for identifying modulators of huE3 $\alpha$  ubiquitin ligase activity.

The rate limiting step of ubiquitin conjugation consists of E3 $\alpha$  catalyzing the transfer of the activated ubiquitin molecule to the target protein. The rate of ubiquitination modulated by huE3 $\alpha$  can be measured in dissected rat skeletal muscles as described in Example 7. The addition of potential huE3 $\alpha$  modulators (inhibitors or stimulators) to this system will allow for the identification of E3 $\alpha$  stimulators and inhibitors by virtue of their ability to modulate the level or rate of ubiquitin conjugation to the target protein. If the addition of the modulator decreases the rate of huE3 $\alpha$ -modulated ubiquitin conjugation, it is considered a huE3 $\alpha$  inhibitor. If the modulator increases the rate of ubiquitin conjugation it is considered a stimulator.

The effect of huE3 $\alpha$  modulators can also be determined by measuring their effect on the rate of protein turnover as described in Example 7. If huE3 $\alpha$  exhibits the biological activity of an ubiquitin ligase, it will induce protein degradation. Protein turnover is measured by quantitating tyrosine release or the degradation of radioactively labeled N-end pathway substrates in the presence of E3 $\alpha$  modulators. The addition of effective huE3 $\alpha$  modulators will either increase or decrease the rate of protein degradation.

#### EXAMPLE 9

## Identification of huE3aI Single Nucleotide Polymorphisms (SNP)

A BLAST search of the Celera Human Genome database was conducted using the huE3αI cDNA sequence (SEQ ID NO: 1) as a probe. The sequences identified in the search were used to manually assemble a polynucleotide sequence (SEQ ID NO: 18) which was discovered to have a single nucleotide mismatch at nucleotide 5397 of the huE3αI cDNA sequence (SEQ ID NO: 1). The polynucleotide sequence of SEQ ID NO: 18 contians a huE3αI SNP with a change of a cytosine to a thymidine at position 4702, which caused the predicted amino acid sequence of SEQ ID NO: 2 to change from an Arg residue to a W (Trp) residue at

25

30

position 1508.

10

15

20

PCR was carried out to confirm the polynucleotide sequence of huE3αI cDNA. Primers were designed to flank the mismatch as follows: 5' AGAAGGAGAGTACAGTGCACTC3' (SEQ ID NO: 20) and 5'CGAAAGCATCCTGTCCTCTG (SEQ ID NO: 21). PCR was carried out as described in Example 1 with the Marathon-Ready cDNA library (Clontech cat no. 7413-1) from which huE3αI cDNA was cloned. The PCR reactions resulted in 8 individual PCR products which had identical sequences to the huE3αI SNP (SEQ ID NO: 18).

These experiments have confirmed the sequence of a huE3αI SNP set out in SEQ ID NO: 17 wherein the nucleotide at position 4702 is a thymidine. Accordingly, the correct predicted amino acid sequence is set out as SEQ ID NO: 19, wherein the residue at position 1568 is W (Trp).

#### **EXAMPLE 10**

### Human E3αI and E3αII Stimulate Ubiquitination

To confirm that huE3 $\alpha$ I and huE3 $\alpha$ II have the predicted enzymatic activity of stimulating ubiquitin conjugation, ubiquitination reactions were carried out in 293 cells. Cultures of 293T cells (ATCC accession no. CRL1573) were transfected with huE3 $\alpha$ I or huE3 $\alpha$ II full length cDNA (SEQ ID NOS: 1 or 3, respectively) that had been subcloned into pcDNA3.1 vector (Invitrogen) under the control of the CMV promoter using Lipofectamine reagent 2000 (Gibco, cat no. 11668-027) according to the manufacture's instructions. As a control, 293T cultures were transfected with pcDNA3.1 vector without the cDNA insert. The transfected cells were lysed in ice-cold lysis buffer (50mM Tris-HCl (pH 8.0), 2mM DTT, 5 mM MgCl<sub>2</sub>) in the presence of Sigma P8340 protease inhibitor cocktail (containing 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin and aprotinin) at 100  $\mu$ l/10 $^7$  cells. The crude lysates were then centrifuged at 10,000 g for 10 minutes.

The supernatants prepared from vector- (Control), human E3 $\alpha$ -I- (hu-E3 $\alpha$ -I) or human E3 $\alpha$ -II- (hu-E3 $\alpha$ -II) transfected cells were subjected to ubiquitination reactions. To measure ubiquitination of endogenous proteins, 30  $\mu$ g of cell lysate was incubated with  $^{125}$ I-ubquitin (0.15 mg/ml, approximately10<sup>7</sup>cpm) in a total volume of 40  $\mu$ l in a buffer containing 50 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl<sub>2</sub>, 2 mM adenosine 5'-[-thio]triphosphate (ATP S), 50  $\mu$ g/ml ubiquitin

25

aldehyde, MG132 20  $\mu$ g/ml and protease inhibitor cocktail (Sigma P8340) at 37 $^{\circ}$ C for 30 minutes. Reactions were stopped by adding sample buffer and were subjected to 12% SDS PAGE. The gels were then dried and autoradiographed.

The ubiquitination of α-lactalbumin, a known substrate for N-end Rule Ubiquitination was also measured with the 239T transfected cells. For these reactions, 30 μg of cell lysate proteins was incubated with 0.15 mg/ml <sup>125</sup>I-α-Lactalbumin and 0.25 mg/ml unlabeled ubiquitin in a total volume of 40 μl in a buffer containing 50 mM Tris (pH 8.0) 2 mM DTT, 5 mM MgCl<sub>2</sub>, 2 mM adenosine 5'-[-thio]triphosphate (ATP S), ubiquitin aldehyde 50 ug/ml, 20 μg/ml MG132 and protease inhibitor cocktail (Sigma P8340) at 37°C for 30 minutes. Reactions were stopped by adding sample buffer and each reaction was run of a 8% SDS PAGE was performed. The gels were then dried and autoradiographed

The amount of radioactivity incorporated into high molecular weight bands denoted as "ubquitin-protein conjugates" in Figure 4 (above 18 kDa for endogenous proteins and above 35 kDa for  $\alpha$ -Lactalbumin) were quantitated by using Phosphalmager and plotted (right panel). These reactions indicated that recombinant expression of huE3 $\alpha$ I or huE3 $\alpha$ II in 293 cells lead to accelerated ubiquination of endogenous cellular proteins and ubiquitin conjugation to  $\alpha$ -lactobumin, a bona fide N-end rule substrate.

To further substantiate the enzymatic activity of huE3 $\alpha$ I and huE3 $\alpha$ II, ubiquitin conjugation to endogenous cellular proteins were measured in cultured muscle cell lines. Cultures of murine  $C_2C_{12}$  or rat L6 myotube cells (ATCC accession nos. CRL-1772 and CRL-1458, respectively) were transfected with huE3 $\alpha$ I or huE3 $\alpha$ II full length cDNA under control of the CMV promoter using Lipofectamine 2000 Reagent (Gibco). Mock transfection with the pcDNA3.1 vector without a cDNA insert was performed as a control. Cell lysates were prepared as described above for the 293T cells and the resulting supernatants were used in ubiquitin conjugation reactions. For each reaction, 30  $\mu$ g of  $C_2C_{12}$  or L6 myotube cell lysate was incubated with <sup>125</sup>I-ubiquitin (0.15 mg/ml, approximately x10<sup>7</sup>cpm) in a total volume of 25-30  $\mu$ l in a buffer containing 50 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl2, 2 mM adenosine 5'-[-thio]triphosphate (ATP S), 50  $\mu$ g/ml ubiquitin aldehyde, 20  $\mu$ g/ml MG132 and protease inhibitor cocktail (Sigma P8340) at 37°C for 30 minutes. Reactions were stopped by adding sample buffer and were subjected to 12% SDS PAGE. The gels were then dried and autoradiographed.

20

15

5

10

30

10

15

20

25

30

The amount of ubiquitinated muscle proteins ( $^{125}$ I-Ubiquitin protein conjugates) were quantitated as the total radioactivity incorporated into high molecular weight bands (above 18 kDa) using a Phsophoimager as shown in Figure 5 (left panel). These reactions indicated that transfection of huE3 $\alpha$ I and huE3 $\alpha$ II increased ubiquitination of cellular proteins 2-3 fold (see Figure 5, right panel) in murine  $C_2C_{12}$  and rat myotube cultures.

#### **EXAMPLE 11**

## Expression of Human E3αI and Human E3αII is Unregulated During Cachexia Disease States

The Yoshida Hepatoma-130 (YAH) cachexia rat model as described in Baracos et al. (Am. J.Physiol., 268(5 Pt 1): E996-1006, 1995) was used to determine if huE3αI and huE3αII are upregulated in cachexia disease states. For tumor implantation, female Sprague-Dawley rats of the Buffalo strain from a colony maintained at the University of Alberta were used as the host for the YAH tumor cells. Tumor cell stocks were maintained in liquid nitrogen and used after two passages in recipient female animals of the same strain. Rats were housed in individual wire mesh cages in a temperature (24°C)- and humidity (80%)-controlled room on a 12:12-h light-dark cycle. Rats were fed ground laboratory chow (Continental Grain, Chicago, IL) containing 24% crude protein.

Rats were allocated by initial body weight to three groups such that the sizes (mean  $\pm$  SE) of the animals receiving each treatment were similar (~ 200g). Two different treatments were compared: YAH-bearing and pair-fed control rats. The pair-fed rats, which received one meal per every day at 9.00am, were fed on the basis of their body weights, the same amount of food consumed by the tumor-bearing rats. On days 1,2,3,4 and 5 after tumor-implantation, food intake was determined in preliminary experiments to be 9, 7.5, 5.3, 1.5, and 0.9% respectively, of initial body weight per day. Rats were implanted with 100 ml of ascites fluid containing YAH cells from a single donor animal. The control rats were implanted with an equal volume of saline buffer. Rats were sacrificed by  $CO_2$  asphyxiation after 3 and 5 days, and epitrochelaris, EDL, soleus, medial gastrocnemius muscles were rapidly dissected and the gastrocnemius muscles were weighed. Tissues were frozen immediately in liquid nitrogen and stored at  $-70^{\circ}C$  until use.

10

15

20

25

30

The gastrocnemius skeletal muscle weights in YAH-130 tumor bearing rats were significantly lower than those measured from the pair-fed control rats. As indicated in the Table V below, the YAH-130 tumor bearing rats underwent muscle wasting by day 3 after tumor implantation which was more apparent at day 5 after implantation. The muscle weights are calculated (in grams) as the mean  $\pm$  standard error.

Days after Tumor Implantation	n	Pair Fed Control (in grams)	Tumor-Bearing (in grams)	Percent Change
3 days	8	$530 \pm 14.6$	$508 \pm 7.3$	-4.3%
5 days	8	593 ± 8.1	$443 \pm 9.4$	-25.3%

n = number of animals

The rate of ubiquitin conjugation of the endogenous muscle proteins were carried out as described in Example 10 using the skeletal musclesfrom the YAH tumor-bearing rats. The frozen gastrocnemius muscles collected (via dissection at sacrifice) from 6 tumor-bearing rats were combined. The muscle extracts (20% weight/volume) were prepared by homogenizing the muscles in a buffer containing 50 mM Tris HCl (pH 8.00), 5 mM MgCl<sub>2</sub>, 2 mM DTT, protease inhibitor cocktail (Sigma P8340) and 10% glycerol. The homogenates were then centrifuged at 40,000g for 1 hr and the resulting supernatants were used as crude muscle extracts.

For some assays, the crude muscle extracts were fractionated further by chromatography on DEAE-cellulose (Whatman, Clifton, New Jersey) to remove endogenous ubiquitin as described by Soloman *et al.* (*Proc. natl. Acad. Sci. U.S.A.*, 95: 12602-7, 1998). The bound material Fraction II, which contained most of the ubiquitin conjugating enzymes were eluted with 50 mM Tris, pH 8.0 containing 0.5M NaCl and 1 mM DTT. Both crude extracts and Fraction II were dialyzed prior to use for ubiquitination assay against buffer containing 20 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl2, and 10% glycerol and stored at 70 °C until use. Crude muscle extracts were used for ubiquitin conjugation to 125I- $\alpha$ -lactalbumin. Fraction II was used when rates of endogenous skeletal muscles proteins were compared and also when effects of E3 $\alpha$  inhibitors on skeletal muscle protein ubiquitination were tested.

The Fraction II from both tumor-bearing and pair-fed control rats were subjected to ubiquitination reactions of the endogenous muscle proteins as described in

Example 10 in the presence of 20 μg/ml of bestatin and 10 mM of either the E3α selective inhibitor arginine methyl ester (Arg-ME) or the control alanine methyl ester (Ala-ME) (Sigma Chemicals, St. Louis MO). The reactions were incubated at 37°C for 20 minutes and the <sup>125</sup>I-Ubiquitin conjugates were resolved by 12% SDS PAGE as described in Example 10.

As shown in Figure 6, the tumor-bearing rats exhibited accelerated muscle protein ubquitination. The increase in ubiquitination within the rat skeletal muscles of the tumor-bearing rats was attributable to the activation of the  $E3\alpha/N$ -end rule pathway, since the addition of  $E3\alpha$  specific inhibitor arginine methylester virtually abolished the accelerated ubiquitination activity (see lanes 9 and 10 on Figure 6).

To further establish the role of huE3 $\alpha$ I and huE3 $\alpha$ II in the N-end rule pathway in muscle wasting in the rat cachexia model, the rates of ubiquitination of N-end rule substrate  $\alpha$ -lactalbumin was measured in skeletal muscle extracts from control and tumor-bearing mice. <sup>125</sup>I- $\alpha$ -lactalbumin (0.15 mg/ml) was incubated with crude skeletal muscle extracts (2 mg/ml) in the presence of 0.25 mg/ml of ubiquitin at 37°C for 0 or 20 minutes as described in Example 10. As shown in Figure 7, the atrophying muscles dissected from the tumor-bearing rats exhibited increased ubiquitin conjugation to <sup>125</sup>I- $\alpha$ -lactalbumin

Northern blot analysis was carried out to measure the huE3 $\alpha$ I and huE3 $\alpha$ II mRNA expression in the gastrocnemius muscles of YAH-130 tumor-bearing mice. RNA from the dissected muscles was isolated with Trizol Reagent (Gibco, cat: 15596-018). The final RNA pellets were resuspended in DEPC-H<sub>2</sub>O and 20  $\mu$ g of total RNA per lane were separated by electrophoresis through 1% agarose gels. The separated RNA was transferred to nylon membranes and cross-linked to the filter by exposure to ultraviolet light.

The cDNA probes were generated by PCR with the following primers: for Hu-E3α–I probe: 5' primer, AGG AAG CTG TGG TCA TGT (SEQ ID NO: 22); 3' primer, GTT AGG AAG AAC AAC TG (SEQ ID NO: 23); for Hu-E3α–II probe: CTA AAG AAC AGC GAA GGC AAC AG (SEQ ID NO: 24); 3' primer, CGC AGC TAC CCC AAC ACA TTA T (SEQ ID NO: 25). PCR was carried out for 30 cycles at 94°C for 45 seconds, 50-58 °C for 45 seconds, and 72°C for 1 minutes using a commercially avaiblae kit (Boehringer Mannheim, cat: 1578553,). The PCR product was cloned into the pCR2.1 vector using the Original TA Cloning kit (Invitrogen). After digestion with EcoRI, the cloned PCR product was sequenced and confirmed.

15

10

5

20

25

The resulting cDNA probes were radiolabeled with [<sup>32</sup>P]dCTP using the Prime-it RMT labeling kit (Stratagene, cat: 300392). Membranes were prehybridized and hybridized (with the cDNA probes) in buffer containing 1% BSA, 7% SDS, 0.5 M Sodium Phosphate (pH 7.0), 1mM EDTA. Subsequently, the blots were washed in buffer containing 1% SDS, 0.04 M Sodium Phosphate, 1 M EDTA, by the method of Church and Gilbert (*Proc. Natl. Acad. Sci. U.S.A.* 81:1991-1995, 1984) and exposed to radiographic film at –70°C overnight.

As shown in Figure 8, the expression of huE3αII mRNA was increased at day 3 post-tumor implantation (see left panal) but the level of huE3αI had not changed significantly at day 3 (see right panel). This coincides with the time point when the significant decrease in muscle mass was detectable in the C26 tumor-bearing mice (See Table VI in Example 12). The expression of both huE3αI and huE3αII was elevated at day 5 post-tumor implantation in the tumor bearing rats. This corresponds to a cachexia state with severe muscle wasting.

15

10

5

# EXAMPLE 12 Expression of Human E3αI and Human E3αII in a Murine Cancer Cachexia Model of C26 Tumor Bearing Mice

20

25

30

The Colon-26 (C-26) tumor model of cachexia was used to demonstrate the role of huE3 $\alpha$ I and huE3 $\alpha$ II as described in Matsumoto *et al.*, *Brit. J. Can.* 79: 764-9 (1999) and Tanaka *et al.*, *Can. Res.*, 50: 2290-5 (1990). Seventy-two week old male CDF1 mice were injected in the left flank with 0.2 ml containing either 0.5 x10 $^6$  C26 cells or PBS. Following injection, body weight and food intake was observed daily. The pair fed control mice (generated as described in Example 11) were fed the daily average food intake of the tumor bearing group. On the day 12 or 17 post-injection, tumor bearing mice and pair fed control mice were sacrificed by  $CO_2$  asphyxiation. Subsequently, a terminal serum sample was collected and the kidney, heart and gastrocnemius muscles were rapidly dissected and weighed. The resulting C26 tumors were also weighed. The tissues were frozen on dry ice and stored at -70 $^\circ$ C.

The wet weight of the skeletal muscles from the tumor-bearing mice were significantly less than the weight of those from the pair-fed control mice as shown below in Table VI:

10

15

20

Days after Tumor Implantation	n	Pair Fed Control (in grams)	Tumor-Bearing (in grams)	Percent Change
12 days	12	$0.127 \pm 0.007$	$0.116 \pm 0.0072$	-8.6%
17 days	12	$0.117 \pm 0.009$	$0.087 \pm 0.001$	-26%

n = number of animals

RNA was isolated at day 12 and day 17 from the gastrocnemius muscle and cardiac muscle from the C26 tumor-bearing and pair-fed control mice as described in Example 11. Northern blot analysis was carried out by loading 20  $\mu g$  of total RNA per lane and seperating by electrophoresis through 1% agarose gels. The separated RNA was transferred to nylon membranes and cross-linked to the filter by exposure to ultraviolet light.

The cDNA probes were generated by PCR with the following primers: for mouse E3α–I probe: 5' primer, TTT CTT CCA TTC CCT GCA TAC A (SEQ ID NO: 26), 3' primer, CAA AAC TTT ATA AAG GTG CCC GTA A (SEQ ID NO: 27), and for Mouse E3α–II probe: 5' primer, ATT CCC TGC ATG CAC TTC AGT AA (SEQ ID NO: 28), 3' primer, CAT TCC CTG CAT GCA CTT CAG SEQ ID NO: 29). PCR was carried out for 30 cycles at 94°C for 45 seconds, 50-58 °C for 45 seconds, and 72°C for 1 minutes using a commercially available kit (Boehringer Mannheim cat: 1578553, ). The PCR product was cloned into the pCR2.1 vector using the Original TA Cloning kit (Invitrogen). After digestion with EcoRI, the cloned PCR product was sequenced and confirmed.

The resulting cDNA probes were radiolabeled with [<sup>32</sup>P]dCTP using the Prime-it RMT labeling kit (Stratagene, cat: 300392). Membranes were prehybridized and hybridized (with the cDNA probes) in buffer containing 1% BSA, 7% SDS, 0.5 M Sodium Phosphate (pH 7.0), 1mM EDTA. Subsequently, the blots were washed in buffer containing 1% SDS, 0.04 M Sodium Phosphate, 1 M EDTA, by the method of Church and Gilbert (*Proc. Natl. Acad. Sci. U.S.A.* 81:1991-1995, 1984) and exposed to radiographic film at –70°C overnight.

As shown in Figure 9, at day 12 after tumor-implantation tehrere was a clear increase in huE3αII mRNA expression in the skeletal muscles of tumor-bearing mice. Expression of both huE3αI and huE3αII was increased at day 17 post-implantation. Increased expression of huE3αII mRNA coincides with the time point

25

when the significant decease in muscle mass became detectable in tumor-bearing mice (See Table VI above). The expression of huE3αI and huE3αII remained unchanged in the cardiac muscle of the tumor-bearing mice. This corresponds to a cachexia state with severe muscle wasting.

5

10

The data described in both Examples 11 and 12 show that in experimental cachexia models, there was a sharp rise in the rate of ubiquitination in skeletal muscle tissues. The accelerated ubiquitination is due largely to the activation of E3 $\alpha$ , since addition of the E3 $\alpha$ -selective inhibitor, arginine methylester, virtually abolished all the increased ubiquitination activities. In addition, the data demonstrated that in two widely used experimental models of cachexia (murine C26 tumor-bearing model and rat YAH-130 tumor-bearing model), the mRNA levels of E3 $\alpha$ -I and E3 $\alpha$ -II increase significantly and specifically within skeletal muscle during the course of cachexia and muscle wasting. In these disease models and during the course of cachexia, the induction of E3 $\alpha$ -II occurred earlier than that of E3 $\alpha$ -I and coincided with the early onset of muscle wasting. During the late stage of cachexia, both E3 $\alpha$ -I and E3 $\alpha$ -II were markedly induced when muscle wasting became pronounced. Therefore, the results suggest that E3 $\alpha$ -II may play a more critical role in cachexia, although both E3 $\alpha$ -I and E3 $\alpha$ -II are apparently involved in the disease

20

process.

IL) for 3 days and 5 days.

15

## **EXAMPLE 13**

# Treatment of Muscle Cells with TNFα and IL-6 leads to Increased Expression of Human E3αII and Increased Ubiquitination

Treatment with the proinflammatory cytokines, TNFα and IL-6,

25

caused the induction of huE3 $\alpha$ II in C<sub>2</sub>C<sub>12</sub> myotube cultures. C<sub>2</sub>C<sub>12</sub> myoblasts were cultured in 100-mm dishes in an atmosphere of 5% CO<sub>2</sub> at 37°C in DMEM supplemented with 10% FBS and L-glutamine to reach 100% confluence. Myoblast differentiation was induced with DMEM supplemented with 2% horse serum and L-glutamine for 96 hours. Differentiated myotubes were then treated with TNF $\alpha$  (10 ng/ml; R&D Systems cat no. 210-TA) or IL-6 (10 ng/ml; R&D Systems cat no. 206-

30

After the 3 or 5 day incubation, RNA from differentiated  $C_2C_{12}$  cultures was isolated with Trizol Reagent and Northern blot analysis was carried out

as described in Example 11. Isolated RNA from untreated  $C_2C_{12}$  cultures were used as a control. The blots were hybridized with a  $^{32}$ P-labeled cDNA probes specific for muE3 $\alpha$ I (lower panels) and muE3 $\alpha$ II (upper panels). The probes were genreated as described in Example 12.

5

As shown in Figure 10, the expression of muE3 $\alpha$ II was markedly increased in the cells treated with TNF $\alpha$  or IL-6 (See upper panels). Conversely, the expression of muE3 $\alpha$ I was not drastically induced in response to proinflammatory cytokine treatment. This data indicates a role for E3 $\alpha$ II in cytokine-mediated protein catabolism and muscle wasting.

10

Cytokine treatment also resulted in accelerated ubiquitination in differentiated C<sub>2</sub>C<sub>12</sub> cells. C<sub>2</sub>C<sub>12</sub> cells were differentiated for 5 days to allow formation of myotubes. The differentiated myotubes were treated with 2 ng/ml of IL-6 for 5, 24 or 48 hours. After the incubation, the cells were lysed and <sup>125</sup>I-Ubiquitin conjugation was carried out as described in Example 10. As shown in Figure 11, IL-6 treatment resulted in a marked increase in ubiquination of cellular proteins (left panel) which was detectable 5 hours post-treatment. The increase in ubiquination was time dependent (see right panel).

15

Differentiated  $C_2C_{12}$  myotubes were also treated with increasing concentrations of TNF $\alpha$  (0, 3, 6, 10, 20 ng/ml) for one hour. This treatment resulted in a dose dependent increase in <sup>125</sup> I- ubiquitin conjugation of cellular proteins as shown in Figure 12.

20

25

TNF $\alpha$  and IL-6 are major proinflammatory cytokines known to be involved in cachexia and tissue wasting. The data reveals that these cytokines significantly upregulate the mRNA expression of E3aII in muscle cells and stimulate muscle protein ubiquitination. Proinflammatory cytokines, such as TNF $\alpha$ , IL-6, IL-1, interferon-gamma, CNTF and leptin, have been shown to be involved in disease states of cachexia and protein/tissue wasting, including cancer cachexia, renal cachexia (energy-protein malnutrition), burn cachexia and AIDS wasting. These findings that TNF $\alpha$  and IL-6 induce the expression of E3 $\alpha$ II (Figure 9) and stimulate protein ubiquitination in muscle cells (Figures 10 and 11) strongly suggest that E3 $\alpha$ II is critical target via which various cachectic factors induce protein catabolism and cachexia/muscle wasting. This argument is further supported by our finding that

While the present invention has been described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

10

5

15

Holy gray was the sale street but the

But the test with sign as

20

25

15

20

25

### **CLAIMS**

### WHAT IS CLAIMED IS:

- An isolated nucleic acid molecule comprising a nucleotide
   sequence selected from the group consisting of:
  - (a) the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
  - (b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 or 4;
  - (c) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of (a) or (b); and
    - (e) a nucleotide sequence complementary to any of (a)-(c).
  - 2. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
  - (b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
  - (c) a nucleotide sequence of SEQ ID NOS: 1; 3; (a); or (b) encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
  - (d) a nucleotide sequence of SEQ ID NOS: 1, 3, or (a)-(c) comprising a fragment of at least about 16 nucleotides;
  - (e) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(d); and
    - (f) a nucleotide sequence complementary to any of (a)-(c).

10

15

20

25

- 3. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (b) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (c) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (d) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (e) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS: 2 or 4 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (f) a nucleotide sequence of (a)-(e) comprising a fragment of at least about 16 nucleotides;
- (g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f); and
  - (h) a nucleotide sequence complementary to any of (a)-(e).
  - 4. A vector comprising the nucleic acid molecule of claims 1, 2, or 3.
  - 5. A host cell comprising the vector of claim 4.
  - 6. The host cell of claim 5 that is a eukaryotic cell.
  - 7. The host cell of claim 5 that is a prokaryotic cell.

- 8. A process of producing a huE3 $\alpha$  polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
  - 9. A polypeptide produced by the process of claim 8.
- 10. The process of claim 8, wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native huE3α polypeptide operatively linked to the DNA encoding the huE3α polypeptide.

11. The isolated nucleic acid molecule according to claim 2 wherein the percent identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

- 12. A process for determining whether a compound inhibits  $huE3\alpha$  polypeptide activity or production comprising exposing a cell according to claims 5, 6, or 7 to the compound, and measuring  $huE3\alpha$  polypeptide activity or production in said cell.
- 13. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NOS: 2 or 4.
- 14. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- (a) the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4 comprising a mature amino terminus at residue 1, optionally further comprising an amino-terminal methionine;
  - (b) an amino acid sequence for an ortholog of SEQ ID NOS: 2 or 4;
- (c) an amino acid sequence that is at least about 70, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of SEQ ID NOS: 2 or 4, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

15

10

5

20

25

10

15

20

25

- (d) a fragment of the amino acid sequence set forth in SEQ ID NOS: 2 or 4 comprising at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (e) an amino acid sequence for an allelic variant or splice variant of either the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, or at least one of (a)-(c).
- 15. An isolated polypeptide of claim 14 wherein the amino acid sequence is a mouse ortholog set out in SEQ ID NO: 6.
- 16. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (b) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (c) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- (d) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4; and
- (e) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4.
- 17. An isolated polypeptide encoded by the nucleic acid molecule of claims 1, 2, or 3.

18. The isolated polypeptide according to claim 14 wherein the percent identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

5

- 19. An antibody produced by immunizing an animal with a peptide comprising an amino acid sequence of SEQ ID NOS: 2 or 4.
- 20. An antibody or fragment thereof that specifically binds the polypeptide of claims 13, 14, 15 or 16.
  - 21. The antibody of claim 20 that is a monoclonal antibody.
  - 22. A hybridoma that produces a monoclonal antibody that binds to a peptide comprising an amino acid sequence of SEQ ID NOS: 2 or 4.
  - 23. A method of detecting or quantitating the amount of huE3 $\alpha$  polypeptide using the anti-huE3 $\alpha$  antibody or fragment of claims 18, 19, or 20.
- 20

30

- 24. A method for determining the presence and/or concentration of huE3 $\alpha$  polypeptide in a biological sample comprising the steps of:
  - (a) obtaining a biological sample;
- (b) contacting the biological sample with an antibody according to claim 22 under conditions which allow for the antibody to bind to the  $huE3\alpha$
- polypeptide;
  - (c) detecting antibody binding to huE3α polypeptide in the biological sample, wherein the detection of antibody binding is indicative of the presence of huE3α polypeptide in said biological sample; and
  - (d) comparing the level of antibody binding to huE3 $\alpha$  polypeptide within said biological sample and the level of the antibody binding to a known concentration of huE3 $\alpha$  polypeptide.

10

15

20

25

- 25. A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4; and
- (b) fragment of the amino acid sequence set forth in at least one of SEQ ID NOS: 2 or 4; or a naturally occurring variant thereof.
- 26. The selective binding agent of claim 25 that is an antibody or fragment thereof.
  - 27. The selective binding agent of claim 25 that is a humanized antibody.
- 28. The selective binding agent of claim 25 that is a human antibody or fragment thereof.
- 29. The selective binding agent of claim 25 that is a polyclonal antibody or fragment thereof.
- 30. The selective binding agent claim 25 that is a monoclonal antibody or fragment thereof.
- 31. The selective binding agent of claim 25 that is a chimeric antibody or fragment thereof.
- 32. The selective binding agent of claim 25 that is a CDR-grafted antibody or fragment thereof.
- 33. The selective binding agent of claim 25 that is an antiidiotypic antibody or fragment thereof.
- 34. The selective binding agent of claim 25 which is a variable region fragment.

10

15

20

- 35. The variable region fragment of claim 25 which is a Fab or a Fab' fragment.
- 36. A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of SEQ ID NOS: 2 or 4.
- 37. The selective binding agent of claim 25 which is bound to a detectable label.
- 38. A selective binding agent produced by immunizing an animal with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2 or 4.
- 39. A hybridoma that produces a selective binding agent capable of binding a polypeptide according to claims 1, 2, or 3.
- 40. A composition comprising the polypeptide of claims 13, 14, or 16 and a pharmaceutically acceptable formulation agent.
- 41. The composition of claim 40 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.
- 42. The composition of claim 40 wherein the polypeptide comprises the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4.
- 43. A polypeptide comprising a derivative of the polypeptide of claims 13, 14, or 16.
- 30 44. The polypeptide of claim 43 which is covalently modified with a water-soluble polymer.

10

15.

20

- 45. The polypeptide of claim 44 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, and polyvinyl alcohol.
- 46. A composition comprising a nucleic acid molecule of claims 1, 2, or 3 and a pharmaceutically acceptable formulation agent.
- 47. A composition of claim 46 wherein said nucleic acid molecule is contained in a viral vector.
  - 48. A viral vector comprising a nucleic acid molecule of claims 1, 2, or 3.
- 49. A fusion polypeptide comprising the polypeptide of claims 13, 14, or 16 fused to a heterologous amino acid sequence.
- 50. The fusion polypeptide of claim 49 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.
- 51. A method for treating, preventing or ameliorating a medical condition in a mammal resulting from decreased levels of huE3α polypeptide comprising administering a huE3α polypeptide to said mammal.
- 52. The method of claim 51 wherein the huE3α polypeptide administered is the amino acid sequence set forth in SEQ ID NOS: 2 or 4 or a fragment thereof at least 25 amino acids or a homolog, analog or variant of said huE3α polypeptide or fragment thereof.
- 53. The method of claim 51 wherein the huE3α polypeptide administered has the amino acid set forth in SEQ ID NOS: 2 or 4 with at least one amino acid substitution.

- 54. The method of claim 51 wherein the huE3 $\alpha$  polypeptide administered has the amino acid sequence set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deleted.
- 55. A method of diagnosing the existence or a susceptibility to a pathological condition in a subject caused by or resulting from abnormal levels of  $huE3\alpha$  in a mammalian subject comprising:
- (a) determining the level of  $huE3\alpha$  in a biological, tissue or cellular sample; and
- (b) comparing the level of huE3 $\alpha$  polypeptide in biological, tissue or cellular samples form normal subjects or the subject at an earlier time; wherein a susceptibility of an existence of a pathological condition is based on the presence or amount of expression of huE3 $\alpha$  polypeptide.
  - 56. A device, comprising:
  - (a) a membrane suitable for implantation; and
- (b) cells encapsulated within said membrane, wherein said cells secrete a protein of claims 13, 14, or 16; said membrane being permeable to said protein product and impermeable to materials detrimental to said cells.

5

10

15

- 57. A device, comprising:
- (a) a membrane suitable for implantation; and
- (b) The  $huE3\alpha$  polypeptide encapsulated within said membrane, wherein said membrane is permeable to the polypeptide.

25

- 58. A method of identifying a compound which binds to a polypeptide comprising:
- (a) contacting the polypeptide of claims 13, 14, or 16 with a compound; and
  - (b) determining the extent of binding of the polypeptide to the compound.

- 59. A diagnostic reagent comprising a detectably labeled polynucleotide encoding the amino acid sequence set out in SEQ ID NOS: 2 or 4; or a fragment, variant or homolog thereof including allelic variants and spliced variants thereof.
- 60. The diagnostic reagent of claim 58, wherein said labeled polynucleotide is a first-strand cDNA.
- 61. A method for determine the presence of huE3 $\alpha$  nucleic acids in a biological sample comprising the steps of:
- (a) providing a biological sample suspected of containing  $huE3\alpha$  nucleic acids;
- (b) contacting the biological sample with a diagnostic reagent according to claim 59 under conditions wherein the diagnostic reagent will hybridize with huE3α nucleic acids contained in said biological sample;
- (c) detecting hybridization between huE3 $\alpha$  nucleic acid in the biological sample and the diagnostic reagent; and
- (d) comparing the level of hybridization between the biological sample and diagnostic reagent with the level of hybridization between a known concentration of huE3 $\alpha$  nucleic acid and the diagnostic reagent.
- 62. A method for detecting the presence of huE3 $\alpha$  nucleic acids in a tissue or cellular sample comprising the steps of:
- (a) providing a tissue or cellular sample suspected of containing  $huE3\alpha$  nucleic acids;
- (b) contacting the tissue or cellular sample with a diagnostic reagent according to claim 59 under conditions wherein the diagnostic reagent will hybridize with huE3α nucleic acids;
- (c) detecting hybridization between huE3 $\alpha$  nucleic acid in the tissue or cellular sample and the diagnostic reagent; and
- (d) comparing the level of hybridization between the tissue or cellular sample and diagnostic reagent with the level of hybridization between a known concentration of huE3 $\alpha$  nucleic acid and the diagnostic reagent.

10

5

20

25

- 63. The method of claim 59 wherein said polynucleotide molecule is DNA.
- The method of claim 59 wherein said polynucleotide molecule isRNA.
  - 65. A method of modulating levels of a polypeptide in an animal comprising administering to the animal the nucleic acid molecule of claims 1, 2, or 3.
- 10 66. A transgenic non-human mammal comprising the nucleic acid molecule of claims 1, 2, or 3.

# ABSTRACT OF THE DISCLOSURE

The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of  $E3\alpha$  ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

# Figure 1

CEO	ID NO:						
3EQ	mouse_E3αII	MASEMEDEVO	ATD-RSILEC	SAFETACDWI.	OATDI.MPEUV	OHIAHCVOKI	49
4	human E3αII						49
15	mouse E3αI			APQRPASWWD	•	-	50
2	human E3αI			TPQRLASWWD		· -	50
_	Consensus			AW.			50
6	$mouse\_E3\alphaII$	YCRGPNPFPQ	KEDTLAQHIL	LGPMEWYICA	EDPALGFPKL	EQANKPSHLC	99
4	human_E3αII	YCRGPNPFPQ	KEDMLAQHVL	LGPMEWYLCG	EDPAFGFPKL	EQANKPSHLC	99
15	$mouse\_E3\alphaI$	YFAEMDPDLE	KQEESVQMSI	LTPLEWYLFG	EDPDICLEKL	KHSG-AFQLC	99
2	human_E3αI			FTPLEWYLFG			99
	Consensus	YP	KQ	L.P.EWYL.G	EDPKL	LC	100
6	mouse E3αII	CDMERMCEDE	VCCDDCAUDD	ECMECET	CCTUPPUDVP	Mmmcaaaaaa	140
6 -4	human E3αII			TCVLCMECFL TCVLCMECFL			149
15	mouse E3aI						149
	human E3αI			TCVLCMDCFQ			149 149
2	Consensus			TCVLCMDCFQ TCVLCM.CF.			150
	COMBCMBAB	ORVIR.OB. 1	ISCRECA. SI	TOVERN.CI.		M. IB. GGGTC	150
6	mouse E3αII	DCGDTEAWKE	GPYCQKHKLS	SSEVVEEEDP	LVHLSEDVIA	RTYNIFAIMF	199
4	human E3αII	DCGDTEAWKE	GPYCQKHELN	TSEIEEEEDP	LVHLSEDVIA	RTYNIFAITF	199
15	mouse E3αI			RAGTTKESLH			198
2	human E3αI			RAGTIKENSR			198
	Consensus			E			200
6	mouse_E3αII			VAEKSDTYYC		-	249
4	human_E3αII			MVEKSDTYYC		~ ~	249
1.5	mouse_E3αI	KYIVEMTIWE	EEKELPPELO	IREKNERYYC	VLFNDEHHSY	DHVIYSLQRA	248
2	human_E3αI			IREKNERYYC			248
	Consensus	.Y.VEWE	.E.ELPL.	EKYYC	.LFNDE.H.Y	VIY.LQ.A	250
6	mouse E3αII	MACTOREVIC	$\pi \Lambda \pi \pi \tau $	RPVRYGDFQY	CDOVRAZITIO	MTCDOTK_DI	298
4	human E3αII			RSVRYGDFQY			298
15	mouse E3aI			RAVKAGVYAT			298
2	human E3αI			RAVKAGAYAA	· -	<del></del>	298
-	Consensus			R.VG			300
6	mouse_E3αII	KVQVMHSSVA	AHQNFGLKAL	SWLGSVIGYS	DGLRRILCQV	GLQEGPDGEN	348
4	human_E3αII	KVQVMHSSIV	AHQNFGLKLL	SWLGSIIGYS	DGLRRILCQV	GLQEGPDGEN	348
15	mouse_E3αI	HVEVLHSVVM	AHQKFALRLG	SWMNKIMSYS	SDFRQIFCQA	CLVEEPGSEN	348
2	human_E3αI			SWMNKIMSYS			348
	Consensus	.V.V.HS	AHQ.F.L.L.	SWIYS	R.I.CQ.	.L.E.PD.EN	350
6	mouse E3αII	CCITADDIMIN	DCKI WKCADC	VYHOLFMSSL	I MIDI KUKKI E	אַר די	200
4	human E3aII			-		~	398
15	mouse E3aI			VYHQLFMSSL			398
2	human E3αI			ILHELIFSSF ILHELIFSSF			398
4	Consensus			H.LSS.			398 400
					***************************************		100
6	mouse_E3αII	LQRDFMEDDH	ERAVSVTALS	VQFFTAPTLA	RMLLTEENLM	TVIIKAFMDH	448
4	human_E3αII			VQFFTAPTLA			448
15	mouse_E3αI			VQMLTVPTLA			448
2	human_E3αI	LQKEYISDDH	DRSISITALS	VQMFTVPTLA	RHLIEEQNVI	SVITETLLEV	448
	Consensus	LQDDH	ERS.TALS	VQ.FT.PTLA	R.LI.E.N	SVIT	450

a ma	) TD NO		
SEÇ 6	~	I IMIDDAGOR OFFICIAL OF DIVERNING TO THE TOTAL OF THE TOT	
	mouse_E3αII		-
4 15	human_E3αII mouse E3αI	7 7	~
2	human E3αI		
۷	Consensus	I LPEYLDRNN- KFN-FQGYSQ DKLGRVYAVI CDLKYILISK PTIWTERI LFKRVI .DLKY.LISK PT.WI	
	00110011000	Z II	11. 500
6	mouse E3αII	I KFLQGFDAFL ELLKCMQGMD PITRQVGQHI EMEPEWEAAF TLQMKLTH	IVI 548
4	human E3αII		
15	mouse E3αI	~	
.2	human E3αI		
	Consensus	.FLEGFFLL.CMQGMI.RQVGQHI EP.WEAAQM.L	
6	mouse_E3αII		
4	human_E3αII	~	
15	mouse_E3αI	•	
2	human_E3αI		
	Consensus	:M.Q.WCA.D ELAYK. CM.CFCGHS.	ET 600
6	mouse_E3αII	I IDVOVCORNO CIUI DICRUI ACUMULICAC EMANARDRIL RIGRICAR	NAT CAO
4	human E3αII		
4 15	mouse E3aI	~	
	_		
2	human_E3αI Consensus	KSYRVSEDLV SIHLPLSRTL AGLHVRLSRL GAVSRLHEFV SFEDFQVEY.VSV SIHLP.SR.L AGLHV.LSE p	
	COMBCHBUS	,.1.vo/ SIMDF.Sk.U AGDAV.LGE P	.12 650
6	mouse E3αII	I IEHPLRCLVL CAQVHAGMWR RNGFSLVNQI YYYHNVKCRR EMFDKDIV	ML 698
4	human E3αII		
15	mouse E3αI	~	
2	- human E3αI		
	Consensus	.E.PLRCLVL .AQV.A.MWR RNG.SLQYYVKCR. EM.DKDI.	
6	mouse_E3αII		
4	human_E3αII	~~	INT 748
15	mouse_E3αI		
2	human_E3 $\alpha$ I	~	
	Consensus	Q.G.S.MDPN .FLL.R. ELTKSDQ.	NT 750
6	mouge E2c/H	I TERMINITI MINGERING NOVEMBER KREITHOLGT NEWSWORK	
	mouse_E3αII	~ ~	
4	human_E3αII	~	
15	mouse_E3αI		
2	human_E3αI Consensus	LIEEMLQVLI YIVGERYVPG VGNVTKEEVT MREIIHLLCI EPMPHSAI LIEEMLIVGERPG VG.VI .REIIH.L.I .PM.HS	
	COMBCMS	DIEBMIVGERPG VG.V REIIH.E.I .PM.HS	.1. 800
6	mouse E3αII	SLPEDENKET GMESVIESVA HFKKPGLTGR GMYELKPECA KEFNLYFY	HF 848
4	human E3αII		
15	mouse E3αI		
2	human E3αI		
	Consensus	LPE.EN.ET G.E.VIVA .FKKPGG. G.YELK.E K.FN.YFY	
	mouse_E3αII	SRAEQSKAEE AQRKLKRENK EDTALPPPAL PPFCPLFASL VNILQCDVM	
	human_E3αII	SRAEQSKAEE AQRKLKRQNR EDTALPPPVL PPFCPLFASL VNILQSDVM	
	mouse_E3αI	SKTQHSKAEH MQKKRRKQEN KDEALPPPPP PEFCPAFSKV VNLLSCDVM	
	human_E3αI	SKTQHSKAEH MQKKRRKQEN KDEALPPPPP PEFCPAFSKV INLLNCDIM	M 888
	Consensus	SSKAEQ.KQD.ALPPP P.FCP.F VN.L.CDVM	900

Figure 1 (continued)

SEQ	ID NO:						
6	mouse_E3αII	YIMGTILQWA	VEHHGSAWSE	SMLQRVLHLI	GMALQEEKHH	LENAVEGHVQ	948
4	human_E3αII	CIMGTILQWA	VEHNGYAWSE	SMLQRVLHLI	${\tt GMALQEEKQH}$	LENVTEEHVV	948
15	mouse_E3aI	YILRTIFERA	VDTESNLWTE	GMLQMAFHIL	ALGLLEEKQQ	LQKAPEEEV-	937
2	human E3αI				ALGLLEEKQQ		937
	Consensus	YITIA	VW.E	.MLQH	L.EEKQ.	LA.EE.V.	950
6	mouse E3αII	TFTFTOKISK	PGDAPHNSPS	ILAMLETLQN	APSLEAHKDM	IRWLLKMFNA	998
4	human E3αII				APYLEVHKDM		998
15	mouse E3αI	AFDFYHKASR	LGSSAMNAQN	IQMLLERLKG	IPQLEGQKDM	ITWILQMFDT	987
2	- human E3αI	TFDFYHKASR	LGSSAMNIQM	LLEKLKG	IPQLEGQKDM	ITWILQMFDT	984
	Consensus	TF.FK.S.	.GN	ILE.L	.P.LEKDM	I.WIL.MF	1000
6	mouse E3αII	TKKTRECS	SSSPVAEAEG	TIMEESSRDK	DKAERKRKAE	IARLRREKIM	1046
4	human E3aI	VKKMRESS	PTSPVAETEG	TIMEESSRDK	DKAERKRKAE	IARLRREKIM	1046
15	mouse E3αI					AARLHRQKIM	
2	human E3αI					AARLHRQKIM	
	Consensus	VKREC.	E.	EEDK	.KAERKRKAE	.ARL.R.KIM	1050
6	mouse E3αII	AOMSEMORHF	IDENKELFOO	TLELDTSASA	TLDSSPPV	SDAALTALGP	1094
4	human E3αII					SDMTLTALGP	
1.5	mouse E3αI	AQMSALQKNF			IMEEESTSAV		1087
2	human E3αI	AQMSALQKNF			IMEEESTPAV		1084
	Consensus	AQMSQF	IK	T.E	S.P.V	SDALGP	1100
6	mouse E3αII	AOTOVPEPRO	FVTCILCOEE	OEVTVGSRAM	VLAAFVORST	VLSKDRTKTI	1144
4	human E3αII					VLSKNRSKFI	
1.5	mouse E3αI					ALTQHRGKPV	
2	human E3α					ALTQHRGKPI	
	Consensus					.LR.K.I	
6	mouse E3αII	Δη - ΡΕΚΥΠΡΙ.	EMHPDI.SCGT	HTGSCGHVMH	AHCWORYFDS	VQAKEQRRQQ	1193
4	human E3αII					VQAKEQRRQQ	
15	mouse E3aI					VQLSSQQ	
2	human E3αI					VQLSSQQ	
_	Consensus					VQQQ	
6	mouse E3αII	RIRLHTSYDV	ENGEFLOPIC	ECLSNTVIPL	L-LPPRSTLS	RRLN-FSDQP	1241
4	human E3αII					NRLN-FSDQP	
15	_					ENAEALAQLL	
2	human E3αI					ENADALAQLL	
	Consensus	R	E.GE.LCPLC	L.NTVIP.	L.PI.S		1250
6	mouse E3αII	TVASTWOA.IG	OOTKVVOMLR	RKHNAA-DTS	SSEDTEAMNT	IPIPEGFRPD	1290
4	human E3αII					LQLPEGFRPD	
15	mouse E3aI					FEFHSILSFG	
2	human E3αI					LEFHSILSFG	
_	Consensus						
6	mouse E3αII	FYDRNDYSDS	TKEMLTTEGT	ΔΔΥΚΛΩΙ.ΚΛΉ	PNEGDPRVPT	LCWGTCAYTI	1340
4	human E3αII					MCWGSCAYTI	
15	mouse E3aI					MTWSTCAFTI	
2	human E3αI					LTWSTCAFTI	
	Consensus					W.TCA.TI	

# Figure 1 (continued)

aro	ID NO:						
5EQ	mouse E3all	OGTEDIT.GDE	FKDVFGDI.DC	PI.DDCL.PSI.T	ΔΛΑΜΤΛΙΔ	LLPVVQGHFC 13:	90
4	human E3αII					SVSVVQGHFC 13	
15	mouse E3αI					PQVLIHKHLA 138	
2	human E3αI					PQVLIQKHLV 13	
_	Consensus					Q.H 14	
6	mouse_E3αII					DFSGSSL 14	
4	human_E3αII					DFSGISL 14	
15	mouse_E3αI					DTVDLQPSPL 143	
2	human_E3αI					DPVDLQPSSV 14	
	Consensus	.LРМ.	EPC.L.	ID.FH.LVG.	VLAFP.L	DSSL 14	50
6	mouse_E3aII	ATGDLHTF	OVIHAMTVJIH	TILTSCTEEN	GMDOENP	TGEEELAILS 14	82
4	human E3αII					PCEEESAVLA 14	
15	mouse E3αI					DSEEARCASA 148	
2	human E3αI					DSEEAHSASS 14	
_	Consensus	LF	HL.TMAHQ	ILLTT	~Q	EE 15	00
6	mouse_E3αII					FHYLNGVPAP 15	
4	human_E3αII					FHYLNGVPSP 15	
15	mouse_E3αI					FHYLLGVAPP 153	
2	human_Ξ3αΙ					FHYLLGVTPP 15	
	Consensus	QYT.	GW	.LW.S.R.GI	.P.L.C.ALF	FHYL.GVP 15	50
6	mouse E3αII	PDLOV-SGTS	HFEHLCNYLS	LPTNLIHLFO	ENSDIMNSLI	ESWCQNSEVK 15	81
4	human E3αII					ESWCRNSEVK 15	
15	mouse E3αI					QRWCGDPALL 158	
2	human E3αI					QRWCADPALL 15	
	Consensus	LS	.FLCSYLS	LPTNLLFQ	EDL.	WC 16	00
6	mouse_E3αlI					SGGDKSRAPT 16	
4	human_E3αII					SGGDKSRAPT 16	
15	mouse_E3αI					SADDERKHPV 163	
2	human_E3αI Consensus	NCLKQKNTVV	RYPRKRNSLI	EPDDASCPP	NOASHFROPR	SADDERKHPV 16 SDP. 16	25 50
	Consensus		KILKK.BI		110110.1.01.	55	
6	mouse E3αII	LCLVCGSLLC	SQSYCCQAEL	EGEDVGACTA	HTYSCGSGAG	IFLRVRECQV 16	81
4	human_E3αII	LCLVCGSLLC	SQSYCCQTEL	EGEDVGACTA	HTYSCGSGVG	IFLRVRECQV 16	81
15	mouse_E3αI	LCLFCGAILC	SQNICCQEIV	NGEEVGACVF	HALHCGAGVC	IFLKIRECRV 168	83
2	$human_E3\alphaI$	LCLFCGAILC	SQNICCQEIV	NGEEVGACIF	HALHCGAGVC	IFLKIRECRV 16	75
	Consensus	LCL.CGLC	SQCCQ	.GE.VGAC	HCG.GV.	IFLREC.V 17	00
6	mouse E3αII	T DT ACKTRCC	עמטטעז.טטע	CETTOCI.PPC	NDI.HI.COFPF	RKIQKLWQQH 17	31
4	human E3αII					KKIQKLWHQH 17	
15	mouse E3aI					RKLHLVWQQH 17:	
2	human E3αI					RKLHLVWQQH 17	
ے	Consensus	GKGC	.YPYLD.Y	GETD.GL.RG	NPLHL.ER.	RKWQQH 17	50
6	mouse_E3αII	SITEEIGHAQ	EANQTLVGID	WQHL	1755		
4	human_E3αII		EANQTLVGID	· -	1755		
15	mouse_E3αI		ETNQMLFGFN		1757		
2	human_E3αI		ETNOMLFGFN		1749		
	Consensus	.1.EE1Q	E.NQ.L.G	wQ.L	1774		

Figure 2 The Expression Profile of huE3lpha-II in Human Tissues







Figure 3 The Expression Profile of huE3lpha-I in Human Tissues







Transfection of Human E3a-I or E3a-II cDNA Stimulates Ubiquitin Conjugation in Cultured Muscle Cell Lines






Figure 6  $\,$   $^{125}$ l-Ubiquitin Conjugation to Muscle Proteins and Its Sensitivity to E3lpha Inhibitor

Free Ub <sup>125</sup>I-Ub-Protein Conjugates Tumor-5D Control Contro v.s. 5-day tumor-bearing +Ala ME Tumor-5D Reaction Time (min) Control Tumor-5D Control in Skeletal Muscle Extracts Tumor-5D Control Tumor-5D 0, Control +Arg ME Contro v.s. 3-day tumor-bearing Tumor-3D Control Tumor-3D +Ala ME Reaction Time (min) Control Tumor-3D 20, Control Tumor-3D Control Tumor-3D 6 Control 1251-Ub-Protein Conjugates Free Ub




in gastrocnemius muscles in YAH-130 exprimental cachexia model Northern blot analysis of E3 $\alpha$ -I & E3 $\alpha$ -II expression



քսաօւ, d17 Northern blot analysis of E3 $\alpha$ -I and E3 $\alpha$ -II expression in 71b ,bət iraq control, d17 E3α-I gastrocnemius muscle and cardiac muscle tumor, dl2 in C26 experimental cachexia model pari fed, d12 control, d12 fumor, d17 71b, bəl iraq 📖 control, d17 E3 $\alpha$ -II tumor, dl2 pari fed, d12 control, dl2 Gastroenmius Heart

Figure 10

Proinflammatory cytokines TNF-α and IL-6



IL-6 Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures





Figure 12

 ${\sf TNF}_{\alpha}$  Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures



## SEQUENCE LISTING

```
<110> Han, Hui-Quan
      Kwak, Keith
<120> Human E3 Alpha Ubiquitin Ligase
<130> 01017/35966
<140>
<141>
<150> US 60/187,911
<151> 1999-03-08
<160> 29
<170> PatentIn Ver. 2.0
<210> 1
<211> 6308
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (696) .. (5942)
<400> 1
gccaagaatt cggcacgagg ggaaaagctg agcccaggaa ccaaattact tgctttacct 60
cattgtgtaa gacaagcgtc aaaaacagct tcaacctatc ttgaacaaga gaacttacct 120
ccaaaggett atcatetgte ttecaettat ecaacaaget getatggeca etgeetgtge 180
cgcacctgga accaccgcca gccccactac tgcctccact accactggtt ctcccaccct 240
gatcagctgc ttgctgctgc catcttatcc gcttctgcct gttctgagta aatgtataca 300
caccetggaa accaccatte taetttetgt gtetatgaat ttgaetaete tagetggate 360
ccgagctttt ttgtacacat gtgcaagtgc ccacggggta gaatcctaaa aatagaagat 420
gtatgcaaca gttcccagca ccaaacccag atatacaacc attcagctac caagagctac 480
gcctgataaa ttagagggga aaaaaaaaat ctccagtccc ttcacgtcgt gacgcttgct 540
tccgggaagc gggccggaag ccactcctcg agtctgcgtc aaacccgact tcaggggccg 600
teqtaaaaqt qteqteectq teteteegae eggeeaeagg ttteegettg cetetggeeg 660
ggggtcggca actgcaggcg tcagtttccc tcaag atg gcg gac gag gag gct
                                                                   713
                                        Met Ala Asp Glu Glu Ala
                                                                    761
gga ggt act gag agg atg gaa atc agc gcg gag tta ccc cag acc cct
Gly Gly Thr Glu Arg Met Glu Ile Ser Ala Glu Leu Pro Gln Thr Pro
                                                                    809
cag cgt ctg gca tct tgg tgg gat cag caa gtt gat ttt tat act gct
Gln Arg Leu Ala Ser Trp Trp Asp Gln Gln Val Asp Phe Tyr Thr Ala
                              30
         25
```

				gca Ala										857
				gaa Glu 60										905
				tgg Trp										953
		-	_	cac His	_		_	_		_				1001
	_			aca Thr				 	_	_	_		_	1049
				tgt Cys										1097
	_		_	atg Met 140								_	_	1145
				gca Ala										1193
				ggt Gly						_	_	_	_	1241
_		_		gtc Val		_								1289
				atg Met										1337
				agg Arg 220										1385
	_	_		cat His			_	_			_			1433
				gag Glu										1481
				cgt Arg										1529
				gaa Glu										1577

							gta Val									1625
							ggt Gly									1673
		_	_			_	atc Ile		_		_				_	1721
gaa Glu	cct Pro	gac Asp 345	tcg Ser	gag Glu	aat Asn	ccc Pro	tgt Cys 350	ctc Leu	ata Ile	agc Ser	agg Arg	tta Leu 355	atg Met	ctt Leu	tgg Trp	1769
							gcc Ala									1817
ttc Phe 375	agc Ser	agt Ser	ttt Phe	ttt Phe	atg Met 380	gag Glu	atg Met	gaa Glu	tac Tyr	aaa Lys 385	aaa Lys	ctc Leu	ttt Phe	gct Ala	atg Met 390	1865
gaa Glu	ttt Phe	gtg Val	aag Lys	tat Tyr 395	tat Tyr	aaa Lys	caa Gln	ctg Leu	cag Gln 400	aaa Lys	gaa Glu	tat Tyr	atc Ile	agt Ser 405	gat Asp	1913
							ata Ile									1961
act Thr	gtt Val	cct Pro 425	act Thr	ctg Leu	gct Ala	cga Arg	cat His 430	ctt Leu	att Ile	gaa Glu	gag Glu	cag Gln 435	aat Asn	gtt Val	atc Ile	2009
							cta Leu									2057
							cag Gln									2105
							gac Asp									2153
ccc Pro	aca Thr	ata Ile	tgg Trp 490	aca Thr	gaa Glu	aga Arg	tta Leu	aga Arg 495	atg Met	cag Gln	ttc Phe	ctt Leu	gaa Glu 500	ggt Gly	ttt Phe	2201
							acc Thr 510									2249
							att Ile									2297
gcc Ala 535	att Ile	gct Ala	ata Ile	cag Gln	atg Met 540	caa Gln	ttg Leu	aag Lys	aat Asn	att Ile 545	tta Leu	ctc Leu	atg Met	ttc Phe	caa Gln 550	2345

gag Glu	tgg Trp	tgt Cys	gct Ala	tgt Cys 555	gat Asp	gaa Glu	gaa Glu	ctc Leu	tta Leu 560	ctt Leu	gtg Val	gct Ala	tat Tyr	aaa Lys 565	gaa Glu	2393
tgt Cys	cac His	aaa Lys	gct Ala 570	gtg Val	atg Met	agg Arg	tgc Cys	agt Ser 575	acc Thr	agt Ser	ttc Phe	ata Ile	tct Ser 580	agt Ser	agc Ser	2441
aag Lys	aca Thr	gta Val 585	gta Val	caa Gln	tcg Ser	tgt Cys	gga Gly 590	cat His	agt Ser	ttg Leu	gaa Glu	aca Thr 595	aag Lys	tcc Ser	tac Tyr	2489
aga Arg	gta Val 600	tct Ser	gag Glu	gat Asp	ctt Leu	gta Val 605	agc Ser	ata Ile	cat His	ctg Leu	cca Pro 610	ctc Leu	tct Ser	agg Arg	acc Thr	2537
ctt Leu 615	gct Ala	ggt Gly	ctt Leu	cat His	gta Val 620	cgt Arg	tta Leu	agc Ser	agg Arg	ctg Leu 625	ggt Gly	gct Ala	gtt Val	tca Ser	aga Arg 630	2585
ctg Leu	cat His	gaa Glu	ttt Phe	gtg Val 635	tct Ser	ttt Phe	gag Glu	gac Asp	ttt Phe 640	caa Gln	gta Val	gag Glu	gta Val	cta Leu 645	gtg Val	2633
gaa Glu	tat Tyr	cct Pro	tta Leu 650	cgt Arg	tgt Cys	ctg Leu	gtg Val	ttg Leu 655	gtt Val	gcc Ala	cag Gln	gtt Val	gtt Val 660	gct Ala	gag Glu	2681
atg Met	tgg Trp	cga Arg 665	aga Arg	aat Asn	gga Gly	ctg Leu	tct Ser 670	ctt Leu	att Ile	agc Ser	cag Gln	gtg Val 675	ttt Phe	tat Tyr	tac Tyr	2729
caa Gln	gat Asp 680	gtt Val	aag Lys	tgc Cys	aga Arg	gaa Glu 685	gaa Glu	atg Met	tat Tyr	gat Asp	aaa Lys 690	gat Asp	atc Ile	atc Ile	atg Met	2777
ctt Leu 695	cag Gln	att Ile	ggt Gly	gca Ala	tct Ser 700	tta Leu	atg Met	gat Asp	ccc Pro	aat Asn 705	aag Lys	ttc Phe	ttg Leu	tta Leu	ctg Leu 710	2825
gta Val	ctt Leu	cag Gln	agg Arg	tat Tyr 715	gaa Glu	ctt Leu	gcc Ala	gag Glu	gct Ala 720	ttt Phe	aac Asn	aag Lys	acc Thr	ata Ile 725	tct Ser	2873
aca Thr	aaa Lys	gac Asp	cag Gln 730	gat Asp	ttg Leu	att Ile	aaa Lys	caa Gln 735	tat Tyr	aat Asn	aca Thr	cta Leu	ata Ile 740	gaa Glu	gaa Glu	2921
atg Met	ctt Leu	cag Gln 745	gtc Val	ctc Leu	atc Ile	tat Tyr	att Ile 750	gtg Val	ggt Gly	gag Glu	cgt Arg	tat Tyr 755	gta Val	cct Pro	gga Gly	2969
gtg Val	gga Gly 760	aat Asn	gtg Val	acc Thr	aaa Lys	gaa Glu 765	gag Glu	gtc Val	aca Thr	atg Met	aga Arg 770	gaa Glu	atc Ile	att Ile	cac His	3017
													aaa Lys			3065
cct Pro	gag Glu	aat Asn	gaa Glu	aat Asn 795	aat Asn	gaa Glu	act Thr	ggc Gly	tta Leu 800	gag Glu	aat Asn	gtc Val	ata Ile	aac Asn 805	aaa Lys	3113

gtg gcc aca Val Ala Thr	ttt aag a Phe Lys 1 810	aaa cca Lys Pro	ggt Gly	gta Val 815	tca Ser	ggc Gly	cat His	gga Gly	gtt Val 820	tat Tyr	gaa Glu	3161
cta aaa gat Leu Lys Asp 825	gaa tca Glu Ser	ctg aaa Leu Lys	gac Asp 830	ttc Phe	aat Asn	atg Met	tac Tyr	ttt Phe 835	tat Tyr	cat His	tac Tyr	3209
tcc aaa acc Ser Lys Thr 840												3257
aaa caa gaa Lys Gln Glu 855	Asn Lys	gat gaa Asp Glu 860	gca Ala	ttg Leu	ccg Pro	cca Pro 865	cca Pro	cca Pro	cct Pro	cct Pro	gaa Glu 870	3305
ttc tgc cct Phe Cys Pro	gct ttc Ala Phe 875	agc aaa Ser Lys	gtg Val	att Ile	aac Asn 880	ctt Leu	ctc Leu	aac Asn	tgt Cys	gat Asp 885	atc Ile	3353
atg atg tac Met Met Tyr												3401
tct aac ttg Ser Asn Leu 905	tgg acc Trp Thr	gaa ggg Glu Gly	atg Met 910	ctc Leu	caa Gln	atg Met	gct Ala	ttt Phe 915	cat His	att Ile	ctg Leu	3449
gca ttg ggt Ala Leu Gly 920	tta cta Leu Leu	gaa gag Glu Glu 925	aag Lys	caa Gln	cag Gln	ctt Leu	caa Gln 930	aaa Lys	gct Ala	cct Pro	gaa Glu	3497
gaa gaa gta Glu Glu Val 935												3545
tca gcc atg Ser Ala Met	aat ata Asn Ile 955	caa atg Gln Met	ctt Leu	ttg Leu	gaa Glu 960	aaa Lys	ctc Leu	aaa Lys	gga Gly	att Ile 965	ccc Pro	3593
cag tta gaa Gln Leu Glu	ggc cag Gly Gln 970	aag gac Lys Asp	atg Met	ata Ile 975	acg Thr	tgg Trp	ata Ile	ctt Leu	cag Gln 980	atg Met	ttt Phe	3641
gac aca gtg Asp Thr Val 985	Lys Arg											3689
aca tca gga Thr Ser Gly 1000	tcg gaa Ser Glu	tct att Ser Ile 1005	aag Lys	aat Asn	gat Asp	Glu	att Ile 1010	act Thr	cat His	gat Asp	aaa Lys	3737
gaa aaa gca Glu Lys Ala 1015	Glu Arg	aaa aga Lys Arg .020	aaa Lys	gct Ala	Glu	gct Ala 1025	gct Ala	agg Arg	cta Leu	His	cgc Arg 1030	3785
cag aag ato Gln Lys Ile	atg gct Met Ala 1035	cag atg Gln Met	tct Ser	Ala	tta Leu 1040	cag Gln	aaa Lys	aac Asn	Phe	att Ile 1045	gaa Glu	3833
act cat aaa Thr His Lys			Asn					Pro				3881

gat too att atg gag gaa gag ago aco coa goa gto agt gao tao tot Asp Ser Ile Met Glu Glu Glu Ser Thr Pro Ala Val Ser Asp Tyr Ser 1065 1070 1075	3929
aga att gct ttg ggt cct aaa cgg ggt cca tct gtt act gaa aag gag Arg Ile Ala Leu Gly Pro Lys Arg Gly Pro Ser Val Thr Glu Lys Glu 1080 1085 1090	3977
gtg ctg acg tgc atc ctt tgc caa gaa gaa cag gag gtg aaa ata gaa Val Leu Thr Cys Ile Leu Cys Gln Glu Gln Glu Val Lys Ile Glu 1095 1100 1105 1110	4025
aat aat gcc atg gta tta tcg gcc tgt gtc cag aaa tct act gcc tta Asn Asn Ala Met Val Leu Ser Ala Cys Val Gln Lys Ser Thr Ala Leu 1115 1120 1125	4073
acc cag cac agg gga aaa ccc ata gaa ctc tca gga gaa gcc cta gac Thr Gln His Arg Gly Lys Pro Ile Glu Leu Ser Gly Glu Ala Leu Asp 1130 1135 1140	4121
cca ctt ttc atg gat cca gac ttg gca tat gga act tat aca gga agc Pro Leu Phe Met Asp Pro Asp Leu Ala Tyr Gly Thr Tyr Thr Gly Ser 1145 1150 1155	4169
tgt ggt cat gta atg cac gca gtg tgc tgg cag aag tat ttt gaa gct Cys Gly His Val Met His Ala Val Cys Trp Gln Lys Tyr Phe Glu Ala 1160 1165 1170	4217
gta cag ctg agc tct cag cag cgc att cat gtt gac ctt ttt gac ttg Val Gln Leu Ser Ser Gln Gln Arg Ile His Val Asp Leu Phe Asp Leu 1175 1180 1185 1190	4265
gaa agt gga gaa tat ctt tgc cct ctt tgc aaa tct ctg tgc aat act Glu Ser Gly Glu Tyr Leu Cys Pro Leu Cys Lys Ser Leu Cys Asn Thr 1195 1200 1205	4313
gtg atc ccc att att cct ttg caa cct caa aag ata aac agt gag aat Val Ile Pro Ile Ile Pro Leu Gln Pro Gln Lys Ile Asn Ser Glu Asn 1210 1215 1220	4361
gca gat gct ctt gct caa ctt ttg acc ctg gca cgg tgg ata cag act Ala Asp Ala Leu Ala Gln Leu Leu Thr Leu Ala Arg Trp Ile Gln Thr 1225 1230 1235	4409
gtt ctg gcc aga ata tca ggt tat aat ata aga cat gct aaa gga gaa Val Leu Ala Arg Ile Ser Gly Tyr Asn Ile Arg His Ala Lys Gly Glu 1240 1245 1250	4457
aac cca att cct att ttc ttt aat caa gga atg gga gat tct act ttg Asn Pro Ile Pro Ile Phe Phe Asn Gln Gly Met Gly Asp Ser Thr Leu 1255 1260 1265 1270	4505
gag ttc cat tcc atc ctg agt ttt ggc gtt gag tct tcg att aaa tat Glu Phe His Ser Ile Leu Ser Phe Gly Val Glu Ser Ser Ile Lys Tyr 1275 1280 1285	4553
tca aat agc atc aag gaa atg gtt att ctc ttt gcc aca aca att tat Ser Asn Ser Ile Lys Glu Met Val Ile Leu Phe Ala Thr Thr Ile Tyr 1290 1295 1300	4601

atg ctg acc tgg agc acc tgc gct ttc act atc cag gca att gaa aat Met Leu Thr Trp Ser Thr Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn 1320 1325 1330	4697
cta ttg gga gat gaa gga aaa cct ctg ttt gga gca ctt caa aat agg Leu Leu Gly Asp Glu Gly Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg 1335 1340 1345 1350	4745
cag cat aat ggt ctg aaa gca tta atg cag ttt gca gtt gca cag agg Gln His Asn Gly Leu Lys Ala Leu Met Gln Phe Ala Val Ala Gln Arg 1355 1360 1365	4793
att acc tgt cct cag gtc ctg ata cag aaa cat ctg gtt cgt ctt cta Ile Thr Cys Pro Gln Val Leu Ile Gln Lys His Leu Val Arg Leu Leu 1370 1375 1380	4841
tca gtt gtt ctt cct aac ata aaa tca gaa gat aca cca tgc ctt ctg Ser Val Val Leu Pro Asn Ile Lys Ser Glu Asp Thr Pro Cys Leu Leu 1385 1390 1395	4889
tct ata gat ctg ttt cat gtt ttg gtg ggt gct gtg tta gca ttc cca Ser Ile Asp Leu Phe His Val Leu Val Gly Ala Val Leu Ala Phe Pro 1400 1405 1410	4937
tcc ttg tat tgg gat gac cct gtt gat ctg cag cct tct tca gtt agt Ser Leu Tyr Trp Asp Asp Pro Val Asp Leu Gln Pro Ser Ser Val Ser 1415 1420 1425 1430	4985
tot too tat aac cac off tat off the cat tog atc acc atg goa cac Ser Ser Tyr Asn His Leu Tyr Leu Phe His Leu Ile Thr Met Ala His 1435 1440 1445	5033
atg ctt cag ata cta ctt aca gta gac aca ggc cta ccc ctt gct cag Met Leu Gln Ile Leu Leu Thr Val Asp Thr Gly Leu Pro Leu Ala Gln 1450 1455 1460	5081
gtt caa gaa gac agt gaa gag gct cat tcc gca tct tct ttc ttt gca Val Gln Glu Asp Ser Glu Glu Ala His Ser Ala Ser Ser Phe Phe Ala 1465 1470 1475	5129
gaa att tot caa tat aca agt ggo too att ggg tgt gat att oot ggo Glu Ile Ser Gln Tyr Thr Ser Gly Ser Ile Gly Cys Asp Ile Pro Gly 1480 1485 1490	5177
tgg tat ttg tgg gtc tca ctg aag aat ggc atc acc cct tat ctt cgc Trp Tyr Leu Trp Val Ser Leu Lys Asn Gly Ile Thr Pro Tyr Leu Arg 1495 1500 1505 1510	5225
tgt gct gca ttg ttt ttc cac tat tta ctt ggg gta act ccg cct gag Cys Ala Ala Leu Phe Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu 1515 1520 1525	5273
Cys Ala Ala Leu Phe Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu	5273 5321
Cys Ala Ala Leu Phe Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu 1515 1520 1525  gaa ctg cat acc aat tct gca gaa gga gag tac agt gca ctc tgt agc Glu Leu His Thr Asn Ser Ala Glu Gly Glu Tyr Ser Ala Leu Cys Ser	

cta aac tgt ttg aag caa aaa aac acc gtg gtc agg tac cct aga aaa Leu Asn Cys Leu Lys Gln Lys Asn Thr Val Val Arg Tyr Pro Arg Lys 1575 1580 1585 1590	5465
aga aat agt ttg ata gag ctt cct gat gac tat agc tgc ctc ctg aat Arg Asn Ser Leu Ile Glu Leu Pro Asp Asp Tyr Ser Cys Leu Leu Asn 1595 1600 1605	5513
caa gct tct cat ttc agg tgc cca cgg tct gca gat gat gag cga aag Gln Ala Ser His Phe Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys 1610 1615 1620	5561
cat cct gtc ctc tgc ctt ttc tgt ggg gct ata cta tgt tct cag aac His Pro Val Leu Cys Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn 1625 1630 1635	5609
att tgc tgc cag gaa att gtg aac ggg gaa gag gtt gga gct tgc att Ile Cys Cys Gln Glu Ile Val Asn Gly Glu Glu Val Gly Ala Cys Ile 1640 1645 1650	5657
ttt cac gca ctt cac tgt gga gcc gga gtc tgc att ttc cta aaa atc Phe His Ala Leu His Cys Gly Ala Gly Val Cys Ile Phe Leu Lys Ile 1655 1660 1665 1670	5705
aga gaa tgc cga gtg gtc ctg gtt gaa ggt aaa gcc aga ggc tgt gcc Arg Glu Cys Arg Val Val Leu Val Glu Gly Lys Ala Arg Gly Cys Ala 1675 1680 1685	5753
tat cca gct cct tac ttg gat gaa tat gga gaa aca gac cct ggc ctg Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr Gly Glu Thr Asp Pro Gly Leu 1690 1695 1700	5801
aag agg ggc aac ccc ctt cat tta tct cgt gag cgg tat cgg aag ctc Lys Arg Gly Asn Pro Leu His Leu Ser Arg Glu Arg Tyr Arg Lys Leu 1705 1710 1715	5849
cat ttg gtc tgg caa caa cac tgc att ata gaa gag att gct agg agc His Leu Val Trp Gln Gln His Cys Ile Ile Glu Glu Ile Ala Arg Ser 1720 1725 1730	5897
caa gag act aat cag atg tta ttt gga ttc aac tgg cag tta ctg Gln Glu Thr Asn Gln Met Leu Phe Gly Phe Asn Trp Gln Leu Leu 1735 1740 1745	5942
tgagetecaa etetgeetea agacaateae aaatgaegae agtagtaaag getgatteaa	6002
aattatggaa aactttctga gggctgggaa agtattggag ggtcttttgc tccatgtcca	6062
ggttcactta catcaataaa atatttctta atggagtatt gctttcaatt agcaaacata	6122
tgcttcacag gaaaaaagga catagatcaa tctgttttat gtgctagtat ttccaggaat	6182
ttattcccct tcataatttg tctcatttca ttttatttca tccacttggt agatgaagtc	6242
acgtcaaaca gttgtagaca ttttatgtgt tggttaactc ttctgcaatt ttgtatttgg	6302
tgtttt	6308

<sup>&</sup>lt;210> 2 <211> 1749 <212> PRT <213> Homo sapiens

<400>2Met Ala Asp Glu Glu Ala Gly Gly Thr Glu Arg Met Glu Ile Ser Ala Glu Leu Pro Gln Thr Pro Gln Arg Leu Ala Ser Trp Trp Asp Gln Gln Val Asp Phe Tyr Thr Ala Phe Leu His His Leu Ala Gln Leu Val Pro Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu Glu Lys Gln Glu Glu Ser Val Gln Met Ser Ile Phe Thr Pro Leu Glu Trp Tyr Leu Phe Gly 70 Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys His Ser Gly Ala Phe Gln Leu Cys Gly Arg Val Phe Lys Ser Gly Glu Thr Thr Tyr Ser Cys Arq Asp Cys Ala Ile Asp Pro Thr Cys Val Leu Cys Met Asp Cys Phe 115 120 Gln Asp Ser Val His Lys Asn His Arg Tyr Lys Met His Thr Ser Thr Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Thr Gly Pro Phe Cys Val Asn His Glu Pro Gly Arg Ala Gly Thr Ile Lys Glu 170 Asn Ser Arg Cys Pro Leu Asn Glu Glu Val Ile Val Gln Ala Arg Lys Ile Phe Pro Ser Val Ile Lys Tyr Val Val Glu Met Thr Ile Trp Glu Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile Arg Glu Lys Asn Glu 215 Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His His Ser Tyr Asp His 230 Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys Glu Leu Ala Glu Ala Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly Arg Arg Ala Val Lys 260 Ala Gly Ala Tyr Ala Ala Cys Gln Glu Ala Lys Glu Asp Ile Lys Ser His Ser Glu Asn Val Ser Gln His Pro Leu His Val Glu Val Leu His 295 Ser Glu Ile Met Ala His Gln Lys Phe Ala Leu Arg Leu Gly Ser Trp 310 Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe Arg Gln Ile Phe Cys

330

325

Gln Ala Cys Leu Arg Glu Glu Pro Asp Ser Glu Asn Pro Cys Leu Ile 340 345 350

Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr Lys Gly Ala Arg Lys 355 360 365

Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe Met Glu Met Glu Tyr 370 375 380

Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr Tyr Lys Gln Leu Gln 385 390 395 400

Lys Glu Tyr Ile Ser Asp Asp His Asp Arg Ser Ile Ser Ile Thr Ala 405 410 415

Leu Ser Val Gln Met Phe Thr Val Pro Thr Leu Ala Arg His Leu Ile 420 425 430

Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu Thr Leu Leu Glu Val 435 440 445

Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe Asn Phe Gln Gly Tyr 450 455 460

Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val Ile Cys Asp Leu Lys 465 470 475 480

Tyr Ile Leu Ile Ser Lys Pro Thr Ile Trp Thr Glu Arg Leu Arg Met 485 490 495

Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys Ile Leu Thr Cys Met 500 505 510

Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly Gln His Ile Glu Val 515 520 525

Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln Met Gln Leu Lys Asn 530 540

Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys Asp Glu Glu Leu Leu 545 550 560

Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val Met Arg Cys Ser Thr 565 570 575

Ser Phe Ile Ser Ser Ser Lys Thr Val Val Gln Ser Cys Gly His Ser 580 585 590

Leu Glu Thr Lys Ser Tyr Arg Val Ser Glu Asp Leu Val Ser Ile His 595 600 605

Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His Val Arg Leu Ser Arg 610 620

Leu Gly Ala Val Ser Arg Leu His Glu Phe Val Ser Phe Glu Asp Phe 625 630 635 640

Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg Cys Leu Val Leu Val 645 650 655

Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn Gly Leu Ser Leu Ile 660 665 670 Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys Arg Glu Glu Met Tyr 675 680 685

Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala Ser Leu Met Asp Pro 690 695 700

Asn Lys Phe Leu Leu Val Leu Gln Arg Tyr Glu Leu Ala Glu Ala 705 710 715 720

Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp Leu Ile Lys Gln Tyr 725 730 735

Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu Ile Tyr Ile Val Gly 740 745 750

Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr Lys Glu Glu Val Thr 755 760 765

Met Arg Glu Ile Ile His Leu Leu Cys Ile Glu Pro Met Pro His Ser 770 775 780

Ala Ile Ala Lys Asn Leu Pro Glu Asn Glu Asn Asn Glu Thr Gly Leu 785 790 795 800

Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys Lys Pro Gly Val Ser 805 810 815

Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn 820 825 830

Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His Ser Lys Ala Glu His 835 840 845

Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys Asp Glu Ala Leu Pro 850 855 860

Pro Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe Ser Lys Val Ile Asn 865 870 870 875 880

Leu Leu Asn Cys Asp Ile Met Met Tyr Ile Leu Arg Thr Val Phe Glu 885 890 895

Arg Ala Ile Asp Thr Asp Ser Asn Leu Trp Thr Glu Gly Met Leu Gln 900 905 910

Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu Glu Glu Lys Gln Gln 915 920 925

Leu Gln Lys Ala Pro Glu Glu Glu Val Thr Phe Asp Phe Tyr His Lys 930 935 940

Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ile Gln Met Leu Leu Glu 945 950 960

Lys Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln Lys Asp Met Ile Thr 965 970 975

Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg Leu Arg Glu Lys Ser 980 985 990

Cys Leu Ile Val Ala Thr Thr Ser Gly Ser Glu Ser Ile Lys Asn Asp 995 1000 1005

- Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg Lys Arg Lys Ala Glu 1010 1020
- Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala Gln Met Ser Ala Leu 025 1030 1035 1040
- Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met Tyr Asp Asn Thr Ser  $1045 \hspace{1cm} 1050 \hspace{1cm} 1055$
- Glu Met Pro Gly Lys Glu Asp Ser Ile Met Glu Glu Glu Ser Thr Pro 1060 1065 1070
- Ala Val Ser Asp Tyr Ser Arg Ile Ala Leu Gly Pro Lys Arg Gly Pro 1075 1080 1085
- Ser Val Thr Glu Lys Glu Val Leu Thr Cys Ile Leu Cys Gln Glu Glu 1090 1095 1100
- Gln Glu Val Lys Ile Glu Asn Asn Ala Met Val Leu Ser Ala Cys Val 105 1110 1115 1120
- Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly Lys Pro Ile Glu Leu 1125 1130 1135
- Ser Gly Glu Ala Leu Asp Pro Leu Phe Met Asp Pro Asp Leu Ala Tyr 1140 1145 1150
- Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met His Ala Val Cys Trp 1155 1160 1165
- Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser Gln Gln Arg Ile His 1170 1175 1180
- Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr Leu Cys Pro Leu Cys 185 1190 1195 1200
- Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile Pro Leu Gln Pro Gln 1205 \$1210 \$1215
- Lys Ile Asn Ser Glu Asn Ala Asp Ala Leu Ala Gln Leu Leu Thr Leu 1220 1225 1230
- Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile Ser Gly Tyr Asn Ile 1235 1240 1245
- Arg His Ala Lys Gly Glu Asn Pro Ile Pro Ile Phe Phe Asn Gln Gly 1250 1260
- Met Gly Asp Ser Thr Leu Glu Phe His Ser Ile Leu Ser Phe Gly Val 265 1270 1275 1280
- Glu Ser Ser Ile Lys Tyr Ser Asn Ser Ile Lys Glu Met Val Ile Leu 1285 1290 1295
- Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys Val Pro Pro Asp Glu 1300 1305 1310
- Arg Asp Pro Arg Val Pro Met Leu Thr Trp Ser Thr Cys Ala Phe Thr
- Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu Gly Lys Pro Leu Phe 1330 1340

- Gly Ala Leu Gln Asn Arg Gln His Asn Gly Leu Lys Ala Leu Met Gln 345 1350 1355 1360
- Phe Ala Val Ala Gln Arg Ile Thr Cys Pro Gln Val Leu Ile Gln Lys 1365 1370 1375
- His Leu Val Arg Leu Leu Ser Val Val Leu Pro Asn Ile Lys Ser Glu 1380 1385 1390
- Asp Thr Pro Cys Leu Leu Ser Ile Asp Leu Phe His Val Leu Val Gly 1395 1400
- Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp Asp Pro Val Asp Leu 1410 1415 1420
- Gln Pro Ser Ser Val Ser Ser Ser Tyr Asn His Leu Tyr Leu Phe His 425 1430 1435 1440
- Leu Ile Thr Met Ala His Met Leu Gl<br/>n Ile Leu Leu Thr Val Asp Thr  $1445 \hspace{1.5cm} 1450 \hspace{1.5cm} 1455$
- Gly Leu Pro Leu Ala Gln Val Gln Glu Asp Ser Glu Glu Ala His Ser 1460 1465 1470
- Ala Ser Ser Phe Phe Ala Glu Ile Ser Gln Tyr Thr Ser Gly Ser Ile 1475 1480 1485
- Gly Cys Asp Ile Pro Gly Trp Tyr Leu Trp Val Ser Leu Lys Asn Gly 1490 1495 1500
- Ile Thr Pro Tyr Leu Arg Cys Ala Ala Leu Phe Phe His Tyr Leu Leu 505 1510 1515 1520
- Gly Val Thr Pro Pro Glu Glu Leu His Thr Asn Ser Ala Glu Gly Glu 1525 1530 1535
- Tyr Ser Ala Leu Cys Ser Tyr Leu Ser Leu Pro Thr Asn Leu Phe Leu 1540 1545 1550
- Leu Phe Gln Glu Tyr Trp Asp Thr Val Arg Pro Leu Leu Gln Arg Trp 1555 1560 1565
- Cys Ala Asp Pro Ala Leu Leu Asn Cys Leu Lys Gln Lys Asn Thr Val 1570 1580
- Val Arg Tyr Pro Arg Lys Arg Asn Ser Leu Ile Glu Leu Pro Asp Asp 585 1590 1595 1600
- Tyr Ser Cys Leu Leu Asn Gln Ala Ser His Phe Arg Cys Pro Arg Ser 1605 1610 1615
- Ala Asp Asp Glu Arg Lys His Pro Val Leu Cys Leu Phe Cys Gly Ala 1620 1630
- Ile Leu Cys Ser Gln Asn Ile Cys Cys Gln Glu Ile Val Asn Gly Glu 1635 1640 1645
- Glu Val Gly Ala Cys Ile Phe His Ala Leu His Cys Gly Ala Gly Val 1650 1660
- Cys Ile Phe Leu Lys Ile Arg Glu Cys Arg Val Val Leu Val Glu Gly 665 1670 1675 1680

- Lys Ala Arg Gly Cys Ala Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr Gly
  1685 1690 1695
- Glu Thr Asp Pro Gly Leu Lys Arg Gly Asn Pro Leu His Leu Ser Arg 1700 1705 1710
- Glu Arg Tyr Arg Lys Leu His Leu Val Trp Gln Gln His Cys Ile Ile 1715 1720 1725
- Glu Glu Ile Ala Arg Ser Gln Glu Thr Asn Gln Met Leu Phe Gly Phe 1730 1740

Asn Trp Gln Leu Leu 745

<210> 3

<211> 6300

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (295)..(5559)

<400> 3

- gccaagaatt cggcacgagg tgtcaggcct ggggttttct gtgtccttcc ctgggtcagg 60
- gacgagccag tgacttgact cttgggcgct aagcttggga gggagcgcag gaggccgctg 120
- teetteettt eeggtteacg teaccettet eteetetgt tgeteeacet geagecaett 180
- ggacggctcc gggactgatt gcctggggca ggggtggcag tcgaggccgc cggggccgag 240
- gtgaggctgc agctctccgg gcggcggtag cgctggggag gaggaggaga gaag atg 297 Met
- gcg tcg gag cta gag cca gag gtg cag gcc atc gac cgg agt ttg ctg 345 Ala Ser Glu Leu Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu Leu 5 10
- gaa tgt tcg gcc gag gag att gcg ggg aaa tgg ctg caa gca act gac 393 Glu Cys Ser Ala Glu Glu Ile Ala Gly Lys Trp Leu Gln Ala Thr Asp 20 25 30
- ctc act aga gaa gtg tac cag cat tta gcc cac tat gta ccc aaa atc 441 Leu Thr Arg Glu Val Tyr Gln His Leu Ala His Tyr Val Pro Lys Ile 35 40 45
- tac tgc agg ggt ccc aac cct ttt cca cag aaa gaa gac atg ctg gca 489 Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Met Leu Ala 50 65
- cag cat gtt ttg ttg gga cca atg gaa tgg tac ctt tgt ggt gaa gat 537 Gln His Val Leu Gly Pro Met Glu Trp Tyr Leu Cys Gly Glu Asp
  70 75 80
- cct gca ttt gga ttt cca aaa ctt gag caa gca aac aaa cct tct cat 585 Pro Ala Phe Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser His 85 90 95

ctt Leu	tgt Cys	ggt Gly 100	cgt Arg	gtt Val	ttt Phe	aaa Lys	gta Val 105	gga Gly	gag Glu	cct Pro	aca Thr	tat Tyr 110	tct Ser	tgc Cys	aga Arg	633
gac Asp	tgt Cys 115	gca Ala	gtt Val	gat Asp	cca Pro	act Thr 120	tgt Cys	gtt Val	ttg Leu	tgc Cys	atg Met 125	gag Glu	tgc Cys	ttt Phe	ttg Leu	681
gga Gly 130	agt Ser	att Ile	cac His	aga Arg	gat Asp 135	cat His	cga Arg	tat Tyr	agg Arg	atg Met 140	aca Thr	aca Thr	tca Ser	gga Gly	ggt Gly 145	729
gga Gly	ggt Gly	ttc Phe	tgt Cys	gac Asp 150	tgt Cys	ggt Gly	gat Asp	act Thr	gaa Glu 155	gcc Ala	tgg Trp	aaa Lys	gag Glu	ggt Gly 160	cct Pro	777
tac Tyr	tgt Cys	caa Gln	aaa Lys 165	cat His	gaa Glu	ctt Leu	aac Asn	acc Thr 170	tct Ser	gaa Glu	att Ile	gag Glu	gaa Glu 175	gaa Glu	gag Glu	825
gat Asp	cct Pro	ctt Leu 180	gtt Val	cat His	tta Leu	tca Ser	gaa Glu 185	gat Asp	gtg Val	ata Ile	gca Ala	aga Arg 190	act Thr	tat Tyr	aac Asn	873
att Ile	ttt Phe 195	gct Ala	att Ile	acg Thr	ttt Phe	cgg Arg 200	tat Tyr	gca Ala	gta Val	gaa Glu	ata Ile 205	tta Leu	acc Thr	tgg Trp	gaa Glu	921
aaa Lys 210	gaa Glu	agt Ser	gaa Glu	ttg Leu	cca Pro 215	gca Ala	gat Asp	tta Leu	gag Glu	atg Met 220	gta Val	gag Glu	aag Lys	agt Ser	gac Asp 225	969
acc Thr	tac Tyr	tat Tyr	tgc Cys	atg Met 230	ctg Leu	ttt Phe	aat Asn	gat Asp	gag Glu 235	gtt Val	cac His	acc Thr	tat Tyr	gaa Glu 240	caa Gln	1017
gtt Val	att Ile	tat Tyr	act Thr 245	ctt Leu	cag Gln	aaa Lys	gct Ala	gtt Val 250	aac Asn	tgt Cys	aca Thr	caa Gln	aaa Lys 255	gaa Glu	gct Ala	1065
att Ile	ggt Gly	ttt Phe 260	gca Ala	act Thr	aca Thr	gta Val	gat Asp 265	cga Arg	gat Asp	gly ggg	cgt Arg	agg Arg 270	tct Ser	gtt Val	cga Arg	1113
tat Tyr	gga Gly 275	gat Asp	ttt Phe	cag Gln	tat Tyr	tgt Cys 280	gag Glu	caa Gln	gca Ala	aaa Lys	tca Ser 285	gta Val	att Ile	gtg Val	aga Arg	1161
aat Asn 290	acc Thr	agt Ser	aga Arg	cag Gln	aca Thr 295	aag Lys	cca Pro	ctc Leu	aaa Lys	gtt Val 300	caa Gln	gtt Val	atg Met	cat His	tcg Ser 305	1209
tct Ser	att Ile	gtc Val	gca Ala	cat His 310	cag Gln	aat Asn	ttt Phe	ggt Gly	ttg Leu 315	aaa Lys	ctt Leu	ttg Leu	tct Ser	tgg Trp 320	ctg Leu	1257
gga Gly	agt Ser	att Ile	att Ile 325	gga Gly	tat Tyr	tca Ser	gat Asp	ggc Gly 330	ctt Leu	cgc Arg	cgg Arg	att Ile	tta Leu 335	tgt Cys	caa Gln	1305
gtt Val	ggt Gly	tta Leu 340	Gln	gaa Glu	gly aaa	cca Pro	gat Asp 345	ggt Gly	gaa Glu	aac Asn	tct Ser	tct Ser 350	cta Leu	gtg Val	gac Asp	1353

aga Arg	ctg Leu 355	atg Met	ctt Leu	agt Ser	gat Asp	tcc Ser 360	aaa Lys	tta Leu	tgg Trp	aaa Lys	ggt Gly 365	gct Ala	agg Arg	agt Ser	gta Val	1401
tat Tyr 370	cat His	cag Gln	ttg Leu	ttc Phe	atg Met 375	agc Ser	agt Ser	ctg Leu	ctt Leu	atg Met 380	gat Asp	ttg Leu	aaa Lys	tac Tyr	aag Lys 385	1449
aaa Lys	cta Leu	ttt Phe	gct Ala	gtt Val 390	cga Arg	ttt Phe	gca Ala	aaa Lys	aat Asn 395	tac Tyr	cag Gln	cag Gln	ttg Leu	cag Gln 400	aga Arg	1497
gat Asp	ttt Phe	atg Met	gag Glu 405	gat Asp	gat Asp	cac His	gag Glu	cga Arg 410	gca Ala	gtg Val	tcg Ser	gtg Val	act Thr 415	gct Ala	cta Leu	1545
tct Ser	gtc Val	cag Gln 420	ttc Phe	ttc Phe	acc Thr	gca Ala	cct Pro 425	act Thr	ctg Leu	gct Ala	cga Arg	atg Met 430	ctc Leu	atc Ile	aca Thr	1593
gaa Glu	gaa Glu 435	aac Asn	ttg Leu	atg Met	agc Ser	att Ile 440	atc Ile	att Ile	aag Lys	act Thr	ttt Phe 445	atg Met	gat Asp	cat His	ttg Leu	1641
aga Arg 450	cat His	cga Arg	gat Asp	gcc Ala	cag Gln 455	ggc Gly	aga Arg	ttt Phe	cag Gln	ttt Phe 460	gaa Glu	cga Arg	tac Tyr	act Thr	gct Ala 465	1689
tta Leu	caa Gln	gcc Ala	ttc Phe	aaa Lys 470	ttt Phe	agg Arg	aga Arg	gta Val	cag Gln 475	agc Ser	ctt Leu	att Ile	tta Leu	gat Asp 480	ctc Leu	1737
aag Lys	tat Tyr	gtg Val	tta Leu 485	att Ile	agc Ser	aaa Lys	cca Pro	act Thr 490	gaa Glu	tgg Trp	tca Ser	gat Asp	gag Glu 495	ctg Leu	agg Arg	1785
cag Gln	aag Lys	ttc Phe 500	cta Leu	gaa Glu	Gly 999	ttt Phe	gat Asp 505	gcc Ala	ttt Phe	ttg Leu	gaa Glu	tta Leu 510	cta Leu	aaa Lys	tgt Cys	1833
atg Met	cag Gln 515	gga Gly	atg Met	gat Asp	cca Pro	att Ile 520	aca Thr	cgt Arg	caa Gln	gta Val	gga Gly 525	caa Gln	cat His	att Ile	gaa Glu	1881
atg Met 530	gaa Glu	cca Pro	gag Glu	tgg Trp	gaa Glu 535	gca Ala	gcc Ala	ttc Phe	aca Thr	cta Leu 540	caa Gln	atg Met	aaa Lys	tta Leu	aca Thr 545	1929
cat His	gtc Val	att Ile	tca Ser	atg Met 550	atg Met	cag Gln	gac Asp	tgg Trp	tgt Cys 555	gct Ala	tca Ser	gat Asp	gaa Glu	aaa Lys 560	gtg Val	1977
tta Leu	atc Ile	gaa Glu	gct Ala 565	tac Tyr	aag Lys	aaa Lys	tgt Cys	ctc Leu 570	gct Ala	gta Val	ctg Leu	atg Met	cag Gln 575	tgt Cys	cat His	2025
ggt Gly	ggt Gly	tat Tyr 580	act Thr	gat Asp	ggt Gly	gaa Glu	cag Gln 585	cca Pro	atc Ile	aca Thr	cta Leu	agc Ser 590	att Ile	tgt Cys	gga Gly	2073
cat His	tca Ser 595	gtg Val	gaa Glu	act Thr	atc Ile	aga Arg 600	Tyr	tgt Cys	gtt Val	tcc Ser	caa Gln 605	Glu	aaa Lys	gtt Val	agc Ser	2121

	cac e His O															2169
ag Se:	c aaa r Lys	agt Ser	gaa Glu	gtg Val 630	gca Ala	tat Tyr	aaa Lys	ttt Phe	cca Pro 635	gag Glu	ctc Leu	cta Leu	cct Pro	cta Leu 640	agt Ser	2217
ga Gl	a ctt u Leu	agc Ser	cca Pro 645	ccc Pro	atg Met	ttg Leu	ata Ile	gaa Glu 650	cac His	cct Pro	ctt Leu	aga Arg	tgt Cys 655	ctt Leu	gtt Val	2265
ct Le	g tgt u Cys	gcc Ala 660	caa Gln	gta Val	cat His	gcc Ala	gga Gly 665	atg Met	tgg Trp	aga Arg	aga Arg	aat Asn 670	999 999	ttc Phe	tct Ser	2313
ct Le	a gta u Val 675	aac Asn	cag Gln	att Ile	tat Tyr	tac Tyr 680	tac Tyr	cat His	aat Asn	gtg Val	aaa Lys 685	tgc Cys	aga Arg	cgt Arg	gag Glu	2361
at Me 69	g ttt t Phe 0	gac Asp	aag Lys	gat Asp	gta Val 695	gta Val	atg Met	ctt Leu	cag Gln	aca Thr 700	ggt Gly	gtc Val	tcc Ser	atg Met	atg Met 705	2409
ga As	t cca p Pro	aat Asn	cat His	ttc Phe 710	ctg Leu	atg Met	atc Ile	atg Met	ctc Leu 715	agc Ser	cgc Arg	ttt Phe	gaa Glu	ctt Leu 720	tat Tyr	2457
ca Gl	g att n Ile	ttc Phe	agt Ser 725	act Thr	cca Pro	gac Asp	tat Tyr	gga Gly 730	aaa Lys	aga Arg	ttt Phe	agt Ser	tct Ser 735	gag Glu	att Ile	2505
ac Th	c cat r His	aag Lys 740	gat Asp	gtt Val	gtt Val	cag Gln	cag Gln 745	aac Asn	aat Asn	act Thr	cta Leu	ata Ile 750	gaa Glu	gaa Glu	atg Met	2553
ct Le	a tac u Tyr 755	Leu	att Ile	ata Ile	atg Met	ctt Leu 760	gtt Val	gga Gly	gag Glu	aga Arg	ttt Phe 765	agt Ser	cct Pro	gga Gly	gtt Val	2601
99 Gl 77	a cag y Gln 0	gta Val	aat Asn	gct Ala	aca Thr 775	gat Asp	gaa Glu	atc Ile	aag Lys	cga Arg 780	gag Glu	att Ile	atc Ile	cat His	cag Gln 785	2649
tt Le	g agt u Ser	atc Ile	aag Lys	cct Pro 790	atg Met	gct Ala	cat His	agt Ser	gaa Glu 795	ttg Leu	gta Val	aag Lys	tct Ser	tta Leu 800	cct Pro	2697
ga Gl	a gat u Asp	gag Glu	aac Asn 805	aag Lys	gag Glu	act Thr	ggc Gly	atg Met 810	gag Glu	agt Ser	gta Val	atc Ile	gaa Glu 815	gca Ala	gtt Val	2745
gc Al	c cat a His	ttc Phe 820	aag Lys	aaa Lys	cct Pro	gga Gly	tta Leu 825	aca Thr	gga Gly	cga Arg	ggc	atg Met 830	tat Tyr	gaa Glu	ctg Leu	2793
aa Ly	a cca s Pro 835	Glu	tgt Cys	gcc Ala	aaa Lys	gag Glu 840	ttc Phe	aac Asn	ttg Leu	tat Tyr	ttc Phe 845	tat Tyr	cac His	ttt Phe	tca Ser	2841
	g gca g Ala O															2889

caa aa Gln A	at a sn A	ıga Arg	gaa Glu	gat Asp 870	aca Thr	gca Ala	ctc Leu	cca Pro	cct Pro 875	ccg Pro	gtg Val	ttg Leu	cct Pro	cca Pro 880	ttc Phe	2937
tgc c Cys P	ct c ro L	eu	ttt Phe 885	gca Ala	agc Ser	ctg Leu	gtt Val	aac Asn 890	att Ile	ttg Leu	cag Gln	tca Ser	gat Asp 895	gtc Val	atg Met	2985
ttg t Leu C	ys I	itc lle	atg Met	gga Gly	aca Thr	att Ile	ctg Leu 905	caa Gln	tgg Trp	gct Ala	gtg Val	gaa Glu 910	cat His	aat Asn	gga Gly	3033
tat g Tyr A 9	cc t la T 15	gg Trp	tca Ser	gag Glu	tcc Ser	atg Met 920	ctg Leu	caa Gln	agg Arg	gtg Val	tta Leu 925	cat His	tta Leu	att Ile	ggc	3081
atg g Met A 930	ca c la I	cta Leu	caa Gln	gaa Glu	gaa Glu 935	aaa Lys	caa Gln	cat His	tta Leu	gag Glu 940	aat Asn	gtc Val	acg Thr	gaa Glu	gag Glu 945	3129
cat g His V	ta ç al V	gta <i>T</i> al	aca Thr	ttt Phe 950	acc Thr	ttc Phe	act Thr	cag Gln	aag Lys 955	ata Ile	tca Ser	aaa Lys	cct Pro	ggt Gly 960	gaa Glu	3177
gcg c Ala P	ca a ro I	aaa Lys	aat Asn 965	tct Ser	cct Pro	agc Ser	ata Ile	cta Leu 970	gct Ala	atg Met	ctg Leu	gaa Glu	aca Thr 975	cta Leu	caa Gln	3225
aat g Asn A	la E	ccc Pro 980	tac Tyr	cta Leu	gaa Glu	gtc Val	cac His 985	aaa Lys	gac Asp	atg Met	att Ile	cgg Arg 990	tgg Trp	ata Ile	ttg Leu	3273
aag a Lys T 9	ict t hr E	tt Phe	aat Asn	gct Ala	Val	aaa Lys 1000	aag Lys	atg Met	agg Arg	Glu	agt Ser 1005	tca Ser	cct Pro	acc Thr	agt Ser	3321
ccc g Pro V 1010	jtg g Val A	gca Ala	gag Glu	Thr	gaa Glu L015	gga Gly	acc Thr	ata Ile	Met	gaa Glu 1020	gag Glu	agt Ser	tca Ser	Arg	gac Asp 1025	3369
aaa g Lys A	ac a	aaa Lys	Ala	gag Glu 1030	agg Arg	aag Lys	aga Arg	Lys	gca Ala 1035	gag Glu	att Ile	gcc Ala	Arg	ctg Leu 1040	cgc Arg	3417
aga g Arg G	gaa a Blu I	Ĺуs	atc Ile 1045	atg Met	gct Ala	cag Gln	Met	tct Ser 1050	gaa Glu	atg Met	cag Gln	Arg	cat His 1055	ttt Phe	att Ile	3465
gat g Asp G	lu A	aac Asn 060	aaa Lys	gaa Glu	ctc Leu	Phe	cag Gln 1065	cag Gln	aca Thr	tta Leu	Glu	ctg Leu 1070	gat Asp	gcc Ala	tca Ser	3513
acc t Thr S	ect of Ser 2	gct Ala	gtt Val	ctt Leu	Asp	cat His 1080	agc Ser	cct Pro	gtg Val	Ala	tca Ser 1085	gat Asp	atg Met	aca Thr	ctt Leu	3561
aca g Thr A 1090	gca d Ala 1	ctg Leu	ggt Gly	Pro	aca Thr 1095	caa Gln	act Thr	cag Gln	Val	cct Pro 1100	gaa Glu	caa Gln	aga Arg	Gln	ttc Phe 1105	3609
gtt a Val I			Ile					Glu					Val			3657

agg gca atg gtc ttg gca gca ttt gtt cag aga tca act gta tta tca Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser 1125 1130 1135	3705
aaa aac aga agt aaa ttt att caa gat cca gaa aaa tat gat cca tta Lys Asn Arg Ser Lys Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu 1140 1145 1150	3753
ttc atg cac cct gat ctg tct tgt gga aca cac act agt agc tgt ggg Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Ser Ser Cys Gly 1155 1160 1165	3801
cac att atg cat gcc cat tgt tgg caa agg tat ttt gat tcc gtt caa His Ile Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln 1170 1175 1180 1185	3849
gct aaa gaa cag cga agg caa cag aga tta cgc tta cat acg agc tat Ala Lys Glu Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser Tyr 1190 1195 1200	3897
gat gta gaa aac gga gaa ttc ctt tgc ccc ctt tgt gaa tgc ttg agt Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser 1205 1210 1215	3945
aat act gtt att cct ctg ctg ctt cct cca aga aat att ttt aac aac Asn Thr Val Ile Pro Leu Leu Pro Pro Arg Asn Ile Phe Asn Asn 1220 1225 1230	3993
agg tta aat ttt tca gac caa cca aat ctg act cag tgg att aga aca Arg Leu Asn Phe Ser Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr 1235 1240 1245	4041
ata tct cag caa ata aaa gca tta cag ttt ctt agg aaa gaa agt Ile Ser Gln Gln Ile Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser 1250 1255 1260 1265	4089
act cct aat aat gcc tct aca aag aat tca gaa aat gtg gat gaa tta Thr Pro Asn Asn Ala Ser Thr Lys Asn Ser Glu Asn Val Asp Glu Leu 1270 1275 1280	4137
cag ctc cct gaa ggg ttc agg cct gat ttt cgt cct aag atc cct tat Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr 1285 1290 1295	4185
Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr	4185 4233
Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr 1285  tct gag agc ata aaa gaa atg cta acg aca ttt gga act gct acc tac Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr	
Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr 1285  tct gag agc ata aaa gaa atg cta acg aca ttt gga act gct acc tac Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr 1300  1305  aag gtg gga cta aag gtt cat ccc aat gaa gag gat cct cgt gtt ccc Lys Val Gly Leu Lys Val His Pro Asn Glu Glu Asp Pro Arg Val Pro	4233
Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr 1295  tct gag agc ata aaa gaa atg cta acg aca ttt gga act gct acc tac Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr 1300  aag gtg gga cta aag gtt cat ccc aat gaa gag gat cct cgt gtt ccc Lys Val Gly Leu Lys Val His Pro Asn Glu Glu Asp Pro Arg Val Pro 1315  ata atg tgt tgg ggt agc tgc gcg tac acc atc caa agc ata gaa aga Ile Met Cys Trp Gly Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg	4233 4281

aca gtg gca tca gtt tca gtg gtg caa gga cat ttt tgt aaa ctt ttt Thr Val Ala Ser Val Ser Val Val Gln Gly His Phe Cys Lys Leu Phe 1380 1385 1390	4473
gca tca ctg gtg cct aat gac agc cat gag gaa ctt cca tgc ata tta Ala Ser Leu Val Pro Asn Asp Ser His Glu Glu Leu Pro Cys Ile Leu 1395 1400 1405	4521
gat att gac atg ttt cat tta ttg gtg ggc ttg gtg ctt gca ttt cct Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe Pro 1410 1415 1420 1425	4569
gcg ttg cag tgt cag gat ttt tca ggg atc agc ctt ggc act gga gac Ala Leu Gln Cys Gln Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp 1430 1435 1440	4617
ctt cac att ttc cat ctg gtt act atg gca cac atc ata cag atc tta Leu His Ile Phe His Leu Val Thr Met Ala His Ile Ile Gln Ile Leu 1445 1450 1455	4665
ctt acc tca tgt aca gaa gag aat ggc atg gat caa gaa aat ccc cct Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Pro 1460 1465 1470	4713
tgt gaa gaa gaa tca gca gtt ctt gct ttg tat aaa aca ctt cac cag Cys Glu Glu Glu Ser Ala Val Leu Ala Leu Tyr Lys Thr Leu His Gln 1475 1480 1485	4761
tat acg gga agt gcc ttg aaa gaa ata cca tcc ggc tgg cat ctg tgg Tyr Thr Gly Ser Ala Leu Lys Glu Ile Pro Ser Gly Trp His Leu Trp 1490 1495 1500 1505	4809
agg agt gtc aga gct gga atc atg cct ttc ctg aag tgt tct gct tta Arg Ser Val Arg Ala Gly Ile Met Pro Phe Leu Lys Cys Ser Ala Leu 1510 1515 1520	4857
ttt ttt cat tac tta aat gga gtt cct tcc cca ccc gac att caa gtt Phe Phe His Tyr Leu Asn Gly Val Pro Ser Pro Pro Asp Ile Gln Val 1525 1530 1535	4905
cct gga aca agc cat ttt gaa cat tta tgt agc tat ctt tcc cta cca Pro Gly Thr Ser His Phe Glu His Leu Cys Ser Tyr Leu Ser Leu Pro 1540 1545 1550	4953
aac aac ctc att tgc ctt ttt caa gaa aat agt gag ata atg aat tca Asn Asn Leu Ile Cys Leu Phe Gln Glu Asn Ser Glu Ile Met Asn Ser 1555 1560 1565	5001
ctg att gaa agt tgg tgc cgt aac agt gaa gtt aaa aga tat cta gaa Leu Ile Glu Ser Trp Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu 1570 1585	5049
ggt gaa aga gat gct ata aga tat cca aga gaa tct aac aaa tta ata Gly Glu Arg Asp Ala Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile 1590 1595 1600	5097
aac ctt cca gag gat tac agc agc ctc att aat caa gca tcc aat ttc Asn Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe 1605 1610 1615	5145
teg tge eeg aaa tea ggt ggt gat aag age aga gee eea act etg tge	

ctt gtg tgc gga tct ctg ctg tgc tcc cag agt tac tgc tgc cag act 5247 Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr 1635 1640 1645	L
gaa ctg gaa ggg gag gat gta gga gcc tgc aca gct cac acc tac tcc 5289 Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser 1650 1665	Э
tgt ggc tct gga gtg ggc atc ttc ctg aga gta cgg gaa tgt cag gtg 533° Cys Gly Ser Gly Val Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val 1670 1675 1680	7
cta ttt tta gct ggc aaa acc aaa ggc tgt ttt tat tct cct cct tac 538! Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr 1685 1690 1695	5
ctt gat gac tat ggg gag acc gac cag gga ctc aga cgg gga aat cct 543: Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro 1700 1705 1710	3
tta cat tta tgc aaa gag cga ttc aag aag att cag aag ctc tgg cac 548: Leu His Leu Cys Lys Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp His 1715 1720 1725	1
caa cac agt gtc aca gag gaa att gga cat gca cag gaa gcc aat cag 552. Gln His Ser Val Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn Gln 1730 1745 1740 1745	9
aca ctg gtt ggc att gac tgg caa cat tta taattattgc accaccaaaa 557 Thr Leu Val Gly Ile Asp Trp Gln His Leu 1750 1755	9
aacacaaact tggatttttt taacccagtt ggctttttaa gaaagaaaga agttctgctg 563	9
aatttggaaa taaattettt atttaaaett teetteeeag ttttatagtt tetggttetg 569	9
aggactgatg aaaatcatct teeatcagea gattttettg caetgtttge tgtgeeecte 575	9
aaatataatg tettgggttt taagategag caaggagett etetteetag attggateee 581	9
ageceettig tgggggtetg actgeatagt eccagecatt atgtgatatt teaegttatt 587	9
gatgatagtg aaccgtgggt ccgaagctga ctcaacggag gcagggaaca aagtctctgt 593	9
ggtctgttgg gtcatacttc ctggttccac tgagtggccc aacactggga ctgggttggt 599	9
gtcccctctg ctgacaggac cctactccta ggagcaaagt ggttgatttt gaaggcagtg 605	9
ttcccttctc tccattgact atgagagagt tgggggacac acatgcagaa gaagcccgtg 611	9
gggagaaggt ggatteetgg tgtgetgget ggttttteag ggetgttaga ggtttttttt 617	9
ttottttttt tttttatggo aagaottttg gotttgagaa aactoactta gagggottto 623	9
caaaaactta ggatggtcta aaaaattagg atattctttt agaattagga agaaaaatta 629	9
g 630	0

<sup>&</sup>lt;210> 4 <211> 1755 <212> PRT <213> Homo sapiens

<400> 4 Met Ala Ser Glu Leu Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu Leu Glu Cys Ser Ala Glu Glu Ile Ala Gly Lys Trp Leu Gln Ala Thr Asp Leu Thr Arg Glu Val Tyr Gln His Leu Ala His Tyr Val Pro Lys Ile Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Met Leu Ala Gln His Val Leu Leu Gly Pro Met Glu Trp Tyr Leu Cys Gly Glu Asp Pro Ala Phe Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser His Leu Cys Gly Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys 105 Arg Asp Cys Ala Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe 120 Leu Gly Ser Ile His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly 135 Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly Pro Tyr Cys Gln Lys His Glu Leu Asn Thr Ser Glu Ile Glu Glu 170 Glu Asp Pro Leu Val His Leu Ser Glu Asp Val Jle Ala Arg Thr Tyr Asn Ile Phe Ala Ile Thr Phe Arg Tyr Ala Val Glu Ile Leu Thr Trp Glu Lys Glu Ser Glu Leu Pro Ala Asp Leu Glu Met Val Glu Lys Ser 215 Asp Thr Tyr Tyr Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu 235 Gln Val Ile Tyr Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu Ala Ile Gly Phe Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Ser Val 265 260 Arg Tyr Gly Asp Phe Gln Tyr Cys Glu Gln Ala Lys Ser Val Ile Val Arg Asn Thr Ser Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His Ser Ser Ile Val Ala His Gln Asn Phe Gly Leu Lys Leu Leu Ser Trp 315 310 Leu Gly Ser Ile Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys 330 325

Gln Val Gly Leu Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val 340 345 350

Asp Arg Leu Met Leu Ser Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser 355 360 365

Val Tyr His Gln Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr 370 375 380

Lys Lys Leu Phe Ala Val Arg Phe Ala Lys Asn Tyr Gln Gln Leu Gln 385 390 395 400

Arg Asp Phe Met Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala 405 410 415

Leu Ser Val Gln Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Ile 420 425 430

Thr Glu Glu Asn Leu Met Ser Ile Ile Ile Lys Thr Phe Met Asp His 435 440 445

Leu Arg His Arg Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr 450 455 460

Ala Leu Gln Ala Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp 465 470 475 480

Leu Lys Tyr Val Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu 485 490 495

Arg Gln Lys Phe Leu Glu Gly Phe Asp Ala Phe Leu Glu Leu Lys 500 505 510

Cys Met Gln Gly Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile 515 520 525

Glu Met Glu Pro Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu 530 540

Thr His Val Ile Ser Met Met Gln Asp Trp Cys Ala Ser Asp Glu Lys 545 550 555

Val Leu Ile Glu Ala Tyr Lys Lys Cys Leu Ala Val Leu Met Gln Cys 575 575

His Gly Gly Tyr Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys 580 585 590

Gly His Ser Val Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val 595 600 605

Ser Ile His Leu Pro Val Ser Arg Leu Leu Ala Gly Leu His Val Leu 610 620

Leu Ser Lys Ser Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu 625 630 635

Ser Glu Leu Ser Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu 645 650 655

Val Leu Cys Ala Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe 660 665 670 Ser Leu Val Asn Gln Ile Tyr Tyr Tyr His Asn Val Lys Cys Arg Arg 675 680 685

Glu Met Phe Asp Lys Asp Val Val Met Leu Gln Thr Gly Val Ser Met 690 695 700

Met Asp Pro Asn His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu 705 710 715 720

Tyr Gln Ile Phe Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu 725 730 735

Ile Thr His Lys Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu 740 745 750

Met Leu Tyr Leu Ile Ile Met Leu Val Gly Glu Arg Phe Ser Pro Gly
755 760 765

Val Gly Gln Val Asn Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His 770 775 780

Gln Leu Ser Ile Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu 785 790 795 800

Pro Glu Asp Glu Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ala 805 810 815

Val Ala His Phe Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu 820 825 830

Leu Lys Pro Glu Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe 835 840 840

Ser Arg Ala Glu Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys 850 855 860

Arg Gln Asn Arg Glu Asp Thr Ala Leu Prc Pro Pro Val Leu Pro Pro 865 870 875 880

Phe Cys Pro Leu Phe Ala Ser Leu Val Asn Ile Leu Gln Ser Asp Val 885 890 895

Met Leu Cys Ile Met Gly Thr Ile Leu Gln Trp Ala Val Glu His Asn 900 905 910

Gly Tyr Ala Trp Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile 915 920 925

Gly Met Ala Leu Gln Glu Glu Lys Gln His Leu Glu Asn Val Thr Glu 930 935 940

Glu His Val Val Thr Phe Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly 945 950 955 960

Glu Ala Pro Lys Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu 965 970 975

Gln Asn Ala Pro Tyr Leu Glu Val His Lys Asp Met Ile Arg Trp Ile 980 985

Leu Lys Thr Phe Asn Ala Val Lys Lys Met Arg Glu Ser Ser Pro Thr 995 1000 1005

- Ser Pro Val Ala Glu Thr Glu Gly Thr Ile Met Glu Glu Ser Ser Arg 1010 1015 1020
- Asp Lys Asp Lys Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu 025 1030 1035 1040
- Arg Arg Glu Lys Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe \$1045\$ 1050 1055
- Ile Asp Glu Asn Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Ala 1060 1065 1070
- Ser Thr Ser Ala Val Leu Asp His Ser Pro Val Ala Ser Asp Met Thr 1075 1080 1085
- Leu Thr Ala Leu Gly Pro Thr Gln Thr Gln Val Pro Glu Gln Arg Gln 1090 1095 1100
- Phe Val Thr Cys Ile Leu Cys Gln Glu Glu Gln Glu Val Lys Val Glu 105 1110 1115 1120
- Ser Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu 1125 1130 1135
- Ser Lys Asn Arg Ser Lys Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro 1140 1145 1150
- Leu Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Ser Ser Cys 1155 1160 1165
- Gly His Ile Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val 1170 1175 1180
- Gln Ala Lys Glu Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser 185 1190 1195 1200
- Tyr Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu 1205 1210 1215
- Ser Asn Thr Val Ile Pro Leu Leu Pro Pro Arg Asn Ile Phe Asn 1220 1225 1230
- Asn Arg Leu Asn Phe Ser Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg 1235 1240 1245
- Thr Ile Ser Gln Gln Ile Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu 1250 1255 1260
- Ser Thr Pro Asn Asn Ala Ser Thr Lys Asn Ser Glu Asn Val Asp Glu 265 1270 1275 1280
- Leu Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro 1285 1290 1295
- Tyr Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr  $1300 \hspace{1.5cm} 1305 \hspace{1.5cm} 1310$
- Tyr Lys Val Gly Leu Lys Val His Pro Asn Glu Glu Asp Pro Arg Val 1315 1320 1325
- Pro Ile Met Cys Trp Gly Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu 1330 1335 1340

- Arg Ile Leu Ser Asp Glu Asp Lys Pro Leu Phe Gly Pro Leu Pro Cys 345 1350 1355 1360
- Arg Leu Asp Asp Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His
  1365 1370 1375
- Trp Thr Val Ala Ser Val Ser Val Val Gln Gly His Phe Cys Lys Leu 1380 1385 1390
- Phe Ala Ser Leu Val Pro Asn Asp Ser His Glu Glu Leu Pro Cys Ile 1395 1400 1405
- Leu Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe 1410 1415 1420
- Pro Ala Leu Gln Cys Gln Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly 425 1430 1435 1440
- Asp Leu His Ile Phe His Leu Val Thr Met Ala His Ile Ile Gln Ile 1445 1450 1455
- Leu Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro 1460 1465 1470
- Pro Cys Glu Glu Glu Ser Ala Val Leu Ala Leu Tyr Lys Thr Leu His 1475 1480 1485
- Gln Tyr Thr Gly Ser Ala Leu Lys Glu Ile Pro Ser Gly Trp His Leu 1490 1495 1500
- Trp Arg Ser Val Arg Ala Gly Ile Met Pro Phe Leu Lys Cys Ser Ala 505 1510 1515 1520
- Leu Phe Phe His Tyr Leu Asn Gly Val Pro Ser Pro Pro Asp Ile Gln
  1525 1530 1535
- Val Pro Gly Thr Ser His Phe Glu His Leu Cys Ser Tyr Leu Ser Leu 1540 1545 1550
- Pro Asn Asn Leu Ile Cys Leu Phe Gln Glu Asn Ser Glu Ile Met Asn 1555 1560 1565
- Ser Leu Ile Glu Ser Trp Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu 1570 1580
- Glu Gly Glu Arg Asp Ala Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu 585 1590 1595 1600
- Ile Asn Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gl<br/>n Ala Ser Asn 1605 1610 1615
- Phe Ser Cys Pro Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu 1620 1625 1630
- Cys Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln 1635 1640 1645
- Thr Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr 1650 1660
- Ser Cys Gly Ser Gly Val Gly Ile Phe Leu Arg Val Arg Glu Cys Gln 665 1670 1680

Val Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro 1685 1690 1695

Tyr Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn 1700 1705 1710

Pro Leu His Leu Cys Lys Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp 1715 1720 1725

His Gln His Ser Val Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn 1730 1735 1740

Gln Thr Leu Val Gly Ile Asp Trp Gln His Leu 745 1750 1755

<210> 5

<211> 6089

<212> DNA

<213> Mouse

<220>

<221> CDS

<222> (766)..(6030)

<400> 5

atg gag ccc gag gtg cag gcc atc gac cgc agt ttg ctg gaa tgt tct 825 Met Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu Leu Glu Cys Ser 5 10 20

gcc gaa gag atc gca ggg aga tgg ctg caa gca acc gac ctc aac aga 873 Ala Glu Glu Ile Ala Gly Arg Trp Leu Gln Ala Thr Asp Leu Asn Arg 25 30 35

gaa Glu	gtg Val	tac Tyr	cag Gln 40	cat His	tta Leu	gcc Ala	cac His	tgt Cys 45	gtg Val	ccc Pro	aaa Lys	atc Ile	tac Tyr 50	tgc Cys	cgg Arg	921
ggc Gly	cct Pro	aac Asn 55	ccc Pro	ttc Phe	cct Pro	cag Gln	aag Lys 60	gaa Glu	gac Asp	acg Thr	ctg Leu	gca Ala 65	cag Gln	cac His	atc Ile	969
ctg Leu	ctg Leu 70	gga Gly	ccg Pro	atg Met	gag Glu	tgg Trp 75	tac Tyr	atc Ile	tgc Cys	gct Ala	gaa Glu 80	gac Asp	cct Pro	gcg Ala	ctg Leu	1017
gga Gly 85	ttt Phe	cca Pro	aag Lys	ctc Leu	gag Glu 90	cag Gln	gca Ala	aac Asn	aag Lys	cct Pro 95	tct Ser	cac His	ctc Leu	tgt Cys	ggc Gly 100	1065
cga Arg	gtg Val	ttt Phe	aaa Lys	gtg Val 105	gly aaa	gaa Glu	cct Pro	aca Thr	tac Tyr 110	tcc Ser	tgc Cys	aga Arg	gac Asp	tgt Cys 115	gca Ala	1113
gtt Val	gac Asp	ccc Pro	acc Thr 120	tgt Cys	gtt Val	tta Leu	tgc Cys	atg Met 125	gag Glu	tgc Cys	ttc Phe	ctg Leu	gga Gly 130	agt Ser	atc Ile	1161
cat His	aga Arg	gac Asp 135	cat His	cga Arg	tat Tyr	agg Arg	atg Met 140	acc Thr	aca Thr	tcg Ser	gga Gly	gga Gly 145	Gly 999	ggc Gly	ttc Phe	1209
tgt Cys	gac Asp 150	tgt Cys	ggt Gly	gac Asp	act Thr	gag Glu 155	gcg Ala	tgg Trp	aaa Lys	gag Glu	gga Gly 160	cct Pro	tac Tyr	tgc Cys	cag Gln	1257
aag Lys 165	cac His	aag Lys	ctc Leu	agc Ser	agc Ser 170	tct Ser	gaa Glu	gtt Val	gtg Val	gag Glu 175	gag Glu	gag Glu	gat Asp	cct Pro	ctt Leu 180	1305
gtg Val	cat His	cta Leu	tca Ser	gaa Glu 185	gat Asp	gtg Val	atc Ile	gcc Ala	aga Arg 190	act Thr	tac Tyr	aac Asn	att Ile	ttt Phe 195	gct Ala	1353
att Ile	atg Met	ttt Phe	cga Arg 200	tat Tyr	gca Ala	gta Val	gat Asp	ata Ile 205	ctg Leu	acc Thr	tgg Trp	gaa Glu	aaa Lys 210	gaa Glu	agt Ser	1401
gaa Glu	ttg Leu	cct Pro 215	gaa Glu	gac Asp	tta Leu	gaa Glu	gtg Val 220	gca Ala	gag Glu	aag Lys	agt Ser	gac Asp 225	acc Thr	tac Tyr	tac Tyr	1449
tgc Cys	atg Met 230	ctg Leu	ttt Phe	aat Asn	gat Asp	gag Glu 235	gtt Val	cac His	acc Thr	tat Tyr	gag Glu 240	caa Gln	gtc Val	att Ile	tat Tyr	1497
acc Thr 245	ctt Leu	cag Gln	aaa Lys	gct Ala	gtg Val 250	aac Asn	tgt Cys	aca Thr	cag Gln	aag Lys 255	gaa Glu	gcc Ala	att Ile	ggc	ttt Phe 260	1545
gca Ala	act Thr	aca Thr	gtt Val	gat Asp 265	cga Arg	gat Asp	ggc Gly	cgt Arg	agg Arg 270	cct Pro	gtc Val	cga Arg	tat Tyr	gga Gly 275	gat Asp	1593
ttc Phe	cag Gln	tac Tyr	tgt Cys 280	gat Asp	caa Gln	gca Ala	aag Lys	aca Thr 285	Val	att Ile	gtg Val	agg Arg	aac Asn 290	Thr	agc Ser	1641

aga Arg	cag Gln	acc Thr 295	aag Lys	ccg Pro	ctc Leu	aaa Lys	gtt Val 300	caa Gln	gtt Val	atg Met	cac His	tcc Ser 305	tcc Ser	gtg Val	gct Ala	1689
gct Ala	cat His 310	cag Gln	aat Asn	ttt Phe	ggt Gly	ttg Leu 315	aaa Lys	gct Ala	ctg Leu	tcg Ser	tgg Trp 320	ctg Leu	gga Gly	agt Ser	gtt Val	1737
att Ile 325	gga Gly	tac Tyr	tca Ser	gat Asp	ggc Gly 330	ctt Leu	cgc Arg	agg Arg	att Ile	ttg Leu 335	tgt Cys	caa Gln	gtt Val	gga Gly	tta Leu 340	1785
caa Gln	gaa Glu	ggt Gly	cca Pro	gat Asp 345	ggc Gly	gaa Glu	aac Asn	tct Ser	tct Ser 350	ctg Leu	gtc Val	gac Asp	aga Arg	ctg Leu 355	atg Met	1833
ctt Leu	aat Asn	gat Asp	tcc Ser 360	aaa Lys	tta Leu	tgg Trp	aaa Lys	999 Gly 365	gct Ala	agg Arg	agt Ser	gtg Val	tat Tyr 370	cac His	cag Gln	1881
ttg Leu	ttc Phe	atg Met 375	agc Ser	agc Ser	ctg Leu	ctc Leu	atg Met 380	gac Asp	ctc Leu	aag Lys	tat Tyr	aag Lys 385	aag Lys	ctg Leu	ttc Phe	1929
gcg Ala	ctt Leu 390	cga Arg	ttt Phe	gct Ala	aaa Lys	aat Asn 395	tac Tyr	cgg Arg	cag Gln	ttg Leu	cag Gln 400	agg Arg	gat Asp	ttt Phe	atg Met	1977
gag Glu 405	gat Asp	gat Asp	cac His	gag Glu	cgg Arg 410	gca Ala	gtg Val	tcg Ser	gtg Val	act Thr 415	gct Ala	ctg Leu	tct Ser	gtc Val	cag Gln 420	2025
ttc Phe	ttc Phe	acc Thr	gca Ala	ccg Pro 425	acg Thr	ctg Leu	gcg Ala	cga Arg	atg Met 430	ctc Leu	ctc Leu	aca Thr	gaa Glu	gag Glu 435	aac Asn	2073
ctg Leu	atg Met	acc Thr	gtt Val 440	atc Ile	att Ile	aag Lys	gct Ala	ttc Phe 445	atg Met	gac Asp	cat His	ttg Leu	aaa Lys 450	cac His	aga Arg	2121
gat Asp	gcc Ala	cag Gln 455	ggc Gly	aga Arg	ttc Phe	cag Gln	ttt Phe 460	gaa Glu	cgc Arg	tac Tyr	act Thr	gcc Ala 465	ctc Leu	caa Gln	gcc Ala	2169
ttc Phe	aag Lys 470	ttc Phe	agg Arg	aga Arg	gtc Val	cag Gln 475	agc Ser	ctc Leu	atc Ile	tta Leu	gat Asp 480	Leu	aag Lys	tat Tyr	gta Val	2217
ttg Leu 485	att Ile	agc Ser	aaa Lys	cca Pro	acg Thr 490	gag Glu	tgg Trp	tca Ser	gat Asp	gag Glu 495	ctg Leu	agg Arg	cag Gln	aag Lys	ttc Phe 500	2265
tta Leu	caa Gln	Gly aaa	ttc Phe	gat Asp 505	gcc Ala	ttc Phe	ttg Leu	gaa Glu	tta Leu 510	Leu	aag Lys	tgc Cys	atg Met	cag Gln 515	gga Gly	2313
atg Met	gac Asp	ccg Pro	atc Ile 520	Thr	cgt Arg	cag Gln	gtg Val	gga Gly 525	Gln	cac His	att Ile	gag Glu	atg Met 530	gag Glu	cca Pro	2361
gag Glu	tgg Trp	gaa Glu 535	gca Ala	gcc Ala	ttc Phe	aca Thr	ctg Leu 540	cag Gln	atg Met	aag Lys	ctg Leu	aca Thr 545	cac His	gtc Val	atc Ile	2409

tca Ser	atg Met 550	gtg Val	cag Gln	gac Asp	tgg Trp	tgt Cys 555	gct Ala	ctg Leu	gac Asp	gaa Glu	aaa Lys 560	gtg Val	tta Leu	att Ile	gaa Glu	2457
gct Ala 565	tac Tyr	aag Lys	aaa Lys	tgc Cys	ctg Leu 570	gct Ala	gtg Val	ctg Leu	aca Thr	cag Gln 575	tgt Cys	cat His	ggc Gly	gga Gly	ttt Phe 580	2505
act Thr	gat Asp	ggt Gly	gaa Glu	cag Gln 585	cca Pro	atc Ile	aca Thr	ctc Leu	agt Ser 590	att Ile	tgt Cys	gga Gly	cac His	tcg Ser 595	gtg Val	2553
gaa Glu	acc Thr	atc Ile	aga Arg 600	tac Tyr	tgt Cys	gtt Val	tcc Ser	caa Gln 605	gaa Glu	aaa Lys	gtt Val	agc Ser	att Ile 610	cac His	ctc Leu	2601
cca Pro	att Ile	tct Ser 615	cgc Arg	ttg Leu	ctt Leu	gca Ala	ggt Gly 620	ttg Leu	cat His	gta Val	ttg Leu	tta Leu 625	agc Ser	aaa Lys	agt Ser	2649
gaa Glu	gtg Val 630	gca Ala	tat Tyr	aaa Lys	ttt Phe	cca Pro 635	gag Glu	ctc Leu	cta Leu	cct Pro	cta Leu 640	agt Ser	gaa Glu	ctg Leu	agc Ser	2697
cca Pro 645	ccc Pro	atg Met	ttg Leu	ata Ile	gaa Glu 650	cat His	cct Pro	ctt Leu	aga Arg	tgt Cys 655	ctt Leu	gtc Val	tta Leu	tgt Cys	gct Ala 660	2745
caa Gln	gtg Val	cat His	gct Ala	665 61y	atg Met	tgg Trp	aga Arg	aga Arg	aat Asn 670	ggc Gly	ttc Phe	tct Ser	cta Leu	gta Val 675	aat Asn	2793
	atc Ile															2841
	gac Asp															2889
cac His	ttc Phe 710	ctg Leu	atg Met	atc Ile	atg Met	ctc Leu 715	agc Ser	cgc Arg	ttt Phe	gaa Glu	ctc Leu 720	tat Tyr	cag Gln	ctc Leu	ttc Phe	2937
agc Ser 725	acg Thr	cct Pro	gac Asp	tat Tyr	999 Gly 730	aag Lys	aga Arg	ttc Phe	agt Ser	tct Ser 735	gag Glu	gtt Val	acc Thr	cat His	aag Lys 740	2985
gac Asp	gtc Val	gtt Val	cag Gln	cag Gln 745	aac Asn	aac Asn	act Thr	ctg Leu	atc Ile 750	gaa Glu	gag Glu	atg Met	ctc Leu	tac Tyr 755	ctc Leu	3033
atc Ile	atc Ile	atg Met	ctt Leu 760	gtg Val	gga Gly	gaa Glu	aga Arg	ttc Phe 765	aac Asn	cct Pro	ggg ggg	gtt Val	gga Gly 770	cag Gln	gtg Val	3081
gct Ala	gcc Ala	aca Thr 775	gat Asp	gaa Glu	atc Ile	aag Lys	agg Arg 780	gag Glu	att Ile	atc Ile	cat His	cag Gln 785	ttg Leu	agc Ser	atc Ile	3129
aag Lys	cct Pro 790	atg Met	gct Ala	cac His	agt Ser	gag Glu 795	ctg Leu	gtg Val	aag Lys	tct Ser	ctg Leu 800	cct Pro	gaa Glu	gat Asp	gag Glu	3177

aac Asn 805	aag Lys	gag Glu	acc Thr	ggc Gly	atg Met 810	gag Glu	agc Ser	gtc Val	atc Ile	gag Glu 815	tcc Ser	gtt Val	gca Ala	cat His	ttc Phe 820	3225
aag Lys	aaa Lys	cct Pro	ggg Gly	ctc Leu 825	aca Thr	Gly ggg	cga Arg	ggc Gly	atg Met 830	tat Tyr	gag Glu	ctg Leu	aag Lys	cca Pro 835	gag Glu	3273
tgt Cys	gcc Ala	aaa Lys	gag Glu 840	ttc Phe	aac Asn	ctg Leu	tat Tyr	ttt Phe 845	tat Tyr	cat His	ttc Phe	tcc Ser	agg Arg 850	gca Ala	gag Glu	3321
cag Gln	tcc Ser	aag Lys 855	gca Ala	gag Glu	gaa Glu	gct Ala	cag Gln 860	cgg Arg	aaa Lys	ttg Leu	aaa Lys	aga Arg 865	gaa Glu	aat Asn	aaa Lys	3369
gaa Glu	gat Asp 870	aca Thr	gca Ala	ctc Leu	cct Pro	cct Pro 875	ccg Pro	gct Ala	ttg Leu	cca Pro	ccg Pro 880	ttc Phe	tgc Cys	cct Pro	ttg Leu	3417
ttc Phe 885	gcg Ala	agt Ser	ctg Leu	gtt Val	aac Asn 890	atc Ile	ttg Leu	cag Gln	tgt Cys	gac Asp 895	gtc Val	atg Met	ctg Leu	tac Tyr	atc Ile 900	3465
atg Met	gga Gly	acg Thr	atc Ile	ctg Leu 905	cag Gln	tgg Trp	gct Ala	gta Val	gag Glu 910	cat His	cac His	gly aaa	tct Ser	gcc Ala 915	tgg Trp	3513
tca Ser	gag Glu	tcc Ser	atg Met 920	cta Leu	cag Gln	agg Arg	gtg Val	ctg Leu 925	cat His	ttg Leu	atc Ile	Gly aaa	atg Met 930	gct Ala	ctc Leu	3561
cag Gln	gaa Glu	gag Glu 935	aag Lys	cac His	cac His	ttg Leu	gag Glu 940	aac Asn	gcc Ala	gtg Val	gaa Glu	999 Gly 945	cac His	gtg Val	cag Gln	3609
acc Thr	ttc Phe 950	acc Thr	ttc Phe	aca Thr	cag Gln	aag Lys 955	att Ile	tca Ser	aag Lys	cct Pro	ggt Gly 960	gat Asp	gca Ala	cca Pro	cat His	3657
aac Asn 965	tcc Ser	ccg Pro	agc Ser	atc Ile	cta Leu 970	gct Ala	atg Met	ctg Leu	gag Glu	acc Thr 975	ttg Leu	cag Gln	aac Asn	gcc Ala	ccc Pro 980	3705
tcc Ser	ctg Leu	gaa Glu	gcc Ala	cac His 985	aag Lys	gac Asp	atg Met	atc Ile	agg Arg 990	tgg Trp	ttg Leu	cta Leu	aag Lys	atg Met 995	ttt Phe	3753
aat Asn	gca Ala	Ile	aag Lys 1000	aag Lys	ata Ile	aga Arg	Glu	tgt Cys 1005	tca Ser	tcc Ser	agc Ser	Ser	cct Pro 1010	gtg Val	gcc Ala	3801
gag Glu	Ala	gag Glu 1015	Gly	acc Thr	ata Ile	Met	gag Glu 1020	gag Glu	agc Ser	tca Ser	Arg	gac Asp 1025	aag Lys	gac Asp	aaa Lys	3849
Ala	gag Glu 1030	Arg	aaa Lys	aga Arg	Lys	gcc Ala 1035	Glu	atc Ile	gcc Ala	Arg	ctg Leu 1040	cgc Arg	cgg Arg	gag Glu	aag Lys	3897
atc Ile 104	Met	gcc Ala	cag Gln	Met	tct Ser 1050	Glu	atg Met	cag Gln	Arg	cac His 1055	Phe	att Ile	gac Asp	gaa Glu	aac Asn 1060	3945

aaa gag ctc ttc cag cag acc cta gag ctg gac acc tct gcc tct gcc Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Thr Ser Ala Ser Ala 1065 1070 1075	3993
act ctt gac agc agc cct ccc gtt tca gac gca gct ctt aca gca ctg Thr Leu Asp Ser Ser Pro Pro Val Ser Asp Ala Ala Leu Thr Ala Leu 1080 1085 1090	4041
ggc cca gca cag aca cag gtc cct gaa ccg aga cag ttt gtc acc tgt Gly Pro Ala Gln Thr Gln Val Pro Glu Pro Arg Gln Phe Val Thr Cys 1095 1100 1105	4089
ata tta tgt caa gag gag caa gag gtg act gtg gga agc agg gcg atg Ile Leu Cys Gln Glu Gln Glu Val Thr Val Gly Ser Arg Ala Met 1110 1115 1120	4137
gtc ttg gca gcg ttt gtt cag agg tca acg gtt ctg tca aaa gac agg Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asp Arg 1125 1130 1135 1140	4185
acg aaa acc atc gcg gac cca gaa aaa tat gat cca tta ttc atg cac Thr Lys Thr Ile Ala Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His 1145 1150 1155	4233
ccc gat ctg tct tgt ggg aca cac act ggc agc tgt ggg cac gtt atg Pro Asp Leu Ser Cys Gly Thr His Thr Gly Ser Cys Gly His Val Met 1160 1165 1170	4281
cat gcc cat tgt tgg caa agg tat ttt gat tcc gtt caa gcc aag gag His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu 1175 1180 1185	4329
cag cga agg cag cag cgg ctg cgc ttg cac act agc tac gat gta gag Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu 1190 1195 1200	4377
aat ggc gag ttc ctc tgc ccg ctc tgt gag tgc ctg agc aac acg gtg Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val 1205 1210 1215 1220	4425
atc ccc ctg ctg ctt cct ccc agg agc atc ctc agc agg agg tta aat Ile Pro Leu Leu Pro Pro Arg Ser Ile Leu Ser Arg Arg Leu Asn 1225 1230 1235	4473
ttt tca gac caa cca gat ctg gca cag tgg acg aga gca gta aca cag Phe Ser Asp Gln Pro Asp Leu Ala Gln Trp Thr Arg Ala Val Thr Gln 1240 1245 1250	4521
cag ata aag gtg gtc cag atg ctg agg aga aag cac aat gct gct gac Gln Ile Lys Val Val Gln Met Leu Arg Arg Lys His Asn Ala Ala Asp 1255 1260 1265	4569
acg tct tct tca gag gac aca gaa gcc atg aat ata ata ccg atc ccc Thr Ser Ser Ser Glu Asp Thr Glu Ala Met Asn Ile Ile Pro Ile Pro 1270 1275 1280	4617
gaa ggc ttc agg cct gat ttt tat cct agg aac cca tat tct gat agc Glu Gly Phe Arg Pro Asp Phe Tyr Pro Arg Asn Pro Tyr Ser Asp Ser 1285 1290 1295 1300	4665
ata aaa gaa atg tta acg aca ttt gga acg gct gct tac aag gtg gga Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Ala Tyr Lys Val Gly 1305 1310 1315	4713

ctg aag gtt cat cct aat gaa ggt gac ccc cgt gtg ccc atc ctg tgc Leu Lys Val His Pro Asn Glu Gly Asp Pro Arg Val Pro Ile Leu Cys 1320 1325 1330	4761
tgg ggg acc tgt gca tac acc atc cag agc ata gaa aga att ttg agt Trp Gly Thr Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser 1335 1340 1345	4809
gat gag gag aag cct gtt ttt gga cct ctg cct tgt aga ctg gac gac Asp Glu Glu Lys Pro Val Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp 1350 1360	4857
tgt ctc agg tcg tta aca cgg ttt gca gca gca cat tgg aca gtg gcg Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His Trp Thr Val Ala 1365 1370 1375 1380	4905
tta ctt cct gtg gta caa gga cac ttc tgt aaa ctc ttt gca tcc ttg Leu Leu Pro Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu 1385 1390 1395	4953
gtg cct agt gac agc tat gaa gac ctc ccg tgc ata cta gac atc gac Val Pro Ser Asp Ser Tyr Glu Asp Leu Pro Cys Ile Leu Asp Ile Asp 1400 1405 1410	5001
atg ttt cac ttg ctg gtg ggc ctg gtg ctc gct ttc cca gct ctg cag Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln 1415 1420 1425	5049
tgt cag gat ttt tca gga agc agc ctg gcc act ggg gac ctg cac atc Cys Gln Asp Phe Ser Gly Ser Ser Leu Ala Thr Gly Asp Leu His Ile 1430 1435 1440	5097
ttc cac ttg gtt acc atg gca cac atc gta cag atc tta ctt acc tca Phe His Leu Val Thr Met Ala His Ile Val Gln 1le Leu Leu Thr Ser 1445 1450 1455 1460	5145
tgt aca gaa gag aat ggc atg gat caa gag aat ccc act ggg gaa gaa Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Thr Gly Glu Glu 1465 1470 1475	5193
gaa ctg gcc att ctc tct ttg cac aaa aca ctt cac cag tat act gga Glu Leu Ala Ile Leu Ser Leu His Lys Thr Leu His Gln Tyr Thr Gly 1480 1485 1490	5241
agt gcc ttg aaa gaa gcc ccc tcc ggc tgg cac ctg tgg agg agc gtc Ser Ala Leu Lys Glu Ala Pro Ser Gly Trp His Leu Trp Arg Ser Val 1495 1500 1505	5289
cgg gcc gcc atc atg cct ttc ctc aag tgc tct gct ttg ttt ttc cac Arg Ala Ala Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His 1510 1515 1520	5337
tat tta aat gga gtc ccg gcc cct cca gac ctt caa gtt tct gga aca Tyr Leu Asn Gly Val Pro Ala Pro Pro Asp Leu Gln Val Ser Gly Thr	5385
1525     1530     1535     1540	
agc cat ttt gaa cac tta tgt aac tac ctt tcc cta cca acc aac ctc Ser His Phe Glu His Leu Cys Asn Tyr Leu Ser Leu Pro Thr Asn Leu 1545 1550 1555	5433

agt tgg tgc cag aac agt gaa gtt aaa cgg tat cta aat ggc gag aga Ser Trp Cys Gln Asn Ser Glu Val Lys Arg Tyr Leu Asn Gly Glu Arg 1575 1580 1585	5529
gga gcg ata agc tac ccc aga gga gct aac aaa ctg ata gac ctt cca Gly Ala Ile Ser Tyr Pro Arg Gly Ala Asn Lys Leu Ile Asp Leu Pro 1590 1595 1600	5577
gag gat tac agc agc ctc att aac caa gca tcc aat ttc tcg tgc ccc Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro 1605 1610 1615 1620	5625
aaa tca ggt ggc gac aag agc aga gct cct act ctg tgc ctc gtg tgt Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys 1625 1630 1635	5673
ggg agt ctc ctc tgc tct cag agt tac tgc tgc caa gct gag ctg gag Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Ala Glu Leu Glu 1640 1645 1650	5721
ggt gag gac gtc gga gcc tgc aca gca cac acc tac tcc tgc ggc tcc Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser 1655 1660 1665	5769
ggg gcc ggc atc ttc ctg aga gtg cgg gaa tgt cag gtg cta ttt tta Gly Ala Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu 1670 1680	5817
gct ggc aaa acc aaa gga tgt ttt tat tct cct cct tac ctt gac gac Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp 1685 1690 1695 1700	5865
tat gga gag acc gac cag gga ctc aga cga gga aat cct tta cat tta Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu 1705 1710	5913
tgc caa gag cgg ttt cga aag atc cag aag ctc tgg cag cag cat agt Cys Gln Glu Arg Phe Arg Lys Ile Gln Lys Leu Trp Gln Gln His Ser 1720 1725 1730	5961
atc aca gag gag atc gga cac gcg cag gag gct aac cag acc ctg gtc Ile Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val 1735 1740 1745	6009
gga att gac tgg cag cat tta taatcgctcc tctactaaaa acttgacttg	6060
gagttttgta acacagctgg cttttccag	6089
<210> 6 <211> 1755 <212> PRT <213> Mouse	
<400> 6 Met Ala Ser Glu Met Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu 1 5 10 15	
Leu Glu Cys Ser Ala Glu Glu Ile Ala Gly Arg Trp Leu Gln Ala Thr 20 25 30	

Asp Leu Asn Arg Glu Val Tyr Gln His Leu Ala His Cys Val Pro Lys
35 40 45

Ile Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Thr Leu 50 55 60

Ala Gln His Ile Leu Leu Gly Pro Met Glu Trp Tyr Ile Cys Ala Glu 65 70 75 80

Asp Pro Ala Leu Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser 85 90 95

His Leu Cys Gly Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys
100 105 110

Arg Asp Cys Ala Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe 115 120 125

Leu Gly Ser Ile His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly
130 135 140

Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly 145 150 155

Pro Tyr Cys Gln Lys His Lys Leu Ser Ser Glu Val Val Glu Glu 165 170 175

Glu Asp Pro Leu Val His Leu Ser Glu Asp Val Ile Ala Arg Thr Tyr 180 185 190

Asn Ile Phe Ala Ile Met Phe Arg Tyr Ala Val Asp Ile Leu Thr Trp
195 200 205

Glu Lys Glu Ser Glu Leu Pro Glu Asp Leu Glu Val Ala Glu Lys Ser 210 215 220

Asp Thr Tyr Tyr Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu 225 230 235

Gln Val Ile Tyr Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu 245 250 255

Ala Ile Gly Phe Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Pro Val 260 265 270

Arg Tyr Gly Asp Phe Gln Tyr Cys Asp Gln Ala Lys Thr Val Ile Val 275 280 285

Arg Asn Thr Ser Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His 290 295 300

Ser Ser Val Ala Ala His Gln Asn Phe Gly Leu Lys Ala Leu Ser Trp 305 310 315 320

Leu Gly Ser Val Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys 325 330 335

Gln Val Gly Leu Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val 340 345 350

Asp Arg Leu Met Leu Asn Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser 355 360 365

Val Tyr His Gln Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr 370 380

Lys Lys Leu Phe Ala Leu Arg Phe Ala Lys Asn Tyr Arg Gln Leu Gln 385 390 395 400

Arg Asp Phe Met Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala 405 410 415

Leu Ser Val Gln Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Leu 420 425 430

Thr Glu Glu Asn Leu Met Thr Val Ile Ile Lys Ala Phe Met Asp His
435
440
445

Leu Lys His Arg Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr 450 455 460

Ala Leu Gln Ala Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp 465 470 475 480

Leu Lys Tyr Val Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu 485 490 495

Arg Gln Lys Phe Leu Gln Gly Phe Asp Ala Phe Leu Glu Leu Lys 500 510

Cys Met Gln Gly Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile 515 520 525

Glu Met Glu Pro Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu 530 540

Thr His Val Ile Ser Met Val Gln Asp Trp Cys Ala Leu Asp Glu Lys 545 550 560

Val Leu Ile Glu Ala Tyr Lys Lys Cys Leu Ala Val Leu Thr Gln Cys
565 570 575

His Gly Gly Phe Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys 580 585 590

Gly His Ser Val Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val 595 600 605

Ser Ile His Leu Pro Ile Ser Arg Leu Leu Ala Gly Leu His Val Leu 610 615 620

Leu Ser Lys Ser Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu 625 630 640

Ser Glu Leu Ser Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu 645 650 655

Val Leu Cys Ala Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe 660 665 670

Ser Leu Val Asn Gln Ile Tyr Tyr Tyr His Asn Val Lys Cys Arg Arg 675 680 685

Glu Met Phe Asp Lys Asp Ile Val Met Leu Gln Thr Gly Val Ser Met 690 695 700

- Met Asp Pro Asn His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu 705 710 715 720
- Tyr Gln Leu Phe Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu
  725 730 735
- Val Thr His Lys Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu 740 745 750
- Met Leu Tyr Leu Ile Ile Met Leu Val Gly Glu Arg Phe Asn Pro Gly 755 760 765
- Val Gly Gln Val Ala Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His 770 780
- Gln Leu Ser Ile Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu 785 790 795 800
- Pro Glu Asp Glu Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ser 805 810 815
- Val Ala His Phe Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu 820 825 830
- Leu Lys Pro Glu Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe 835 840 845
- Ser Arg Ala Glu Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys 850 855 860
- Arg Glu Asn Lys Glu Asp Thr Ala Leu Pro Pro Pro Ala Leu Pro Pro 865 870 875 880
- Phe Cys Pro Leu Phe Ala Ser Leu Val Asn Ile Leu Gln Cys Asp Val 885 890 895
- Met Leu Tyr Ile Met Gly Thr Ile Leu Gln Trp Ala Val Glu His His 900 905 910
- Gly Ser Ala Trp Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile 915 920 925
- Gly Met Ala Leu Gln Glu Glu Lys His His Leu Glu Asn Ala Val Glu 930 935 940
- Gly His Val Gln Thr Phe Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly 945 950 955 960
- Asp Ala Pro His Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu 965 970 975
- Gln Asn Ala Pro Ser Leu Glu Ala His Lys Asp Met Ile Arg Trp Leu 980 985 990
- Leu Lys Met Phe Asn Ala Ile Lys Lys Ile Arg Glu Cys Ser Ser Ser 995 1000 1005
- Ser Pro Val Ala Glu Ala Glu Gly Thr Ile Met Glu Glu Ser Ser Arg 1010 1015 1020
- Asp Lys Asp Lys Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu 025 1030 1035 1040

- Arg Arg Glu Lys Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe 1045  $\phantom{0}1055$
- Ile Asp Glu Asn Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Thr
  1060 1065 1070
- Ser Ala Ser Ala Thr Leu Asp Ser Ser Pro Pro Val Ser Asp Ala Ala 1075 1080 1085
- Leu Thr Ala Leu Gly Pro Ala Gln Thr Gln Val Pro Glu Pro Arg Gln 1090 1095 1100
- Phe Val Thr Cys Ile Leu Cys Gln Glu Glu Gln Glu Val Thr Val Gly 105 1110 1115 1120
- Ser Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu 1125 1130 1135
- Ser Lys Asp Arg Thr Lys Thr Ile Ala Asp Pro Glu Lys Tyr Asp Pro 1140 1145 1150
- Leu Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Gly Ser Cys 1155 1160 1165
- Gly His Val Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val 1170 1175 1180
- Gln Ala Lys Glu Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser 185 1190 1195 . 1200
- Tyr Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu 1205 1210 1215
- Ser Asn Thr Val Ile Pro Leu Leu Leu Pro Pro Arg Ser Ile Leu Ser 1220 1225 1230
- Arg Arg Leu Asn Phe Ser Asp Gln Pro Asp Leu Ala Gln Trp Thr Arg 1235 1240 1245
- Ala Val Thr Gln Gln Ile Lys Val Val Gln Met Leu Arg Arg Lys His 1250 1255 1260
- Asn Ala Ala Asp Thr Ser Ser Ser Glu Asp Thr Glu Ala Met Asn Ile 265 1270 1275 1280
- Ile Pro Ile Pro Glu Gly Phe Arg Pro Asp Phe Tyr Pro Arg Asn Pro 1285 1290 1295
- Tyr Ser Asp Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Ala 1300 1305 1310
- Tyr Lys Val Gly Leu Lys Val His Pro Asn Glu Gly Asp Pro Arg Val 1315 1320 1325
- Pro Ile Leu Cys Trp Gly Thr Cys Ala Tyr Thr Ile Gln Ser Ile Glu 1330 1340
- Arg Ile Leu Ser Asp Glu Glu Lys Pro Val Phe Gly Pro Leu Pro Cys 345 1350 1360
- Arg Leu Asp Asp Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His
  1365 1370 1375

- Trp Thr Val Ala Leu Leu Pro Val Val Gln Gly His Phe Cys Lys Leu 1380 1385 1390
- Phe Ala Ser Leu Val Pro Ser Asp Ser Tyr Glu Asp Leu Pro Cys Ile 1395 1400 1405
- Leu Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe 1410 1415 1420
- Pro Ala Leu Gln Cys Gln Asp Phe Ser Gly Ser Ser Leu Ala Thr Gly 425 1430 1435 1440
- Asp Leu His Ile Phe His Leu Val Thr Met Ala His Ile Val Gln Ile 1445 1450 1455
- Leu Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro 1460 1465 1470
- Thr Gly Glu Glu Leu Ala Ile Leu Ser Leu His Lys Thr Leu His 1475 1480 1485
- Gln Tyr Thr Gly Ser Ala Leu Lys Glu Ala Pro Ser Gly Trp His Leu 1490 1500
- Trp Arg Ser Val Arg Ala Ala Ile Met Pro Phe Leu Lys Cys Ser Ala 505 1510 1515 1520
- Leu Phe Phe His Tyr Leu Asn Gly Val Pro Ala Pro Pro Asp Leu Gln
  1525 1530 1535
- Val Ser Gly Thr Ser His Phe Glu His Leu Cys Asn Tyr Leu Ser Leu 1540 1545 1550
- Pro Thr Asn Leu Ile His Leu Phe Gln Glu Asn Ser Asp Ile Met Asn 1555 1560 1565
- Ser Leu Ile Glu Ser Trp Cys Gln Asn Ser Glu Val Lys Arg Tyr Leu 1570 1580
- Asn Gly Glu Arg Gly Ala Ile Ser Tyr Pro Arg Gly Ala Asn Lys Leu 1585 1590 1595 1600
- Ile Asp Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn 1605 1610 1615
- Phe Ser Cys Pro Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu 1620 1625 1630
- Cys Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln 1635 1640 1645
- Ala Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr 1650 1660
- Ser Cys Gly Ser Gly Ala Gly Ile Phe Leu Arg Val Arg Glu Cys Gln 665 1670 1680
- Val Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro 1685 1690 1695
- Tyr Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn 1700 1705 1710

<212> DNA

```
Pro Leu His Leu Cys Gln Glu Arg Phe Arg Lys Ile Gln Lys Leu Trp
                           1720
Gln Gln His Ser Ile Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn
   1730
                       1735
Gln Thr Leu Val Gly Ile Asp Trp Gln His Leu
                   1750
<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Primer
      -2282-91
<400> 7
                                                                    21
ctgctcgagt ctgcgtcaaa c
<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Primer -
      2385-35
<400> 8
                                                                    24
tctcgatatg ttgcagcctt gcta
<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Primer 2282-94
<400> 9
                                                                    23
gtatgaactt gccgaggctt tta
<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer 2294-37
<400> 10
                                                                    23
caatactttc ccagccctca gaa
<210> 11
<211> 18
```

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer 2380-88
                                                                   18
atggcgtcgc tagagcca
<210> 12
<211> 23
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Primer 2378-32
<400> 12
                                                                    23
caaagegget gageatgate ate
<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Primer 2381-48
<400> 13
                                                                    23
tgaacagcca atcacactaa gca
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer 2385-94
<400> 14
                                                                    20
ttataaatgc caaatgccaa
<210> 15
<211> 1757
<212> PRT
<213> Mouse
Met Ala Asp Glu Glu Met Asp Gly Ala Glu Arg Met Asp Val Ser Pro
Glu Pro Pro Leu Ala Pro Gln Arg Pro Ala Ser Trp Trp Asp Gln Gln
Val Asp Phe Tyr Thr Ala Phe Leu His His Leu Ala Gln Leu Val Pro
Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu Glu Lys Gln Glu Glu
```

55

60

The state of the s

j 4

Busy Bush

22

ia

Han san

Ser Val Gln Met Ser Ile Leu Thr Pro Leu Glu Trp Tyr Leu Phe Gly Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys His Ser Gly Ala Phe 90 Gln Leu Cys Gly Lys Val Phe Lys Ser Gly Glu Thr Thr Tyr Ser Cys Arg Asp Cys Ala Ile Asp Pro Thr Cys Val Leu Cys Met Asp Cys Phe 120 Gln Ser Ser Val His Lys Asn His Arg Tyr Lys Met His Thr Ser Thr Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Thr Gly 155 Pro Phe Cys Val Asp His Glu Pro Gly Arg Ala Gly Thr Thr Lys Glu Ser Leu His Cys Pro Leu Asn Glu Glu Val Ile Ala Gln Ala Arg Arg 185 Ile Phe Pro Ser Val Ile Lys Tyr Ile Val Glu Met Thr Ile Trp Glu 200 195 Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile Arg Glu Lys Asn Glu 215 Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His His Ser Tyr Asp His 230 Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys Glu Leu Ala Glu Ala 245 Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly Arg Arg Ala Val Lys Ala Gly Val Tyr Ala Thr Cys Gln Glu Ala Lys Glu Asp Ile Lys Ser 280 285 His Ser Glu Asn Val Ser Gln His Pro Leu His Val Glu Val Leu His Ser Val Val Met Ala His Gln Lys Phe Ala Leu Arg Leu Gly Ser Trp 310 Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe Arg Gln Ile Phe Cys 330 Gln Ala Cys Leu Val Glu Glu Pro Gly Ser Glu Asn Pro Cys Leu Ile Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr Lys Gly Ala Arg Lys Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe Met Glu Met Glu Tyr 375 380 Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr Tyr Lys Gln Leu Gln 390 395

Lys Glu Tyr Ile Ser Asp Asp His Glu Arg Ser Ile Ser Ile Thr Ala Leu Ser Val Gln Met Leu Thr Val Pro Thr Leu Ala Arg His Leu Ile 420 425 Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu Thr Leu Leu Glu Val Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe Asn Phe Gln Gly Tyr Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val Ile Cys Asp Leu Lys 475 Tyr Ile Leu Ile Ser Lys Pro Val Ile Trp Thr Glu Arg Leu Arg Ala 485 490 Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys Ile Leu Thr Cys Met Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly Gln His Ile Glu Val 520 Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln Met Gln Leu Lys Asn 535 530 Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys Asp Glu Asp Leu Leu 555 Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val Met Arg Cys Ser Thr Asn Phe Met Ser Ser Thr Lys Thr Val Val Gln Leu Cys Gly His Ser 585 Leu Glu Thr Lys Ser Tyr Lys Val Ser Glu Asp Leu Val Ser Ile His Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His Val Arg Leu Ser Arg Leu Gly Ala Ile Ser Arg Leu His Glu Phe Val Pro Phe Asp Ser Phe 630 Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg Cys Leu Val Leu Val Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn Gly Leu Ser Leu Ile 665 Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys Arg Glu Glu Met Tyr Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala Ser Ile Met Asp Pro Asn Lys Phe Leu Leu Leu Val Leu Gln Arg Tyr Glu Leu Thr Asp Ala 710 Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp Leu Ile Lys Gln Tyr

730

725

- Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu Ile Tyr Ile Val Gly 740 745 750
- Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr Arg Glu Glu Val Ile 755 760 765
- Met Arg Glu Ile Thr His Leu Leu Cys Ile Glu Pro Met Pro His Ser 770 780
- Ala Ile Ala Arg Asn Leu Pro Glu Asn Glu Asn Glu Thr Gly Leu 785 790 795 800
- Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys Lys Pro Gly Val Ser 805 810 815
- Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn 820 825 830
- Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His Ser Lys Ala Glu His 835 840 845
- Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys Asp Glu Ala Leu Pro 850 860
- Pro Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe Ser Lys Val Val Asn 865 870 875 875
- Leu Leu Ser Cys Asp Val Met Ile Tyr Ile Leu Arg Thr Ile Phe Glu 885 890 895
- Arg Ala Val Asp Thr Glu Ser Asn Leu Trp Thr Glu Gly Met Leu Gln 900 905 910
- Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu Glu Glu Lys Gln Gln 915 920 925
- Leu Gln Lys Ala Pro Glu Glu Glu Val Ala Phe Asp Phe Tyr His Lys 930 940
- Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ala Gln Asn Ile Gln Met 945 950 955 960
- Leu Leu Glu Arg Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln Lys Asp 965 970 975
- Met Ile Thr Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg Leu Arg 980 985 990
- Glu Lys Ser Cys Leu Val Val Ala Thr Thr Ser Gly Leu Glu Cys Ile 995 1000
- Lys Ser Glu Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg Lys Arg 1010 1015 1020
- Lys Ala Glu Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala Gln Met 1025 1030 1035 1040
- Ser Ala Leu Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met Tyr Asp 1045 1050 1055
- Asn Thr Ser Glu Val Thr Gly Lys Glu Asp Ser Ile Met Glu Glu Glu 1060 1065 1070

- Ser Thr Ser Ala Val Ser Glu Ala Ser Arg Ile Ala Leu Gly Pro Lys 1075 1080 1085
- Arg Gly Pro Ala Val Thr Glu Lys Glu Val Leu Thr Cys Ile Leu Cys 1090 1095 1100
- Gln Glu Glu Gln Glu Val Lys Leu Glu Asn Asn Ala Met Val Leu Ser 1105 1110 1115
- Ala Cys Val Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly Lys Pro \$1125\$ \$1130\$ \$1135
- Val Asp His Leu Gly Glu Thr Leu Asp Pro Leu Phe Met Asp Pro Asp 1140 1145 1150
- Leu Ala His Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met His Ala 1155 1160 1165
- Val Cys Trp Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser Gln Gln 1170 1175 1180
- Arg Ile His Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr Leu Cys 1185 1190 1195 1200
- Pro Leu Cys Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile Pro Leu 1205 1210 1215
- Gln Pro Gln Lys Ile Asn Ser Glu Asn Ala Glu Ala Leu Ala Gln Leu 1220 1225 1230
- Leu Thr Leu Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile Ser Gly
  1235 1240 1245
- Tyr Asn Ile Lys His Ala Lys Gly Glu Ala Pro Ala Val Pro Val Leu 1250 1260
- Phe Asn Gln Gly Met Gly Asp Ser Thr Phe Glu Phe His Ser Ile Leu 1265 1270 1275 1280
- Ser Phe Gly Val Gln Ser Ser Val Lys Tyr Ser Asn Ser Ile Lys Glu 1285 1290 1295
- Met Val Ile Leu Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys Val 1300 1305 1310
- Pro Pro Asp Glu Leu Asp Pro Arg Val Pro Met Met Thr Trp Ser Thr 1315 1320 1325
- Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu Gly 1330 1340
- Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg Gln His Ser Gly Leu Lys 1345 1350 1355 1360
- Ala Leu Met Gln Phe Ala Val Ala Gln Arg Ala Thr Cys Pro Gln Val 1365 1370 1375
- Leu Ile His Lys His Leu Ala Arg Leu Leu Ser Val Ile Leu Pro Asn 1380 1385 1390
- Leu Gln Ser Glu Asn Thr Pro Gly Leu Leu Ser Val Asp Leu Phe His 1395 1400 1405

- Val Leu Val Gly Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp Asp 1410 1420
- Thr Val Asp Leu Gln Pro Ser Pro Leu Ser Ser Ser Tyr Asn His Leu 1425 1430 1435 1440
- Tyr Leu Phe His Leu Ile Thr Met Ala His Met Leu Gln Ile Leu Leu 1445 1450 1455
- Thr Thr Asp Thr Asp Leu Ser Pro Gly Pro Pro Leu Ala Glu Gly Glu
  1460 1465 1470
- Glu Asp Ser Glu Glu Ala Arg Cys Ala Ser Ala Phe Phe Val Glu Val 1475 1480 1485
- Ser Gln His Thr Asp Gly Leu Thr Gly Cys Gly Ala Pro Gly Trp Tyr 1490 1495 1500
- Leu Trp Leu Ser Leu Arg Asn Gly Ile Thr Pro Tyr Leu Arg Cys Ala 1505 1510 1515 1520
- Ala Leu Leu Phe His Tyr Leu Leu Gly Val Ala Pro Pro Glu Glu Leu 1525 1530 1535
- Phe Ala Asn Ser Ala Glu Gly Glu Phe Ser Ala Leu Cys Ser Tyr Leu 1540 1545 1550
- Ser Leu Pro Thr Asn Leu Phe Leu Leu Phe Gln Glu Tyr Trp Asp Thr 1555 1560 1565
- Ile Arg Pro Leu Leu Gln Arg Trp Cys Gly Asp Pro Ala Leu Leu Lys 1570 1575 1580
- Ser Leu Lys Gln Lys Ser Ala Val Val Arg Tyr Pro Arg Lys Arg Asn 1585 1590 1595 1600
- Ser Leu Ile Glu Leu Pro Glu Asp Tyr Ser Cys Leu Leu Asn Gln Ala 1605 1610 1615
- Ser His Phe Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys His Pro \$1620\$
- Val Leu Cys Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn Ile Cys 1635 1640 1645
- Cys Gln Glu Ile Val Asn Gly Glu Glu Val Gly Ala Cys Val Phe His 1650 1660
- Ala Leu His Cys Gly Ala Gly Val Cys Ile Phe Leu Lys Ile Arg Glu 1665 1670 1680
- Cys Arg Val Val Leu Val Glu Gly Lys Ala Arg Gly Cys Ala Tyr Pro 1685 1690 1695
- Ala Pro Tyr Leu Asp Glu Tyr Gly Glu Thr Asp Pro Gly Leu Lys Arg 1700 1705 1710
- Gly Asn Pro Leu His Leu Ser Arg Glu Arg Tyr Arg Lys Leu His Leu 1715 1720 1725
- Val Trp Gln Gln His Cys Ile Ile Glu Glu Ile Ala Arg Ser Gln Glu 1730 1735 1740

```
Thr Asn Gln Met Leu Phe Gly Phe Asn Trp Gln Leu Leu
                   1750
1745
<210> 16
<211> 11
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: peptide
<400> 16
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg
<210> 17
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: peptide
<400> 17
Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
<210> 18
<211> 5205
<212> DNA
<213> Homo sapiens
<400> 18
atggcggacg aggaggctgg aggtactgag aggatggaaa tcagcgcgga gttaccccag 60
acccctcagc gtctggcatc ttggtgggat cagcaagttg atttttatac tgctttcttg 120
catcatttgg cacaattggt gccagaaatt tactttgctg aaatggaccc agacttggaa 180
aagcaggagg aaagtgtaca aatgtcaata ttcactccac tggaatggta cttatttgga 240
gaagatccag atatttgctt agagaaattg aagcacagtg gagcatttca gctttgtggg 300
agggttttca aaagtggaga gacaacctat tcttgcaggg attgtgcaat tgatccaaca 360
tgtgtactct gtatggactg cttccaggac agtgttcata aaaatcatcg ttacaagatg 420
catacttcta ctggaggagg gttctgtgac tgtggagaca cagaggcatg gaaaactggc 480
cctttttgtg taaatcatga acctggaaga gcaggtacta taaaagagaa ttcacgctgt 540
ccgttgaatg aagaggtaat tgtccaagcc aggaaaatat ttccttcagt gataaaatat 600
gtcgtagaaa tgactatatg ggaagaggaa aaagaactgc ctcctgaact ccagataagg 660
knryycvndh hsydhgtcat atacagccta caaagagctc ttgactgtga gctcgcagag 720
gcccagttgc ataccactgc cattgacaaa gagggtcgtc gggctgttaa agcgggagct 780
tatgctgctt gccaggaagc aaaggaagat ataaagagtc attcagaaaa tgtctctcaa 840
```

catccacttc atgtagaagt attacactca gagattatgg ctcatcagaa atttgctttg 900 cgtcttggtt cctggatgaa caaaattatg agctattcaa gtgactttag gcagatcttt 960 tgccaagcat gccttagaga agaacctgac tcggagaatc cctgtctcat aagcaggtta 1020 atgctttggg atgcaaagct ttataaaggt gcccgtaaga tccttcatga attgatcttc 1080 agcagttttt ttatggagat ggaatacaaa aaactctttg ctatggaatt tgtgaagtat 1140 tataaacaac tgcagaaaga atatatcagt gatgatcatg acagaagtat ctctataact 1200 gcactttcag ttcagatgtt tactgttcct actctggctc gacatcttat tgaagagcag 1260 aatgttatct ctgtcattac tgaaactctg ctagaagttt tacctgagta cttggacagg 1320 aacaataaat tcaacttcca gggttatagc caggacaaat tgggaagagt atatgcagta 1380 atatgtgacc taaagtatat cctgatcagc aaacccacaa tatggacaga aagattaaga 1440 atgcagttcc ttgaaggttt tcgatctttt ttgaagattc ttacctgtat gcagggaatg 1500 gaagaaatcc gaagacaggt tgggcaacac attgaagtgg atcctgattg ggaggctgcc 1560 attgctatac agatgcaatt gaagaatatt ttactcatgt tccaagagtg gtgtgcttgt 1620 gatgaagaac tettaettgt ggettataaa gaatgteaca aagetgtgat gaggtgeagt 1680 accagtttca tatctagtag caagacagta gtacaatcgt gtggacatag tttggaaaca 1740 aagtoctaca gagtatotga ggatottgta agcatacato tgocactoto taggaccott 1800 gctggtcttc atgtacgttt aagcaggctg ggtgctgttt caagactgca tgaatttgtg 1860 tottttgagg actttcaagt agaggtacta gtggaatatc ctttacgttg totggtgttg 1920 gttgcccagg ttgttgctga gatgtggcga agaaatggac tgtctcttat tagccaggtg 1980 ttttattacc aagatgttaa gtgcagagaa gaaatgtatg ataaagatat catcatgctt 2040 cagattggtg catctttaat ggatcccaat aagttcttgt tactggtact tcagaggtat 2100 gaacttgccg aggettttaa caagaccata tetacaaaag accaggattt gattaaacaa 2160 tataatacac taatagaaga aatgcttcag gtcctcatct atattgtggg tgagcgttat 2220 gtacctggag tgggaaatgt gaccaaagaa gaggtcacaa tgagagaaat cattcacttg 2280 ctttgcattg aacccatgcc acacagtgcc attgccaaaa atttacctga gaatgaaaat 2340 aatgaaactg gcttagagaa tgtcataaac aaagtggcca catttaagaa accaggtgta 2400 tcaggccatg gagtttatga actaaaagat gaatcactga aagacttcaa tatgtacttt 2460 tatcattact ccaaaaccca gcatagcaag gctgaacata tgcagaagaa aaggagaaaa 2520 caagaaaaca aagatgaagc attgccgcca ccaccacctc ctgaattctg ccctgctttc 2580 agcaaagtga ttaaccttct caactgtgat atcatgatgt acattctcag gaccgtattt 2640 gagogggcaa tagacacaga ttctaacttg tggaccgaag ggatgctcca aatggctttt 2700 catattctgg cattgggttt actagaagag aagcaacagc ttcaaaaagc tcctgaagaa 2760 gaagtaacat ttgactttta tcataaggct tcaagattgg gaagttcagc catgaatata 2820 caaatgcttt tggaaaaact caaaggaatt ccccagttag aaggccagaa ggacatgata 2880 acgtggatac ttcagatgtt tgacacagtg aagcgattaa gagaaaaatc ttgtttaatt 2940 gtagcaacca catcaggatc ggaatctatt aagaatgatg agattactca tgataaagaa 3000 aaagcagaac gaaaaagaaa agctgaagct gctaggctac atcgccagaa gatcatggct 3060 cagatgtctg ccttacagaa aaacttcatt gaaactcata aactcatgta tgacaataca 3120 tcagaaatgc ctgggaaaga agattccatt atggaggaag agagcacccc agcagtcagt 3180 gactacteta gaattgettt gggteetaaa eggggteeat etgttaetga aaaggaggtg 3240 ctgacgtgca tcctttgcca agaagaacag gaggtgaaaa tagaaaataa tgccatggta 3300 ttatoggoot gtgtocagaa atotaotgoo ttaacccago acaggggaaa acccatagaa 3360 ctctcaggag aagccctaga cccacttttc atggatccag acttggcata tggaacttat 3420 acaggaaget gtggteatgt aatgeaegea gtgtgetgge agaagtattt tgaagetgta 3480 cagctgagct ctcagcagcg cattcatgtt gacctttttg acttggaaag tggagaatat 3540 ctttgccctc tttgcaaatc tctgtgcaat actgtgatcc ccattattcc tttgcaacct 3600 caaaagataa acagtgagaa tgcagatgct cttgctcaac ttttgaccct ggcacggtgg 3660 ccaattccta ttttctttaa tcaaggaatg ggagattcta ctttggagtt ccattccatc 3780 ctgagttttg gcgttgagtc ttcgattaaa tattcaaata gcatcaagga aatggttatt 3840 ctctttgcca caacaattta tagaattgga ttgaaagtgc cacctgatga aagggatcct 3900 cgagtcccca tgctgacctg gagcacctgc gctttcacta tccaggcaat tgaaaatcta 3960 ttgggagatg aaggaaaacc tctgtttgga gcacttcaaa ataggcagca taatggtctg 4020 aaagcattaa tgcagtttgc agttgcacag aggattacct gtcctcaggt cctgatacag 4080 aaacatctgg ttcgtcttct atcagttgtt cttcctaaca taaaatcaga agatacacca 4140 tgccttctgt ctatagatct gtttcatgtt ttggtgggtg ctgtgttagc attcccatcc 4200 ttgtattggg atgaccetgt tgatetgeag cettetteag ttagttette etataaceae 4260 ctttatctct tccatttgat caccatggca cacatgcttc agatactact tacagtagac 4320 acaggcctac cccttgctca ggttcaagaa gacagtgaag aggctcattc cgcatcttct 4380 ttctttgcag aaatttctca atatacaagt ggctccattg ggtgtgatat tcctggctgg 4440 tatttgtggg tctcactgaa gaatggcatc accccttatc ttcgctgtgc tgcattgttt 4500 ttccactatt tacttggggt aactccgcct gaggaactgc ataccaattc tgcagaagga 4560 gagtacagtg cactetgtag etatetatet ttacetacaa atttgtteet getetteeag 4620 gaatattggg atactgtaag gcccttgctc cagaggcggt gtgcagatcc tgccttacta 4680 aactgtttga agcaaaaaa caccgtggtc aggtacccta gaaaaagaaa tagtttgata 4740 gagcttcctg atgactatag ctgcctcctg aatcaagctt ctcatttcag gtgcccacgg 4800 tctgcagatg atgagcgaaa gcatcctgtc ctctgccttt tctgtggggc tatactatgt 4860 tctcagaaca tttgctgcca ggaaattgtg aacggggaag aggttggagc ttgcattttt 4920 cacgcacttc actgtggagc cggagtctgc attttcctaa aaatcagaga atgccgagtg 4980 gtcctggttg aaggtaaagc cagaggctgt gcctatccag ctccttactt ggatgaatat 5040 ggagaaacag accctggcct gaagaggggc aacccccttc atttatctcg tgagcggtat 5100 cggaagctcc atttggtctg gcaacaacac tgcattatag aagagattgc taggagccaa 5160 gagactaatc agatgttatt tggattcaac tggcagttac tgtga

<210> 19 <211> 1735

<212> PRT

<213> Homo sapiens

<400> 19

Ala Met Glu Gly Asn Met Ala Asp Glu Glu Ala Gly Gly Thr Glu Arg 1 5 10 15

Met Glu Ile Ser Ala Glu Leu Pro Gln Thr Pro Gln Arg Leu Ala Ser 20 25 30

Trp Trp Asp Gln Gln Val Asp Phe Tyr Thr Ala Phe Leu His His Leu 45

Ala Gln Leu Val Pro Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu 50 55 60

Glu Lys Gln Glu Glu Ser Val Gln Met Ser Ile Phe Thr Pro Leu Glu 65 70 75 80

Trp Tyr Leu Phe Gly Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys
85 90 95

His Ser Gly Ala Phe Gln Leu Cys Gly Arg Val Phe Lys Ser Gly Glu 100 105 110

Thr Thr Tyr Ser Cys Arg Asp Cys Ala Ile Asp Pro Thr Cys Val Leu 115 120 125

Cys Met Asp Cys Phe Gln Asp Ser Val His Lys Asn His Arg Tyr Lys 130 135 140

Met His Thr Ser Thr Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu 145 150 155 160

Ala Trp Lys Thr Gly Pro Phe Cys Val Asn His Glu Pro Gly Arg Ala 165 170 175

Gly Thr Ile Lys Glu Asn Ser Arg Cys Pro Leu Asn Glu Glu Val Ile 180 185 190

Val Gln Ala Arg Lys Ile Phe Pro Ser Val Ile Lys Tyr Val Val Glu 195 200 205 Met Thr Ile Trp Glu Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile 210 215 220

Arg Glu Lys Asn Glu Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His 225 230 235 240

His Ser Tyr Asp His Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys 245 250 255

Glu Leu Ala Glu Ala Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly
260 265 270

Arg Arg Ala Val Lys Ala Gly Ala Tyr Ala Ala Cys Gln Glu Ala Lys 275 280 285

Glu Asp Ile Lys Ser His Ser Glu Asn Val Ser Gln His Pro Leu His 290 295 300

Val Glu Val Leu His Ser Glu Ile Met Ala His Gln Lys Phe Ala Leu 305 310 315 320

Arg Leu Gly Ser Trp Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe 325 330 335

Arg Gln Ile Phe Cys Gln Ala Cys Leu Arg Glu Glu Pro Asp Ser Glu 340 345 350

Asn Pro Cys Leu Ile Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr 355 360 365

Lys Gly Ala Arg Lys Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe 370 375 380

Met Glu Met Glu Tyr Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr 385 390 395 400

Tyr Lys Gln Leu Gln Lys Glu Tyr Ile Ser Asp Asp His Asp Arg Ser 405 410 415

Ile Ser Ile Thr Ala Leu Ser Val Gln Met Phe Thr Val Pro Thr Leu 420 425 430

Ala Arg His Leu Ile Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu 435 440 445

Thr Leu Leu Glu Val Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe 450 455 460

Asn Phe Gln Gly Tyr Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val 465 470 475 480

Ile Cys Asp Leu Lys Tyr Ile Leu Ile Ser Lys Pro Thr Ile Trp Thr 485 490 495

Glu Arg Leu Arg Met Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys 500 505 510

Ile Leu Thr Cys Met Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly
515 520 525

Gln His Ile Glu Val Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln 530 540

Met Gln Leu Lys Asn Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys 555 Asp Glu Glu Leu Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val 570 Met Arq Cys Ser Thr Ser Phe Ile Ser Ser Ser Lys Thr Val Val Gln 585 Ser Cys Gly His Ser Leu Glu Thr Lys Ser Tyr Arg Val Ser Glu Asp 600 Leu Val Ser Ile His Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His 615 Val Arg Leu Ser Arg Leu Gly Ala Val Ser Arg Leu His Glu Phe Val 635 630 Ser Phe Glu Asp Phe Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg 650 Cys Leu Val Leu Val Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn Gly Leu Ser Leu Ile Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys 675 Arg Glu Glu Met Tyr Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala 695 Ser Leu Met Asp Pro Asn Lys Phe Leu Leu Leu Val Leu Gln Arg Tyr 710 Glu Leu Ala Glu Ala Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp 730 725 Leu Ile Lys Gln Tyr Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu Ile Tyr Ile Val Gly Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr 760 Lys Glu Glu Val Thr Met Arg Glu Ile Ile His Leu Leu Cys Ile Glu Pro Met Pro His Ser Ala Ile Ala Lys Asn Leu Pro Glu Asn Glu Asn 790 Asn Glu Thr Gly Leu Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys 810 Lys Pro Gly Val Ser Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His Ser Lys Ala Glu His Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys 855 Asp Glu Ala Leu Pro Pro Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe 875 870

- Ser Lys Val Ile Asn Leu Leu Asn Cys Asp Ile Met Met Tyr Ile Leu 885 890 895
- Arg Thr Val Phe Glu Arg Ala Ile Asp Thr Asp Ser Asn Leu Trp Thr 900 905 910
- Glu Gly Met Leu Gln Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu 915 920 925
- Glu Glu Lys Gln Gln Leu Gln Lys Ala Pro Glu Glu Glu Val Thr Phe 930 940
- Asp Phe Tyr His Lys Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ile 945 950 955 960
- Gln Met Leu Glu Lys Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln
  965 970 975
- Lys Asp Met Ile Thr Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg 980 985 990
- Leu Arg Glu Lys Ser Cys Leu Ile Val Ala Thr Thr Ser Gly Ser Glu 995 1000 1005
- Ser Ile Lys Asn Asp Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg 1010 1015 1020
- Lys Arg Lys Ala Glu Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala 1025 1030 1035 1040
- Gln Met Ser Ala Leu Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met 1045 1050 1055
- Tyr Asp Asn Thr Ser Glu Met Pro Gly Lys Glu Asp Ser Ile Met Glu 1060 1065 1070
- Glu Glu Ser Thr Pro Ala Val Ser Asp Tyr Ser Arg Ile Ala Leu Gly 1075 1080 1085
- Pro Lys Arg Gly Pro Ser Val Thr Glu Lys Glu Val Leu Thr Cys Ile 1090 1095 1100
- Leu Cys Gln Glu Glu Gln Glu Val Lys Ile Glu Asn Asn Ala Met Val 1105 1110 1115 1120
- Leu Ser Ala Cys Val Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly
  1125 1130 1135
- Lys Pro Ile Glu Leu Ser Gly Glu Ala Leu Asp Pro Leu Phe Met Asp 1140 1145 1150
- Pro Asp Leu Ala Tyr Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met 1155 1160 1165
- His Ala Val Cys Trp Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser 1170 1175 1180
- Gln Gln Arg Ile His Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr 1185 1190 1195 1200
- Leu Cys Pro Leu Cys Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile 1205 1210 1215

- Pro Leu Gln Pro Gln Lys Ile Asn Ser Glu Asn Ala Asp Ala Leu Ala 1220 1225 1230
- Gln Leu Leu Thr Leu Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile 1235 1240 1245
- Ser Gly Tyr Asn Ile Arg His Ala Lys Gly Glu Asn Pro Ile Pro Ile 1250 1255 1260
- Phe Phe Asn Gln Gly Met Gly Asp Ser Thr Leu Glu Phe His Ser Ile 1265 1270 1275 1280
- Leu Ser Phe Gly Val Glu Ser Ser Ile Lys Tyr Ser Asn Ser Ile Lys 1285 1290 1295
- Glu Met Val Ile Leu Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys 1300 1305 1310
- Val Pro Pro Asp Glu Arg Asp Pro Arg Val Pro Met Leu Thr Trp Ser 1315 1320 1325
- Thr Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu 1330 1340
- Gly Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg Gln His Asn Gly Leu 1345 1350 1355 1360
- Lys Ala Leu Met Gln Phe Ala Val Ala Gln Arg Ile Thr Cys Pro Gln  $1365 \hspace{1cm} 1370 \hspace{1cm} 1375$
- Val Leu Ile Gln Lys His Leu Val Arg Leu Leu Ser Val Val Leu Pro 1380 1385 1390
- Asn Ile Lys Ser Glu Asp Thr Pro Cys Leu Leu Ser Ile Asp Leu Phe 1395 1400 1405
- His Val Leu Val Gly Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp 1410 1420
- Asp Pro Val Asp Leu Gln Pro Ser Ser Val Ser Ser Ser Tyr Asn His 1425 1430 1435 1440
- Leu Tyr Leu Phe His Leu Ile Thr Met Ala His Met Leu Gln Ile Leu 1445 1450 1450
- Leu Thr Val Asp Thr Gly Leu Pro Leu Ala Gl<br/>n Val Gl<br/>n Glu Asp Ser \$1460\$ \$1470\$
- Glu Glu Ala His Ser Ala Ser Ser Phe Phe Ala Glu Ile Ser Gln Tyr 1475 1480 1485
- Thr Ser Gly Ser Ile Gly Cys Asp Ile Pro Gly Trp Tyr Leu Trp Val 1490 1495 1500
- Ser Leu Lys Asn Gly Ile Thr Pro Tyr Leu Arg Cys Ala Ala Leu Phe 1505 1510 1515 1520
- Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu Glu Leu His Thr Asn 1525 1530 1535
- Ser Ala Glu Gly Glu Tyr Ser Ala Leu Cys Ser Tyr Leu Ser Leu Pro \$1540\$ \$1550\$

Thr Asn Leu Phe Leu Leu Phe Gln Glu Tyr Trp Asp Thr Val Arg Pro 1560 Leu Leu Gln Arg Arg Cys Ala Asp Pro Ala Leu Leu Asn Cys Leu Lys 1575 Gln Lys Asn Thr Val Val Arg Tyr Pro Arg Lys Arg Asn Ser Leu Ile Glu Leu Pro Asp Asp Tyr Ser Cys Leu Leu Asn Gln Ala Ser His Phe 1605 Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys His Pro Val Leu Cys 1625 Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn Ile Cys Cys Gln Glu Ile Val Asn Gly Glu Glu Val Gly Ala Cys Ile Phe His Ala Leu His Cys Lys Ala Arg Gly Cys Ala Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr 1675 Gly Glu Thr Asp Pro Gly Leu Lys Arg Gly Asn Pro Leu His Leu Ser Arg Glu Arg Tyr Arg Lys Leu His Leu Val Trp Gln Gln His Cys Ile 1705 Ile Glu Glu Ile Ala Arg Ser Gln Glu Thr Asn Gln Met Leu Phe Gly 1720 1725 1715 Phe Asn Trp Gln Leu Leu \* 1735 1730 <210> 20 <211> 22 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: PCR Primer <400> 20 22 agaaggagag tacagtgcac tc <210> 21 <211> 20 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: PCR Primer <400> 21 20 cgaaagcatc ctgtcctctg

<210> 22

<211> 18

```
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Primer
<400> 22
                                                                    18
aggaagctgt ggtcatgt
<210> 23
<211> 14
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Primer
<400> 23
                                                                    14
gttaggaaga actg
<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Primer
<400> 24
                                                                    20
aagaacagcg aaggcaacag
<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR Primer
<400> 25
                                                                    22
cgcagctacc ccaacacatt ct
<210> 26
<211> 22
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Primer
<400> 26
                                                                    22
tttcttccat tccctgcata ca
<210> 27
<211> 25
<212> DNA
<213> Artificial Sequence
```

And we in grow I wife line, had

22

Will the Br

<220>	
<223> Description of Artificial Sequence: PCR Primer	
<400> 27	
caaaacttta taaaggtgcc cgtaa	25
<210> 28	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PCR Primer	
<400> 28	
attccctgca tgcacttcag taa	23
<210> 29	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PCR Primer	
<400> 29	
cattccctgc atgcacttca g	21